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Chronic low back pain (CLBP) causes ongoing pain, disability and 
psychological suffering, at a huge personal and socio-economic cost. CLBP 
is a heterogeneous condition and its mechanisms are poorly understood. 
Characterisation and classification of low back pain (LBP) is controversial, 
there is disagreement on the characterisation and diagnosis of neuropathic 
low back pain (NuLBP) in relation to mechanical LBP (MLBP). Diagnostic 
uncertainty is coupled with poor clinical outcomes for treatment. There is 
therefore an urgent need to develop more effective assessment strategies to 
identify and better differentiate NuLBP from MLBP in order to facilitate a 
better understanding of underlying mechanisms and more successful 
treatments.  
The primary aim of this study was to establish clinical profiles of CLBP, in 
particular, differences between MLBP and NuLBP using Questionnaire-
based behavioural evaluation and sensory testing, structural neuroimaging 
(voxel based morphometry) and functional neuroimaging (arterial spin 
labelling). Significant differences were identified between CLBP patients and 
healthy controls and between NuLBP and MLBP patients in multiple 
behavioural domains measuring pain, function and psychological well-being. 
Significant differences were demonstrated in CLBP patients compared to 
controls in both tactile threshold discrimination and two-point discrimination 
and between NuLBP and MLBP in tactile threshold discrimination. Functional 
and structural neuroimaging showed significant differences between all 
groups in widespread brain regions involved in the evaluation of decision-
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making and planning, mood and emotion, modulation of pain and 
representation of body schema. 
This study has demonstrated the ability to characterise CLBP using a battery 
of behavioural, examination and functional and structural neuroimaging 
methodologies and has been able to differentiate between CLBP patients 
and controls and importantly, between NuLBP and MLBP patients. This work 
demonstrates the impact of CLBP across sensory-discriminative, affective-
motivational and cognitive-evaluative dimensions of the pain experience and 
shows the increased impact and burden on those who suffer with NuLBP 
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Chapter 1 INTRODUCTION 
“And yet the prevalence of back pain is perhaps matched in degree only by the lingering 
mystery accompanying it…..’’ (Deyo 1998) 
Low back pain (LBP) is the leading global cause of disability (Hoy, March et 
al. 2014) and affects nearly everyone at some point in their lives. For most 
people the problem is intermittent and does not drastically affect their quality 
of life. However, a significant minority develop chronic low back pain (CLBP), 
which can cause on-going pain, disability and psychological suffering, at a 
huge socio-economic cost. 
It is estimated that approximately 5% of back pain is due to nerve root 
pathology and less than 1% of CLBP is due to underlying medical pathology 
(so called “red flags”) (Waddell 2005). The remainder of CLBP is diagnosed 
as non-specific low back pain (NSLBP) as clinical assessment, imaging 
investigations and diagnostic testing and are unable to explain its underlying 
causes and mechanisms (Waddell 2005, Krismer and van Tulder 2007). 
Diagnostic uncertainty is inherently unsatisfactory. Waddell, writing in 2005, 
states “However semantically correct, nonspecific low back pain is not a 
good clinical diagnosis. It is intellectually and scientifically inadequate and 
fails to provide any biological basis for real understanding……, the Holy Grail 
of low back pain research is to find a way to sub-classify nonspecific low 
back pain”   (Waddell 2005). 
Diagnostic uncertainty is coupled with poor clinical outcomes for treatment. 
Most treatment studies show at best slight to moderate improvement in short 
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term outcomes across a wide range of conservative and non-conservative 
interventions which, unfortunately, are not sustained in the long term (van 
Tulder, Koes et al. 2006). Ultimately, improved diagnostic efficiency and 
more accurate differentation of mechanical and neuropathic LBP will lead to 
appropriately targeted treatment strategies and therefore improved outcomes 
. 
This chapter will: 
• Introduce a conceptual framework for the understanding of pain that 
will be used throughout this thesis 
• Summarise the current epidemiology of LBP  
• Review current methods for characterising and differentiating 
mechanical and neuropathic CLBP  
• Review debates and controversies concerning the definition and 
characterisation of neuropathic pain  
• Identify problems in assessment methods for characterising and 
differentiating mechanical and neuropathic CLBP methods  
• Suggest new directions in assessment and differentiation methods 
based on an understanding of CNS mechanisms in CLBP  
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1.1 Models of Pain 
 The Three-Dimensional Model Of Pain  1.1.1
Throughout this thesis I adopt an approach that accepts that the sensory-
discriminative, affective-motivational and cognitive-evaluative dimensions of 
pain are inherently linked (Melzack and Casey 1968, Mollet and Harrison 
2006, Wiech and Tracey 2013). Although this view is no longer controversial, 
the emergence of models incorporating purely non-biomedical elements is a 
relatively recent phenomenon. In the following paragraphs I will briefly 
summarise the development of current models used to stratify the 
experience of chronic pain. 
 Biomedical Models Of Pain 1.1.2
The traditional Cartesian view of pain as a nociceptive, stimulus-related 
reflex phenomenon was prevalent throughout much of the 20thC. In this 
model pain was seen as a straightforward transmission of pain impulses via 
specific pain fibres along specific pain pathways to a pain centre in the brain 
(specificity theory). Pain experience was therefore considered proportionate 
to injury and pathology. There was little room for the psychological 
experience of pain in this model. Cartesian dualism saw the body as a 
machine and though the mind (or soul) existed it had nothing to do with the 
experience of pain. Pain treatment involved blocking the transmission of 
impulses to the pain centre in the brain by pharmacological or surgical 
means. Unfortunately, many patients with chronic pain did not benefit from 
this approach. In addition, many patients with chronic pain (and there is no 
 23 
better example than back pain) did not demonstrate clearly identifiable signs 
of peripheral pathology. These patients, and those that failed to get better, 
were labelled as malingerers, either lacking in moral fibre (‘workshy’) or else 
psychologically disturbed (Waddell 2004). In the second half of the 20thC, 
however, researchers and clinicians increasingly challenged specificity 
theory.  
 Melzack And Wall: Gate Control Theory And The Three-1.1.3
Dimensional Model Of Pain 
Melzack and Wall’s gate control theory was the first to posit central nervous 
system mechanisms for the modulation of pain, to explain the non-linear 
relationship of pain stimulus to intensity (Melzack and Wall 1965). A few 
years later, Melzack and Casey’s proposed a three-dimensional model of 
pain as “sensory-discriminative”, “affective-motivational” and “cognitive-
evaluative” that clearly outlined the role by which cognitive and psychological 
processes (inherently associated with brain function) are capable of 
modulating nociceptive stimuli (Melzack and Casey 1968). Stimulus 
magnitude is not enough to explain pain perception. For instance, in 
situations where the threat value of pain is less than a greater threat, the 
pain response may be attenuated (Moseley 2007). “Battle field analgesia” is 
a well-documented phenomenon in which the relative importance of dealing 
with the task in hand (ie the supreme motivational importance of survival) 
overrides the threat value of injury, resulting in analgesia. Conversely, in 
other circumstances, pain may appear out of proportion to an injury (Melzack 
and Wall 1996). Moreover, in many common clinical chronic pain conditions, 
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including CLBP, it is often difficult to identify pathology commensurate with 
symptoms or any pathology at all (Melzack and Wall 1996, Koes, Tulder et 
al. 2006). In fact, damage/nociception is not even necessary for pain 
perception; pain may be induced by hypnosis in the absence of any noxious 
stimulus (Derbyshire, Whalley et al. 2004).  
 The ‘Neuromatrix’ 1.1.4
Famously, phantom limb pain phenomena after amputation and spinal cord 
injury, inspired Melzack to the development of a new conceptual pain model 
(the ‘neuromatrix’) (Melzack 1990, Melzack 1999, Melzack 2001). The 
presence of pain in the absence of inputs from the body (but which is felt as 
keenly as pain that derives from peripheral injury) suggests strongly that 
brain neural networks underlie and subserve the experience of pain and that, 
although peripheral mechanisms can obviously be the cause of pain, pain is 
not exclusive to these peripheral mechanisms. In addition, the concept of a 
body identified as the ‘self’, distinct from the world around it, is genetically 
inherited and produced by the brain; it is not dependent on the periphery or 
spinal cord, though it may be modified by peripheral input. Melzack proposed 
that the anatomical substrate of the ‘Body-Self Neuromatrix’ consists of 
networks of ‘neuromodules’ of input areas (mediating sensory, affective and 
cognitive processing), which produce the outputs that together comprise the 
multi-dimensional nature of the pain experience. The process is cyclical; the 
input and output process converge in a continuing cycle of evaluation and 
assessment to form a characteristic dynamic ‘neurosignature’ composed of 
the activation and processing patterns of the neuromatrix, that is unique to 
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the individual. The qualitative experience of pain is not inherent in the 
properties of the injury but is generated by the unique configuration and 
convergence of the components of the matrix, whose unique patterns 
account for the non-uniform qualities of every sufferer’s pain experience. An 
unfortunate development has been that the original neuromatrix theory has 
been confused by the development of a specific ‘pain neuromatrix’ based on 
the anatomical findings from imaging studies. I feel it is important that a 
distinction between the two is made clear and will discus the construct of a 
‘pain neuromatrix’ later in this thesis.  
 The Mature Organism Model (MOM) 1.1.5
 Melzack’s neuromatrix model was reconceptualised by Gifford in terms of 
evolutionary biology (Gifford 2013). The mature organism model (MOM) took 
as its starting point that all organisms look to maintain homeostasis. In 
response to a homeostasis-threatening situation (which may or my not be 
nociceptive; it may be sensory, internally or externally generated, cognitive or 
affective), the individual (organism) scrutinises and evaluates the internal 
and external environment. Based on this evaluation, the individual decides 
on a course of action, involving any number of output responses (motor, 
sensory, autonomic, cardiovascular, immune) that may be generated to deal 
with the threat. Pain is one of these possible responses. The MOM 
emphasises the role of the organism in scrutinising the environment in order 
to approach a reward or withdraw from a threat, in the manner of all 
organisms from the most simple to the most complex.  
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 Salience 1.1.6
Patients with CLBP are involved in an ongoing assessment of internal and 
external stimuli, in order to evaluate potential threats and rewards based on 
the saliency of competing stimuli. Salience is defined as “the physical 
distinctiveness or conspicuity of a stimulus, a relative property that depends 
on its relationship to the other surrounding stimuli”  - stimulus saliency is 
dependent not only on its inherent properties, but also on its context 
(Legrain, Iannetti et al. 2011). Pain is usually associated with danger, as a 
warning of an actual, or perceived, threat to well-being and homeostasis 
(Melzack and Wall 1996) and is therefore inherently salient. There is 
compelling evidence that the saliency of a stimulus (in other words the 
magnitude of the threat associated with the stimulus, which may or may not 
in itself be noxious) is a key factor in an emergent pain response and that 
saliency is intimately linked to both endogenous and exogenous pain 
modulation (Borsook, Edwards et al. 2013). Pain sensory-discrimination and 
affective-motivational behavioural responses are therefore intimately 
connected to the meaning of the pain itself (cognitive-evaluative).  
 Biopsychoscial Models 1.1.7
The three-dimensional model of pain has been utilised in numerous ways to 
provide a number of alternatives to the classical biomedical Cartesian model. 
Most of these models can be loosely termed ‘biopsychoscial’ (Engel 1977), 
as they acknowledge the central role of psychological, cognitive and 
environmental factors in the pain experience. In addition, they serve as 
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conceptual frameworks around which treatment approaches can be 
developed. For instance, the operant conditioning model, developed by 
Fordyce in the 1970s focuses the modification of chronic maladaptive pain 
behaviours with positive and negative reinforcement (Fordyce 1976). In 
addition, models were developed to include cognitive as well as behavioural 
elements (Turk 1983). Specifically, the fear-avoidance model (Lethem, Slade 
et al. 1983, Slade, Troup et al. 1983, Vlaeyen and Linton 2000) and, drawing 
on many of its approaches for low back pain, the Glasgow back pain model 
(Waddell, Main et al. 1984) incorporate patient-centred (and occasionally 
therapist-centred!) anxieties (catastrophising) in underlying pain pathology, to 
describe a framework in which the pain sufferer fails to confront and 
overcome a threatening pain situation, instead becoming trapped in a vicious 
circle of pain, disability driven by fear of pain.  
 Low back Pain – the Problem 1.2
 Incidence 1.2.1
The lifetime prevalence of low back pain is reported between 70% up to 84% 
of the adult population (Andersson 1999, Maniadakis and Gray 2000, Wand 
and O'Connell 2008, Savigny, Watson et al. 2009). Although back pain in 
childhood is relatively rare, by the end of adolescence 50% of the general 
population will have also experienced an episode (Balague, Troussier et al. 
1999). Incidence rises with age, peaking between the ages of 35-55 (Burton, 
Balague et al. 2006). In the UK, one-third of adult population is affected each 
year with around 20-25% consulting their GP (Dunn and Croft 2005, 
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Macfarlane, Jones et al. 2006). Other studies suggest these figures may be 
even higher; Carey and colleagues reported that more than 20% of patients 
denied ever having had LBP when interviewed 4 to 16 months after an acute 
episode requiring a medical consultation (Carey, Garrett et al. 1995).  
 Prognosis  1.2.2
Conventionally, low back pain is categorised by its duration: acute (<6 
weeks), sub-acute (6 weeks - 12 weeks) and chronic (>12 weeks) (Waddell 
2004). However, this convention is arbitrary; the definition of acute and 
chronic is not based on any pathologic or disease process or in relation to 
underlying mechanisms (Apkarian, Baliki et al. 2009). Most people with acute 
low back pain have a favourable prognosis with pain and disability improving 
rapidly during the first month in the region of 58% and full recovery occurring 
within 3 months (Pengel, Herbert et al. 2003).  
However, there is evidence that the experience of many sufferers is rather 
different. For those whose symptoms resolve, more than 28% of cases recur 
within 6 months (Cassidy, Cote et al. 2005) and 73% of patients have at least 
one recurrence within 12 months. Recurrences may occur more frequently 
and be more severe depending on the length and severity of previous 
episodes (Von Korff, Balderson et al. 2005). For those whose symptoms do 
not resolve fully, after three months little further improvement is observed for 
pain, disability, and return to work (Pengel, Herbert et al. 2003). One year 
after a first episode of back pain between 60-80% of people still have pain 
and disability (Croft, Macfarlane et al. 1998, Hestbaek, Leboeuf-Yde et al. 
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2003) and 16% of those initially unable to work are still not working after one 
year (Hestbaek, Leboeuf-Yde et al. 2003). Overall, less than one third of 
cases resolve annually and more than 40% of those with low back pain have 
persistent symptoms (Pengel, Herbert et al. 2003, Cassidy, Cote et al. 2005). 
Therefore, it has been suggested that the acute/sub-acute/chronic 
classification system is arbitrary and rigid and not applicable to a large 
proportion of the back pain population (Croft, Dunn et al. 2006, van Tulder, 
Becker et al. 2006). 
 Costs 1.2.3
Low back pain is associated with substantial socioeconomic costs. Back pain 
typically affects the working population, as incidence peaks between 35 and 
55 years of age (Andersson 1999). In 2005, the Trades Union Congress 
(TUC) estimated that 4.9 million working days per year were lost due to back 
pain (T.U.C 2005). Direct health care costs in the UK in 1998 were £1632 
million, including £565 million spent on non-NHS health care costs. If indirect 
costs due to work absenteeism and disablement are added to the direct 
costs then the true cost of LBP is substantially higher. In 2006, the total costs 
of back pain in the Netherlands in 1991 were more than 4 billion Euro, in the 
United Kingdom in 1992 more than 2.7 billion Euro, and in Sweden in 1995 
more than 2 billion Euro (van Tulder, Becker et al. 2006). It is estimated that 
80% of the total costs for the management of back pain in the UK are used 
on the 10% of people who develop chronic LBP (NICE clinical guideline 88 
from www.nice.org.uk/CG88.)(Nachemson 2000) 
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The figures above describe a massive economic problem. The rates of 
chronicity in the previous section highlight that for many people, low back 
pain refuses to go away, at a huge personal cost not only economically but 
also in terms of family and social relationships and general mental health 
(Croft, Papageorgiou et al. 1995, Hoogendoorn, van Poppel et al. 2000, 
Currie and Wang 2004, Linton 2005, Linton 2011). The primary motivation for 
this study is to better understand and characterise CLBP in order to target 
treatments to relieve the suffering associated with this often-debilitating 
condition.  
 Classification of LBP 1.3
 Diagnostic Low Back Pain Triage 1.3.1
 
Specific guidelines for diagnostic triage vary internationally but all 
recommend grouping patients with LBP into three categories (Deyo, Rainville 
et al. 1992, Waddell 2004, Airaksinen, Brox et al. 2006, Rubinstein and van 
Tulder 2008, Koes, van Tulder et al. 2010, Lee, Gupta et al. 2013): 
1. Suspected or confirmed serious pathology, which may also include 
inflammatory pathology (so called “red flags”) 
2. Mechanical low back pain (also known as ‘Ordinary’ or ‘simple’ back 
pain or non-specific low back pain 
3. Nerve root pain  
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 Mechanical Low Back Pain 1.3.2
MLBP is described as pain, tension, soreness and/or stiffness in the lower 
back region (defined as the area bounded by the bottom of the rib cage and 
the buttock creases. Dysfunction or pathology in any one of numerous 
structures in the back (for instance, intervertebral disc degeneration or 
herniation, facet joint degeneration, spondylolisthesis, sacro-iliac joint 
degeneration) is thought to contribute to signs and symptoms of back or leg 
pain (Nachemson 2000, Bogduk 2010). Mechanical pain is caused by 
activation of nociceptors in peripheral tissues and viscera by noxious stimuli 
and is therefore also known as nociceptive pain. Nociceptive transmission is 
relayed to second order neurons in the spinal cord and thence to supra-
spinal centres. The noxious input generates a complex output response, 
modulated by supra-spinal cognitive and affective processing, involving 
motor, hormonal, cardiovascular and autonomic responses. Tissue damage 
also initiates an inflammatory response leading to a change in local 
metabolism and cellular activity. This process, known as peripheral 
sensitisation, leads to local and distal hypersensitivity (hyperalgesia and 
allodynia) (Costigan and Woolf 2000). Furthermore, it is important to note 
that alterations in afferent sensory inputs result in sensitisation of the spinal 
cord and supraspinal sites. It is essential therefore that we understand that 
the presence of hypersensitivity is not, in itself, evidence of peripheral nerve 
involvement.  
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 Non-Specific MLBP 1.3.3
It is not possible to find a specific cause for the pain in the majority of MLBP 
sufferers. More than 80% of patients with MLBP are therefore said to suffer 
from non-specific low back pain (NSLBP). NSLBP is essentially a diagnosis 
arrived at by exclusion of red flags, systemic inflammatory disorders or nerve 
root pain (Koes, Tulder et al. 2006). Therefore, by default, NSLBP is 
described as mechanical low back pain (MLBP) in that pain is assumed to 
originate from somatic nociceptive structures of the lower back.  
 Low Back Pain With Leg Pain: Categorisation In To 1.3.4
Somatic And Radicular Components 
Patients with low back pain frequently report the presence of distal 
symptoms radiating into the buttocks and lower limbs. Radiating back pain is 
usually divided into neuropathic radicular (leg pain resulting from sensory 
nerve root or dorsal root ganglia irritation or compression) or somatic 
pseudoradicular (leg pain arising from non-nervous tissue, therefore by 
definition mechanical/somatic) (Saal 2002). Patients with mechanical somatic 
leg pain are generally described as complaining of axial back pain that is 
worse than leg pain, with leg pain generally not radiating past the knee and 
with no neurological signs on examination (Waddell 2004). 
 Neuropathic Radicular Low Back Pain  1.3.5
Back pain patients with neuropathic nerve root pain are described as having 
leg pain that is worse than back pain, which radiates below the knee to the 
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foot or toes. They may have all, or a combination of the following; pain and/or 
parasthesia in a dermatomal distribution (most commonly L5, S1), weakness 
and reduction or loss of tendon reflexes - all in the distribution of a nerve root 
(Waddell 2004, Konstantinou and Dunn 2008). 
Estimation of the prevalence of lumbosacral nerve root pain in the general 
population varies from as little as 1.2% to as much as 66%. (Freynhagen, 
Baron et al. 2006, Freynhagen, Baron et al. 2006, Hill, Dunn et al. 2008, 
Konstantinou and Dunn 2008, Beith, Kemp et al. 2011). The most likely 
reason for the large variability is confusion over what constitutes radicular leg 
pain and the frequent use of the term ‘sciatica’ in both clinical and research 
settings. Sciatica is most commonly used to describe the presence of 
lumbosacral nerve-root related leg pain. Unfortunately, sciatica is often 
applied as a catch-all term for back pain with leg pain symptoms. However, 
as discussed in section 1.3.2, leg pain in itself is not definitive evidence of a 
neuropathic component – leg pain may arise as referred pain from somatic 
structures in the back. In addition, there is little consistency in diagnostic 
methodology to arrive at a diagnosis of radicular nerve root related low back 
pain, both clinically and in research settings. Prevalence rates therefore likely 
reflect the confusion in clinical and research settings regarding the diagnosis 
of mechanical and neuropathic leg pain (Waddell 2004, Konstantinou and 
Dunn 2008). In sections1.4, 1.5 and 1.6 below I will discuss the challenges, 
controversies and debates regarding the assessment, diagnosis and 
definition of mechanical and neuropathic low back pain. In particular, I will 
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highlight methodological and diagnostic controversies and debates regarding 
the definition of neuropathic pain itself.  
 Methods of Assessment  1.4
 Radiographic And Imaging Investigations For MLBP 1.4.1
There is an abundance of radiographic and MRI imaging studies that show a 
non-linear association between structural abnormalities, degeneration, signs 
of injury, pathology and pain (Jarvik and Deyo 2002, van Tulder, Becker et 
al. 2006). Up to 47% of patients with LBP have been shown to have normal 
magnetic resonance imaging (MRI) of the lumbar spine (Savage, 
Whitehouse et al. 1997). Conversely, asymptomatic individuals also show a 
high prevalence (20–76%) of lumbar disc abnormalities with MRI (Jensen, 
Brant-Zawadzki et al. 1994, Boos, Semmer et al. 2000). Similarly, other 
studies also demonstrate that radiographic evidence of osteoarthritis in other 
bodily locations does not correlate well to reports of pain or function 
(Teichtahl, Wluka et al. 2008). There is also little correlation between the 
degree of structural abnormality and treatment outcomes (Kleinstuck, Dvorak 
et al. 2006). Identification of disc abnormalities in asymptomatic subjects also 
does not predict future episodes of back pain or sciatica. MRI cannot be 
used as a screening tool to identify risk of developing LBP (Savage, 
Whitehouse et al. 1997). 
Nevertheless, investigations are still routinely ordered, in spite of evidence 
that the use of radiography or MRI for NSLBP does not aid diagnosis, result 
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in better treatment outcomes (Kendrick, Fielding et al. 2001) or offer 
reassurance for patients worried about their back pain (van Ravesteijn, van 
Dijk et al. 2012). 5% of all x-rays in the NHS are of the lumbar spine 
(Kendrick, Fielding et al. 2001).It is estimated that as many as 50% of 
investigations are most likely unnecessary (Halpin, Yeoman et al. 1991). 
 Radiographic And Imaging Investigations For Lumbar 1.4.2
Radicular Pain 
Guidelines recommend MRI for lumbar nerve root patients with chronic non-
resolving symptoms seeking medical intervention (van Tulder, Becker et al. 
2006). However, as with non-specific MLBP, there is also an uncertain 
correlation between imaging signs and patient symptoms. Patients frequently 
present with neuropathic symptoms without any objective imaging signs; in a 
recent study, only 28% of LBP patients identified with neuropathic pain 
components using the painDETECT screening questionnaire had MRI scans 
identifying nerve root impingement (Beith, Kemp et al. 2011). Conversely, the 
majority of lesions to the nervous system do not result in neuropathic pain 
nor correlate to symptoms (Bennett 2003). In the lumbar spine, the presence 
of disc prolapse or nerve root compression does not necessarily result in 
neuropathic symptoms (Boden, Davis et al. 1990). Neither positive or 
negative lumbar investigation findings are able to confirm or deny a 
diagnosis of both mechanical and neuropathic LBP. 
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 Clinical Examination: MLBP 1.4.3
Evidence for the accuracy and diagnostic benefit of clinical examination 
procedures and interventional diagnostic testing for LBP is also limited 
(Carragee, Paragioudakis et al. 2000, Huston and Slipman 2002, Saal 2002, 
Airaksinen, Brox et al. 2006). A recent systematic review found low reliability 
of most commonly used examination procedures, including tests for 
evaluation of muscle tension or spasm, spinal instability, and provocative 
manoeuvres for diagnosing SI joint pain or facet joint pain (Rubinstein and 
van Tulder 2008).  
Of all common examination tests, only manual pain provocation tests have 
any inter-tester reliability (Rubinstein and van Tulder 2008). CLBP patients 
frequently present with widespread pain and tenderness. Studies show that 
patients with CLBP exhibit greater tenderness and lower mechanical pain 
thresholds compared to healthy controls not only over the lumbar spine but 
also elsewhere (R Jason S Giesbrecht). CLBP patients also report more pain 
to noxious thermal stimulation (Kleinbohl, Holzl et al. 1999) and to saline 
injection at distal sites (O'Neill, Manniche et al. 2007). However, widespread 
pain and greater sensitivity is suggestive of central sensitization mechanisms 
rather than underlying pathology; studies have been unable to find any 
relation between tender points and underlying pathology nor abnormalities in 
the tender points themselves (Kendrick, Fielding et al. 2001). 
 37 
 Clinical Examination Of Lumbar Radicular Pain  1.4.4
Passive straight leg raising (SLR) is the most commonly used clinical test 
used to diagnose lumbar radicular pain and to differentiate neuropathic nerve 
root pain from MLBP. Numerous reviews have studied its sensitivity and 
specificity. The consensus of these studies is that the test is highly sensitive 
but is not very specific and is not, therefore, a useful tool to differentiate 
neuropathic from mechanical pain, nor to confirm or deny its presence 
(Deyo, Rainville et al. 1992, van den Hoogen, Koes et al. 1995, Vroomen, de 
Krom et al. 1999, Rubinstein and van Tulder 2008). Furthermore, pain that is 
due to hamstring tightness may lead to false positives (Airaksinen, Brox et al. 
2006, Scaia, Baxter et al. 2012). 
Recent reviews have found poor diagnostic performance of most common 
physical tests (such as passive straight leg raising, reflex examination and 
neurological examination of muscle weakness and sensory loss) to identify 
lumbar radiculopathy due to disc herniation and to differentiate neuropathic 
nerve root pain from MLBP (Van der Windt D.A.W.M. 2010, Al Nezari, 
Schneiders et al. 2013, Iversen, Solberg et al. 2013). Evidence for the 
diagnostic utility of nerve root blocks is also limited (Datta, Manchikanti et al. 
2013). Physical examination also shows limited agreement with the results of 
electro diagnostic nerve testing. Positive and negative neurological 
examination findings correlate poorly with electroneuromyographic testing 
(Inal, Eser et al. 2013). 
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 Are We Failing To Detect Significant Neuropathic 1.5
Elements In Patients With LBP? 
The previous sections have highlighted the difficulties in identifying patients 
with radicular nerve root pain with standard examination procedures. The 
clinical presentation of patients with signs and symptoms of possible 
neuropathic back pain is often different from what is described in clinical 
textbooks. Many patients with symptoms of radicular nerve root pain do not 
demonstrate signs of nerve root compression on MRI and may also fail to 
demonstrate positive examination findings. Equally, many patients with 
positive examination findings do not show classical patterns of pain 
distribution, with attendant neurological changes. Failure to demonstrate 
consistency in signs and symptoms of neuropathy inevitably leads to a 
rejection of a neuropathic diagnosis. However, recent work indicates that 
current clinical examination methods and characterisation paradigms may fail 
to detect neuropathic components in many patients with LBP with both axial 
and distal presentations. The issues raised from this body of work are central 
to debates on the definition, diagnosis and categorisation of neuropathic pain 
that have taken place between members of the International Association for 
the Study of Pain (IASP) over the last 15 years. This debate is central to the 
issues of characterisation and diagnosis of neuropathic pain outlined in this 
thesis. 
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 Definitions Of Neuropathic Pain: A Mechanisms 1.6
Or Disease Based Approach? 
The current International Association for the Study of Pain (IASP) definition 
of neuropathic pain, updated in 2011, is “Pain caused by a lesion or disease 
of the somatosensory nervous system” (https://www.iasp-
pain.org/Education/Content.aspx?ItemNumber=1698) (see Appendix 1 for 
full definition). This definition replaces the previous definition from 1994 of 
“pain initiated or caused by a primary lesion, dysfunction, or transitory 
perturbation of the peripheral or central nervous system”.  
The taxonomy of neuropathic pain has inspired substantial debate over the 
last decade. In 2008, an IASP Neuropathic Pain Special Interest Group 
(NeuPSIG) was convened in order to arrive at a clear definition of 
neuropathic pain and how best to distinguish it from nociceptive pain. A 
resulting paper appeared in the journal Neurology (Treede, Jensen et al. 
2008) with a definition more or less identical to the current IASP definition. 
The key difference between the 1994 and later definitions centred on the 
term ‘dysfunction’, which was dropped from the earlier definition and 
replaced by ‘disease’. Disease, in the IASP statement is defined as the 
underlying cause of the identified lesion to the nervous system (i.e. stroke). 
The dropping of the term dysfunction clearly fixes the categorization of 
neuropathic pain as requiring evidence of a lesion or disease state, as 
‘objective’ markers of pathology that give a degree of confidence to a 
neuropathic diagnosis. Too many conditions, it was felt, whose mechanisms 
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were essentially unknown (i.e. fibromyalgia, CRPS) were falling under the 
“umbrella of neuropathic pain” (Jensen, Baron et al. 2011). Without a link to 
an identifiable lesion, the relationship of “structure to function” could not be 
determined and consequently, the stringency of a neuropathic diagnosis was 
weakened. A diagnosis of neuropathic pain without a lesion or disease state 
risked becoming vague and insignificant, an umbrella term for conditions in 
which the mechanisms were unusual and unclear. Additionally, it was argued 
that giving a (false) neuropathic diagnostic label to conditions without any 
clear lesion or disease state might prevent clinicians and researchers from 
further exploration of underlying mechanisms (Jensen, Baron et al. 2011). A 
grading system of certainty of neuropathic pain diagnosis was proposed 
(‘definite’, ‘probable’ or ‘unconfirmed’) based on positive history, 
somatosensory abnormality on clinical examination and a confirmatory 
diagnostic test. By these criteria, to arrive at a ‘definite’ diagnosis of 
neuropathic radicular leg pain, a) the history would have to indicate leg pain 
worse than back pain in a dermatomal distribution, b) examination should 
demonstrate positive altered sensation in the dermatome and c) MRI would 
show the presence of nerve root compression. However, possible negative 
implications and consequences of not achieving ‘definite status’ in a three-
tiered system were highlighted (Eisenberg 2011). A patient with ‘probable’ 
symptoms might be considered somehow ‘less’ neuropathic than a patient 
with a ‘definite’ diagnosis. It was also suggested that failure to meet the 
grading criteria might result in patients having their symptoms questioned 
and/or result in treatment being withheld, either by clinicians or by insurance 
companies. For instance, the radicular patient mentioned above might 
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present with a positive symptom history but with a negative MRI and pain 
outside the suggested innervation territory of the injured dermatome. The 
clinical experience of this author is that many, if not the majority of CLBP 
patients with severe back and leg pain would fail to meet all three criteria. In 
fact, many of these patients end up in pain management clinics precisely 
because they fail to fit into neat diagnostic criteria and conform to standard 
neurological textbook descriptions. These concerns were raised in a reply to 
the authors of the revised definition (Lynch, Clark et al. 2011) that animal 
studies demonstrate spread of sensory abnormalities outside the territories 
of lesioned nerves (Tal and Bennett 1994, Malan, Ossipov et al. 2000) which 
corresponds to the clinical experience of patients with nerve lesions 
(Koltzenburg 2005). 
Alternative diagnostic paradigms have been suggested that accommodate 
the heterogeneity of clinical presentations of patients with signs and 
symptoms of neuropathic pain. Instead of requiring a lesion or disease state, 
neuropathic diagnosis requires a sensitive profiling based around pain 
descriptions and symptom clusters as well as sensory profiling by clinical 
examination (Attal, Bouhassira et al. 2011, Bouhassira and Attal 2011, 
Baron, Forster et al. 2012). Underlying this approach is the belief that 
neuropathic pain, rather than being a single entity common across all 
disease states, is instead characterised by specific mechanisms that may be 
identified by different constellations of symptom clusters. A clinical condition 
identified by a homogenous label such as ‘low back pain’ may in fact 
encompass different symptom clusters and sensory examination profiles that 
 42 
suggest different underlying mechanisms for each presentation, rather than 
one homogenous neuropathic pain mechanism.  
Screening tools have been developed to recognize symptom clusters 
suggestive of neuropathic pain and are widely used both in clinical and 
research settings as an important aid in diagnosis (Bennett, Attal et al. 2007, 
Jones and Backonja 2013). These screening tools are generally designed to 
alert the clinician or researcher to the presence of a possible neuropathic 
component – the diagnosis is then confirmed by physical examination (and in 
current IASP taxonomy by the presence of a confirmatory lesion and disease 
state). No sign or symptom, in itself, is pathognomonic of neuropathic pain 
(Rasmussen, Sindrup et al. 2004, Bennett, Attal et al. 2007, Dworkin, Jensen 
et al. 2007, Jones and Backonja 2013). Although signs and symptoms may 
indicate underlying mechanisms, signs and symptoms are not equivalent 
with mechanisms (Finnerup and Jensen 2006). In fact the current IASP 
definition of neuropathic pain explicitly states, “The presence of symptoms or 
signs (e.g., touch-evoked pain) alone does not justify the use of the term 
neuropathic”. Nevertheless, several large-scale studies have shown 
heterogeneity of symptom and sensory profiles in patients with the same 
clinical condition (Attal, Fermanian et al. 2008). Baron and colleagues 
(Baron, Forster et al. 2012) identified five different profiles from two studies 
combining 4200 patients with post herpetic neuralgia, painful diabetic 
polyneuropathy and painful radiculopathy using the painDETECT 
questionnaire (Baron, Tolle et al. 2009, Mahn, Hullemann et al. 2011). 
Clusters of different neuropathic sensory profiles in CLBP have also recently 
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been demonstrated using the DN4 questionnaire in a mixed LBP cohort 
(Attal, Perrot et al. 2011) and in axial LBP patients using the painDETECT 
questionnaire (Forster, Mahn et al. 2013). Importantly, in the context of this 
study, these LBP studies demonstrate that neuropathic pain is not restricted 
to patients that present with a typical radicular presentation. Freynhagen and 
colleagues provided further evidence of possible neuropathic components in 
patients with a diagnosis of non-neuropathic low back pain (Freynhagen, 
Rolke et al. 2008). Subtle subclinical sensory deficits were found in the distal 
dermatomes of the foot in a group of fifteen patients with chronic so-called 
‘‘pseudoradicular’’ low-back pain radiating into the leg, as well as in in a 
radicular (neuropathic) group of twelve patients, using somatosensory 
profiling. Radicular patients had more pronounced (but not statistically 
significant) sensory deficits. In the radicular group, the sensory deficit and 
the pain distribution were present in the same dermatomal area; both areas 
were congruent. In the pseudoradicular group, however, the pain radiation 
and the sensory deficit were not congruent; in these patients pain was not 
felt in the foot. Contralateral sensory deficits were also found in both groups 
of patients The authors proposed that the subclinical sensory deficits 
identified in the pseudoradicular low-back pain patients are evidence of an 
occult neuropathic component in a group whose symptoms have been 
previously been associated exclusively with somatic mechanical pain. 
Furthermore, the authors suggested that in addition to low back pain 
classification categories of nociceptive and neuropathic, another category, 
described as ‘mixed’ or ‘unclear,’ be included. 
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This study employs the painDETECT screening tool developed by 
Freynhagen and colleagues (Freynhagen, Baron et al. 2006) to initially 
characterise our CLBP cohort into patients with a significant likelihood of 
either mechanical pain or neuropathic pain. The painDETECT questionnaire 
was specifically developed in order to identify neuropathic components in 
LBP and, in particular, to discriminate between low back pain of mechanical 
and neuropathic origin. PainDETECT has been shown to have a high 
sensitivity (85%), specificity, (80%) and positive predictive accuracy (83%) in 
LBP (Freynhagen, Baron et al. 2006). However, its usefulness in other 
conditions has been questioned (Tampin, Slater et al. 2013, Elias, Yilmaz et 
al. 2014). Throughout this study I have decided to call patients identified by 
painDETECT as having a significant neuropathic component to their pain, 
neuropathic low back pain patients (NuLBP). It is important to note that this 
does not imply that they are patients with a clearly identifiable nerve root 
lesion, according to conventional diagnostic triaging paradigms. Rather these 
are patients, who demonstrate a significant neuropathic component to their 
pain irrespective of their lesion or pathological status. 
Although the painDETECT questionnaire has been designed as a screening 
tool and screening tools consistently fail to identify 10-20% of patients 
diagnosed with neuropathic pain by expert clinicians (Bennett, Attal et al. 
2007), the decision was made to use the questionnaire to characterise our 
LBP groups without the use of a confirmatory diagnosis from a specialist 
clinician. The principal reason for this decision was that we sought to classify 
subjects with a significant neuropathic component to their pain as NuLBP 
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patients, rather than patients with specific nerve root or stenotic 
presentations that correspond to with conventional LBP triaging protocols. It 
is a primary hypothesis of this thesis that there are a significant number of 
people with LBP with a significant neuropathic component that is 
inconsistently identified who subsequently fail to receive appropriate 
treatment. The painDETECT questionnaire is specifically designed to identify 
this cohort of patients, who present with an occult neuropathic component 
that may not be identified by examining clinicians. 
Furthermore, in a research context, use of the painDETECT questionnaire 
has the value of standardizing the identification of patient groups. While 
acknowledging the limitations of the painDETECT questionnaire, use of the 
questionnaire allows a consistent approach to all patients and allows 
comparison across studies by the use of an objective measure. Clinical 
assessment is also a qualitative rather than quantitative tool and therefore 
subject to variability. Clinical tests also have limitations with sensitivity, 
specificity as detailed in section 1.4.4. I feel that identification of groups by 
screening questionnaires reduces therefore reduces possible inconsistencies 
in patient selection criteria. 
 What Are The Mechanisms That Underlie Changes In 1.6.1
Sensory Profiles In Patients With No Identifiable Signs 
Of A Lesion Or Disease State? 
Several explanations have been offered for ‘mixed’ or ‘unclear’ presentations 
of symptoms in CLBP. For instance, an acutely injured or degenerative 
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lumbar disc might leak inflammatory mediators (such as substance P), 
chemically activating local nociceptors, while at the same time irritating nerve 
root fibres in the same or neighbouring spinal segment (Coppes, Marani et 
al. 1997). The chemical irritation would result in neuropathic pain, 
independent of mechanical compression of the nerve root and subsequent 
overt neurological sensory or motor deficits. Widely diffused inflammatory 
mediators from a damaged disc may also explain the contralateral sensory 
deficits found in both radicular and pseudoradicular patients (Freynhagen, 
Rolke et al. 2008). In addition, a transition from pseudoradicular to radicular 
pain could result from a gradual increase of nerve compression from a 
herniated disc affecting, in order, myelinated A beta nerve fibres, A delta cold 
fibres, A delta nociceptive and finally C fibres. A similar pattern of fibre 
damage has been reported in animal studies by several authors (Nygaard, 
Kloster et al. 1998, Yamashita, Kanaya et al. 2002).  
However, mechanisms other than peripheral neuropathy may explain 
unorthodox clinical presentations. Pain and sensory deficits are associated 
with supraspinal plasticity in numerous clinical pain conditions such as 
patients with complex regional pain syndrome (CRPS) (Flor 1995, Juottonen, 
Gockel et al. 2002, Maihofner, Handwerker et al. 2003, Pleger, Tegenthoff et 
al. 2004, Maihofner, Forster et al. 2005) and phantom limb pain (PLP) (Flor, 
Elbert et al. 1995, Lotze, Flor et al. 2001). Alterations in QST profiles may not 
therefore be related to peripheral events but instead to spinal/supraspinal 
plasticity in the central nervous system. However, unlike disease-based 
lesions, these changes are not observable with conventional examination 
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methodologies. In this thesis I intend to use novel methods of sensory clinical 
profiling and structural and functional neuroimaging to explore the 
relationships between sensory and neuroimaging profiles and investigate 
whether these can be utilised to identify differences between CLBP patients 
and healthy controls and also between LBP patients with mechanical and 
neuropathic presentations. 
 Supraspinal Plasticity 1.7
In addition to LBP, there is increasing evidence that patients suffering from 
conditions assumed to be entirely somatic in origin (i.e hip and knee 
osteoarthritis (Kosek and Ordeberg 2000), patello-femoral (Jensen, Kvale et 
al. 2008) and shoulder pain (Gwilym, Oag et al. 2011) as well as other pain 
conditions of uncertain aetiology (ie complex regional pain syndrome, 
phantom limb pain, fibromyalgia syndrome (Flor, Denke et al. 2001, 
Maihofner, Herzner et al. 2006, Moseley, Zalucki et al. 2008, Lee, Nassikas 
et al. 2011, Staud 2011)) present with symptoms and subtle sensory profiles 
that suggest a neuropathic component. However, these patients do not 
demonstrate any objective signs of a lesion to the peripheral or central 
nervous system. The last decade has seen a large amount of studies that 
have used neuroimaging techniques to explore structural, functional and 
chemical plasticity in the brain in response to both experimentally induced 
and clinical pain states (May 2007, Tracey and Mantyh 2007, May 2008, 
Apkarian, Baliki et al. 2009, Davis 2011, Davis and Moayedi 2013). These 
studies have shown objective signs of CNS plasticity and modulation in these 
patients, which indicate perpetuating neural mechanisms, in addition to 
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possible peripheral mechanisms for the maintenance of on-going pain 
conditions.  
Neuroplasticity is defined as adaptive change in structure, function and 
chemistry within the nervous system (Pascual-Leone, Amedi et al. 2005) 
involving multiple levels from brain networks to cellular and synaptic 
reorganisation (Shaw 2001). Although it is commonly discussed in terms of 
brain plasticity, plasticity may of course occur anywhere in the nervous 
system (Woolf and Salter 2000) . In fact, changes that occur in the periphery 
are likely to be reflected in the central nervous system and vice versa. These 
paradigms will be tested in this thesis. I aim to show evidence of both 
structural and functional central nervous system changes associated with low 
back pain. Chemical plasticity is beyond the scope of this thesis and will only 
be discussed where the findings from other groups support/negate, extend or 
inform the discussions presented. I will be making reference to the body of 
work on brain-related changes in chronic pain that initially influenced this 
thesis in chapters 4 and 5. This thesis therefore aims to characterise the 
behavioural and examination correlates of CLBP (differentiating mechanical 
and neuropathic phenotypes) together with the functional and structural brain 
changes associated with the physical and emotional demands of living with 
on-going pain.  
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 Why Is It Important To Accurately Identify 1.8
Patients With Neuropathic Pain? 
A failure to identify patients with occult neuropathic symptoms is of more 
than mere academic interest. Neuropathic pain patients report significantly 
higher pain and disability scores, reduced quality of life and higher 
psychological co-morbidities compared to non-neuropathic pain patients 
(Freynhagen, Baron et al. 2006, Jensen, Chodroff et al. 2007, Smith, 
Torrance et al. 2007, Smith and Torrance 2012). Recent data suggest there 
may be a failure to identify many chronic back pain patients with a significant 
neuropathic component. Freynhagen’s and colleagues found that 37% of 
patients with CLBP attending pain management clinics in Germany had a 
significant neuropathic component to their pain. (Freynhagen, Baron et al. 
2006).  Mayne and Thacker in 2007 (personal communication), also using 
the PainDETECT questionnaire, found a significant neuropathic pain 
component in 22% (n=201) of patients with low back pain referred to 
physiotherapy at a major London NHS Foundation Trust. These figures are 
clearly higher than standard estimates for the prevalence of neuropathic pain 
in LBP (Waddell 2005), which estimate that only 5% of patients presenting 
with LBP are likely to have neuropathic pain.  
Diagnostic uncertainty is coupled with poor clinical outcomes for treatment. 
Most treatment studies show at best slight to moderate improvement in short 
term outcomes across a wide range of conservative and non-conservative 
interventions which, unfortunately, are not sustained in the long term (van 
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Tulder, Koes et al. 2006). A prolonged painful response is characteristic of 
neuropathic pain long after an initiating stimulus has passed and tissue 
healing has occurred (Woolf and Salter 2000). A failure to identify patients 
with occult neuropathic symptoms may lead to inappropriate targeted 
treatments directed towards somatic tissue, resulting in unnecessary ongoing 
pain, disability and suffering. There is therefore an urgent need to develop 
more effective assessment strategies to identify and better differentiate 
neuropathic from mechanical low back pain. Ultimately, improved diagnostic 
efficiency and more accurate differentation of mechanical and neuropathic 
LBP will lead to appropriately targeted treatment strategies and therefore 
improved outcomes. 
 Overall hypotheses of the study 1.9
 Hypothesis one: 1.9.1
There are differences between CLBP and controls across a range of 
domains: 
1. Questionnaire-based behavioural characterisation 
2. Sensory examination profiling 
3. Functional neuroimaging (ASL) 
4. Structural neuroimaging (VBM) 
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 Hypothesis two: 1.9.2
There are differences between MLBP and NuLBP  across a range of 
domains: 
1. Questionnaire-based behavioural characterisation 
2. Sensory examination profiling 
3. Functional neuroimaging (ASL) 
4. Structural neuroimaging (VBM) 
 Aims of the study 1.10
The primary aim of this study is to better characterise and clinically profile 
patients with CLBP. In particular, I wish to characterise differences between 
MLBP and NuLBP using using a battery of methodologies: Questionnaire-
based behavioural evaluation and sensory testing, structural neuroimaging 
(voxel based morphometry) and functional neuroimaging (arterial spin 
labelling). I hope to establish that these modalities have the ability to 
differentiate not only between CLBP patients and controls but importantly, 
between patients with mechanical and neuropathic chronic back pain. 
It is hoped that improved differentiation will ultimately lead to better 




 Description Of Study Chapters. 1.11
Following initial screening with painDETECT, the study will use novel 
characterisation strategies across a number of different methods to explore 
group differences: 
• Methodology (Chapter 2). This chapter outlines the overall study 
design, the specific imaging methodology and the statistical analysis 
methods used in chapters 4 and 5. 
• Questionnaire-based behavioural evaluation and sensory testing 
(chapter 3). This chapter uses questionnaire-based psychometric 
testing and sensory examination using two-point and tactile threshold 
discrimination to examine the clinical and behavioural profiles of 
CLBP. 
• Structural neuroimaging (voxel based morphometry) (chapter 4). This 
chapter uses voxel-based morphometry to analyse structural 
differences in grey matter between mechanical and neuropathic back 
pain groups and between back pain groups and controls.   
• Functional neuroimaging (arterial spin) (chapter 5). This chapter uses 
arterial spin labelling to analyse differences in regional cerebral blood 
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flow between mechanical and neuropathic back pain groups and 
between back pain groups and controls. 
• Discussion (Chapter 6). This chapter summarises key findings in the 
context of the assessment and treatment of CLBP.  
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Chapter 2 METHODS  
Preface: This chapter includes descriptions of the overall study design 
and an introduction to MRI Acquisition and MRI Statistical Analysis. Details 
are included here in order to avoid unnecessary repetition of common 
methodologies in chapters 4 and 5.  
 Study Design 2.1
 Participants 2.1.1
50 LBP patients and 20 healthy controls were recruited for all three 
components of the study (characterisation, structural and functional 
neuroimaging). Patients were recruited from the Musculoskeletal 
Assessment Service and Physiotherapy department of Guy’s and St 
Thomas’ NHS Foundation Trust. Control subjects were recruited from 
colleagues at Guy’s and St Thomas’ NHS Foundation Trust and King’s 
College. Subjects undergoing assessment at the hospital were asked if they 
would be interested in taking part in the study. If so, they were given the 
opportunity to ask questions and provided with an information sheet giving 
full details of the study. They were asked if they would agree to be contacted 
again by telephone or if they preferred, when they next visited the hospital to 
find out whether they were interested in the study and given the opportunity 
to ask any further questions. The same process was adhered to for 
colleagues recruited as controls. All subjects gave written informed consent 
on the day of scanning.  
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 Ethical Approval 2.1.2
Formal ethical approval for the study was granted by NRES (08/H0810/51). 
 Inclusion Criteria 2.1.3
All patients had LBP for at least 12 months. Patients rated their pain on an 
11 point numerical rating scale (NRS) at screening and on the day of 
scanning (anchors: 0=”no pain”, 10 “worst pain” imaginable”); all patients 
who scored 3 or greater were eligible for inclusion. All subjects were right 
handed. Initially, all patients who met the inclusion and screening criteria 
were included in the study regardless of mechanical or neuropathic status, 
as determined by the PainDETECT questionnaire. Although all patients were 
selected at random, towards the end of recruitment process it was observed 
that rather more MLBP than NuLBP patients had been recruited. It was 
therefore deemed necessary to preferentially bias selection of LBP subjects 
with symptoms that appeared, in the opinion of the clinician examining the 
patient, to suggest a significant neuropathic component, in order to balance 
patient numbers between the LBP groups. 
 Screening 2.1.4
Subjects were screened to meet safety criteria for 3T MRI scanning. Due to 
the stringent requirements of the 3T safety screening criteria, a number of 
subjects with a history of spinal, abdominal or soft tissue surgery, whom we 
were unable to provide medical notes for, were excluded from the study. 
Subjects were excluded if they complained of chronic or current pain 
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conditions other than LBP or if they were currently experiencing, or had any 
history of, clinically significant or unstable medical or psychological 
conditions that would compromise participation in the study. Altogether, 143 
CLBP subjects were approached to take part in the study. Of these, 73 were 
unable to take part due to previous or current medical history. There were no 
exclusion criteria for pain medication and all subjects continued with their 
usual medication use. A list of CLBP subjects is listed in the appendix giving 
details of medication use. Medications were grouped into the following 
categories: Paracetamol; Paracetamol combined with opiates (ie co-
codamol, co-dydramol); Opiates (ie dihydrocoedine); Non-steroidal anti-
inflamatories (ie ibuprofen, diclofenac, voltarol); Anti-convulsants (ie 
pregablin, gabapentin) and Anti-depressants (ie amitriptyline). As differences 
in medication usage might significantly affect brain morphometry and 
perfusion, Chi-square tests were used to identify differences between the 
groups in medication use. Using chi-squared tests for independence (with 
Yate’s continuity correction) no significantly different levels of medication 
usage were found between groups: NSAIDS X2 = 4.06, p = .09; paracetamol 
X2 = .031, p = 1.00; paracetamol and opiates combined X2 = .675, p = .624; 
opiates X2 = 4.71, p = .099; anti-convulsants X2 = 2.279, p = .299; anti-
depressants X2 = .273, p = .909; A list of CLBP subjects is listed in Appendix 
3, giving details of age, gender, diagnosis, medication use and any previous 
non-conservative intervention. 
Prior to scanning, all subjects underwent an initial familiarisation ‘scanning’ 
session in a ‘mock’ scanner environment, in order to minimize participant 
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anxiety and to familiarise participants with the requirements of an imaging 
environment.   
 Study Participation 2.1.5
50 LBP patients and 20 healthy controls were recruited for all three 
components of the study (characterisation, structural and functional 
neuroimaging).  
All subjects completed the questionnaire data. Due to administrative errors 
sensory testing data was not completed by three of the fifty LBP patients and 
two of the twenty controls (CLBP n = 47 (MLBP n = 24, NuLBP = 23), 
controls n= 18). 
In the structural neuroimaging VBM study, one CLBP subject and one 
healthy control were excluded as inadequate structural images were 
obtained (CLBP n = 49 (MLBP n = 26, NuLBP = 23), controls n= 19). 
In the functional neuroimaging ASL study, four CLBP subjects were excluded 
as inadequate functional images were obtained (CLBP n = 46 (MLBP n = 24, 
NuLBP = 22), controls n= 20). 
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 Imaging the Brain: Magnetic Resonance Imaging 2.2
 The Hydrogen Nucleus 2.2.1
MRI technology utilises the electromagnetic properties of hydrogen (H+) 
atoms in order to produce highly detailed images of the body’s tissues. The 
nucleus of an atom is composed of two particles – protons, which have a +ve 
charge and neutrons, which are neutral. Orbiting the nucleus are electrons, 
which have a negative charge. All the particles are in motion and spin about 
their axes. The rotation of each particle around its axis is termed its ‘angular 
momentum or ‘spin’’ and each charged particle produces a magnetic field at 
right angles to the direction of motion. This is termed its ‘magnetic dipole 
moment’ (MDM). H+ nuclei protons are used due to their abundance in the 
human body and their large magnetic moment (McRobbie, Moore et al. 2007, 
Huettel 2008, Westbrook 2011). 
 
 




 The Hydrogen Nucleus In The Magnetic Field 2.2.1.1
An MRI scanner contains a large superconducting magnet formed of coils of 
wire containing electric current. The wires are kept at 269 degrees Celsius 
below zero in liquid helium (surrounded by a thermos-type flask) to enable 
resistance in the wire to drop to zero. 
Before entering the magnetic field of the scanner, H+ protons are arranged in 
a random fashion, according to each proton’s magnetic properties. Net 
magnetization is practically zero. When a subject enters the magnetic field, 
protons within the individual become subject to the external field’s magnetic 
properties. Protons either align with the magnetic field (in classical 
mechanics, parallel, or in quantum mechanics, low energy state) or against it 
(anti-parallel or high energy state. More protons adopt the low-energy 





Figure 2: Hydrogen Nuclei 
H+ Nuclei (a) Random orientation in the absence of an external magnetic field (b) aligned paralell or 
anti-paralell to an externally applied field (B0) (from http://www.mikepuddephat.com). 
 
The greater the external magnetic field (B0), the greater the number of spins 
align in the low-energy, parallel state and the greater the net magnetization 
differential occurs between the two spin states. This is called the spin 
excess. In a field containing 10 million protons, only fractionally more protons 
will align parallel rather than anti-parallel (10,000,007/10,000,000) 
(McRobbie, Moore et al. 2007). As more protons are in alignment (parallel) 
with the B0 field there is a net longitudinal magnetisation parallel to the Z axis 
of the magnetic field (B0). 
 Precession 2.2.1.2
Each proton not only spins around its own axis but also the axis of the 
external magnetic field. This is called precession. The frequency of 
precession is determined by the characteristics of the spinning proton and 
the strength of the magnetic field. It is described by the Larmor equation 
(ReviseMRI.com.): 
ω0 = B0*y 
The symbol ω0 equals the frequency (radians per second) and γ the 
gyromagnetic constant (the ratio between the angular momentum and the 
magnetic moment specific to each element) times B0 (the external magnetic 
field). H+ nuclei have a precession frequency of 127.6 MHz in a 3 tesla (3T) 
scanner (Duggan-Jahns 2008). 
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Figure 3: Precession of the H+ nucleus in the magnetic field B0  
(from McRobbie,  Picture to Proton (2006) Cambridge University Press). 
 
 Generation Of Mri Images 2.2.2
 Resonance 2.2.2.1
In order to produce images, a radio-frequency (RF) pulse (B1) must be 
generated. The RF pulse is an oscillating electromagnetic field (radio wave), 
which is set at the same precession frequency as hydrogen H+ protons. 
Sending in a pulse at the same oscillation frequency selects H+ protons 
exclusively, as other protons have different precessional frequencies. Most 
importantly, the RF pulse causes a phenomenon known as ‘resonance’ in the 
H+ protons. When exposed to their own oscillating frequency, the hydrogen 
nuclei gain energy. H+ protons at lower thermal energies (parallel) are able 
to absorb enough energy to become high-energy protons (anti-parallel). 
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When the amount of high and low -energy protons are equal, net 
magnetization along the longitudinal axis decreases or even disappears. This 
causes a change in the net magnetization vector (NMV) from longitudinal to 




Figure 4: Change in net magnetization vector (NMV) from longitudinal to transverse.  
The net magnetic moment is flipped from the Z-axis to the x-y plane (from 
http://www.mikepuddephat.com). 
Protons now also begin to spin ‘in phase’ with each other – this is called 
phase coherence, as the MDMs of the individual nuclei precess in a 
synchronized manner. The NMV angle depends on the RF pulse strength 
and duration. The change in the NMV from a longitudinal to a transverse 
orientation is called the ‘flip angle’ and a change from longitudinal to 90 
degrees is termed a 90-degree flip angle. The transverse magnetization 
precesses around the B0 axis. The moving NMV causes an electric current, 




Figure 5: (a) Magentisation in the x-y plane (b) FID  
(from http://www.mikepuddephat.com). 
 
 After Resonance: T1 Recovery And T2 Decay  2.2.2.2
In order to generate an image, the RF pulse is switched off. The electrical 
signal induced by the transverse NMV is maximal at the instant of switching 
off the RF pulse, as the NMV is then maximal in the transverse plane at this 
point. The signal then starts to decay (‘relax’) as nuclei lose the energy 
gained by the resonance effect and start to move out of phase with each 
other once again. The gradual signal loss occurs due to two separate 
processes  – the recovery of longitudinal net magnetization (T1 recovery) 
and the decay of the transverse net magnetization (T2 decay). T1 and T2 
processes are fundamental to the generation of MRI images.  
 T1 Recovery 2.2.2.3
T1 recovery describes the rate of the gradual return to longitudinal 
magnetization (B0). When the RF pulse is switched off, the higher thermal 
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state protons (anti-parallel) release their absorbed energy to the surrounding 
‘lattice’ (the molecular environment surrounding the proton - water, fat etc.) 
and revert towards a low thermal energy, parallel state. The reabsorption of 
energy to the lattice occurs at different rates, according to the characteristics 
of the surrounding tissue. Different T1 relaxation times can be used to 
characterise different tissue types. T1 relaxation is therefore also known as 
“spin lattice” relaxation and describes the efficiency of the local environment 
for absorbing the energy of excited protons during relaxation. T1 is a time 
constant describing when 63% of the original longitudinal magnetization (B0) 
has been reached. T1 is a longer process than T2 and takes between 300-
3000 milliseconds (T2 takes between 30-150msec). 
 
Figure 6: T1 recovery. 
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Figure shows recovery of the original longitudinal magnetization (B0). T1 is a time constant describing 
when 63% original longitudinal magnetization has been reached 
 
 T2 Decay 2.2.2.4
T2 decay (also called “spin-spin relaxation”) describes loss of phase 
coherence (‘dephasing’) after the switching off of the RF pulse and the 
subsequent decay of transverse magnetization. Precession at different 
frequencies results in loss of phase coherence as the protons drift further 
apart, with a loss of transverse net magnetic vector and signal to the receiver 
coil. The greater the homogeneity in the field, the slower the decay and vice-
versa.  
 
Figure 7: T2 decay. 
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Image shows time taken for the magnetic resonance signal to decay to 37% 
of its initial value after its generation by tipping the longitudinal magnetization 
towards the magnetic transverse plane. 
 T2* Decay 2.2.2.5
Dephasing occurs due to two essential processes. Magnetic fields of 
adjacent nuclei with different precessional rates act upon each other (spin-
spin interaction) causing loss of coherence (intrinsic inhomogeneity). The 
exponential decay of transverse magnetization caused by spin-spin 
interactions to 37% of its original value is described by a time constant 
termed T2. The external magnetic field (B0) also contains variations in its 
field strength (extrinsic inhomogeneity), which causes H+ protons to have 
small variations in precessional rates according to their location in the 
magnetic field. The decay of transverse magnetisation caused by both B0 
inhomogeneity and local tissue inhomogeneity is known as T2*. This process 
occurs at a faster rate than T2 (spin/spin) relaxation alone. The Free 
Induction Decay (FID) describes the diminution of the electrical signal 
produced after the pulse is switched off. Functional imaging relies on the 




Figure 8 Transverse (T2 and T2*) relaxation processes  
Free Induction Decay (FID): Initially, there is maximum amplitude of transverse magnetization as spins 
rotate in phase. The spins begin to dephase and the amplitude of the net transverse magnetization 
decays (from: Ridgway Journal of Cardiovascular Magnetic Resonance 2010 
12:71   doi:10.1186/1532-429X-12-71). 
 
 Using T1 And T2 To Differentiate The Tissues: Contrast 2.2.2.6
Mechanisms 
T1 and T2 relaxation rates are not uniform in the body but depend on tissue 
composition (liquid or solid), structure and surroundings (Damadian and 
Cope 1974). 
With T2 relaxation, the relative inhomogeneities of the tissues influence the 
rate of relaxation. If the tissues are relatively inhomogeneous, relaxation time 
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is short. Fatty tissues demonstrate marked differences in magnetic fields 
between molecules, creating clashing magnetic fields, which cause quick 
loss of coherence. Therefore T2 relaxation for fat is quick.  
Furthermore, fat has a high efficiency for absorbing energy and therefore 
also has a short T1 relaxation time. Fat contains large molecules, which 
move relatively slowly and have a high probability for interaction with 
fluctuating magnetic fields, so energy can be transferred faster. Fat contains 
carbon bonds at the end of fatty acids with frequencies near the Lamor 
frequency, which also facilitates a quick transfer of energy. Therefore, T1 
time for fat is shorter than for liquids.  
In contrast, T2 relaxation of water is long. Water molecules are small and 
move fast, causing quickly fluctuating magnetic fields that average each 
other out. This causes no big net differences in magnetic fields and protons 
therefore stay coherent (in phase) for longer, resulting in greater T2 
relaxation times.  
Water also has a low efficiency for absorbing energy and therefore also has 
a long T1 relaxation time. Water (liquid) has many H+ atoms relative to other 
tissues (i.e. fat). Because it has many H+ atoms, it has a very strong net 
magnetization vector (i.e. it becomes very strongly magnetized). Water 
molecules are small and move rapidly making it therefore difficult for protons 
to get rid of their energy quickly. Therefore T1 relaxation for liquids is slow -
water has a long T1 relaxation time. 
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 T1 And T2 Weighting  2.2.2.7
By utilising the inherent properties of the tissues and manipulating scanning 
parameters, an image can be produced that clearly differentiates the different 
components of the tissues examined (i.e. fluid, fat, bone, white matter, grey 
matter).  
Extrinsic factors are determined by the parameters of the scanner settings. 
For instance: repetition time of one RF to the next (TR); echo time – time 
between the pulse and collection of the signal (TE); flip angle (angle of the 
NMV produced by RF pulse). Intrinsic factors relate to the inherent properties 
of the examined tissues. For instance: T1 recovery; T2 decay; proton 
density; flow and apparent diffusion co-efficient.  
 T1 Weighting 2.2.2.8
A T1 weighted image identifies CSF (and liquids) as dark and grey matter 
(and fat) as bright. It uses a short repetition time (TR) of 300-600ms. TR is a 
defining feature of T1 weighted images as the TR determines the proportion 
of longitudinal relaxation that is sampled. Therefore, a short time between 
pulses does not allow sufficient longitudinal relaxation to occur if the T1 is 
long. Water and fat both relax at different rates. If the RF pulse is resent 
quickly (TR short), fat may have relaxed completely and achieved total 
longitudinal NMV. Therefore, a marked difference in the signal intensity of 
each tissue will be recorded, according to the amount of longitudinal 
magnetisation achieved. A longer pause, however between pulses (TR long), 
allows the longitudinal NMV (T1) of both fat and water to be regained when 
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the signal is received by the receiver. An image would therefore show no 
contrast.  By also utilising a short TE, little T2 decay will have occurred 
before measurement and the image will thus depend primarily on tissue T1 
relaxation properties. 
 
Figure 9: T1 weighting 
Relative relaxation rates shown for grey matter, white matter and CSF (from http://mri-
2010.blogspot.co.uk/2010/10/october-lecture-notes-1-image-density.html). 
 
 T2 Weighting 2.2.2.9
By choosing a long TR and TE, the signal can be T2 weighted. A T2 
weighted image shows CSF as bright. A long TR allows longitudinal 
magnetisation to occur fully and therefore T1 will provide no image contrast, 
allowing imaging contrast to be determined by T2 decay factors alone. TE 
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parameters determine T2 weighting. A short TE will result in high signal 
intensity but show little contrast between the tissues, as there will not have 
been enough time for T2 relaxation to occur. An excessively long TE will 
allow contrast between the tissues but result in a very weak signal with 
excess static. The correct TE will result in optimal signal to noise ratio (SNR) 
whilst still achieving contrast. 
 
Figure 10: T2 weighting  
Relative relaxation rates shown for grey matter, white matter and CSF (from http://mri-
2010.blogspot.co.uk/2010/10/october-lecture-notes-1-image-density.html). 
 
 Uses Of T1 And T2 Scans 2.2.2.10
Both T1 and T2 weighted scans can be used for structural imaging of the 
brain. T2* weighted images are particularly relevant in functional imaging. 
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 Image Acquisition: The Spin Echo Sequence 2.2.2.11
The spin echo sequence is the most commonly used pulse sequence used to 
obtain both T1 &T2 weighted images. It is used to counteract the non-
uniformities of the magnetic field found in T2* relaxation, so that the images 
produced reflect differences in the inherent properties of the tissues alone 
without the influence of inhomogeneity of the external field.  
An initial 90-degree pulse (“excitation pulse”) is switched on, causing H+ 
protons to move in phase on a transverse plane along the X-Y axis. The 
excitation pulse is then switched off, resulting in a loss of phase coherence 
due to spin/spin relaxation. Protons fan out at different rates due to external 
and internal magnetic inhomogeneities. A 180-degree pulse along the Y axis 
(“refocusing pulse”) is then switched on at TE/2, which causes the protons to 
now precess in the opposite direction towards the beginning point. Protons 
precessing at the fastest rates will now be the furthest away. The protons 
return at the same precessing rates as they went away at, so eventually they 
all arrive back at the same point in phase. This can be likened to an echo 
bouncing back off a wall and the sequence is therefore called a spin echo. 
The signal intensity recorded when H+ protons arrive back at the starting 
point therefore depends solely on the inherent properties of the tissue itself 
and not on magnetic inhomogeneities of the external field.  
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Figure 11: Spin echo sequence  
(http://en.wikipedia.org/wiki/File:Spin_Echo_Diagram.jpg). 
 
The process may be repeated in an on-going fashion. Fast Spin Echo (FSE) 
makes use of multiple 180-degree pulses. Signal intensity declines after 
each RF application due to internal T2 effects. The curve connecting the 
declining signal intensities describes a curve known as the T2 curve.  
A weakness of spin echo sequences is the necessity of a long repetition time 
(TR). Reducing the TR would result in faster imaging. However, shortening 
the TR leaves little time for longitudinal magnetisation to recover, resulting in 
less transverse magnetisation with each successive flip and therefore 
successively less signal intensity.  
 Image Acquisition: The Gradient Echo Sequence 2.2.2.12
A different approach is to use a magnetic field gradient instead of a RF pulse 
to dephase the spins, which results in considerably faster imaging times. 
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Initially, a RF pulse is applied using smaller flip angles (10-35 degrees). As a 
result, the longitudinal magnetisation does not totally disappear when the 
next pulse is applied.   
 
Figure 12: Fig 6; Gradient Echo Sequence  
(http://bitc.bme.emory.edu/seq_dia.html). 
 
Immediately thereafter, a magnetic field gradient is applied, containing an 
uneven (small and large) magnetic field, superimposed over the existing B0. 
This causes greater inhomogeneity in the external magnetic field (in addition 
to the existing inhomogeneity of the external field and the local tissues) with 
subsequent quicker dephasing of protons and decay of transverse 
magnetization. To reverse the spin dephasing, the magnetic gradient is then 
turned off and turned on in its opposite direction, causing protons that were 
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precessing at quicker rates in a strong field to suddenly be exposed to weak 
fields and therefore move slowly (and vice-versa). Rephasing occurs again to 
give a maximum signal at the end of the opposite gradient pulse. 
 Obtaining The Final Image: Magnetic Field Gradients 2.2.2.13
In order to generate a spatially specific final image in three dimensions so 
that the MR signal can be anatomically localised, three magnetic gradient 
fields (in 3 planes) are superimposed on the existing longitudinal magnetic 
field (B0). These are termed the i) Slice selection gradient, ii) Frequency 
encoding gradient, iii) Phase encoding gradient. 
 Slice Selection Gradient  2.2.2.14
To select a slice perpendicular to the z-axis (for example), a magnetic 
gradient is applied along the z-axis (from head to toe), resulting in differing 
magnetic field strengths, causing protons to precess at different frequencies. 
A RF pulse (called the selective pulse) is then applied at the particular 
frequency of the gradient to be examined. The selective pulse causes 
transverse magnetization only of the protons with the same precessing 
frequency as the pulse and therefore does not affect protons either side of it, 
which have a different precessing frequency due to the magnetic gradient. 
Slices of varying thickness can be obtained by altering the bandwidth of the 
RF pulse (to accommodate more or less of the gradient) or by modifying the 
steepness of the gradient field. A larger gradient allows more variation in 
gradient from head to toe, greater variation of precessing frequencies and 
subsequent choice of selective pulses.  
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 Frequency-Encoding Gradient  2.2.2.15
The selective pulse produces rows and columns of protons all precessing in 
phase at the same frequency. In order to localise signal within a slice, a 
further magnetic gradient is delivered across the slice (i.e. from L to R) called 
a frequency-encoding gradient. This causes the columns of protons to 
dephase at different speeds according to where they are in the gradient (i.e. 
from L to R).  
 Phase-Encoding Gradient 2.2.2.16
 In order to localise to the exact location of each proton within a column, 
another magnetic gradient field is delivered, known as the phase encoding 
gradient. This results in different precessing frequencies up and down the 
column (see previous paragraph). When this gradient is switched off, the 
nuclei now precess at a regular Lamor frequency in line with B0 but are out of 
phase with other nuclei along the gradient. This allows each protons to now 
be individually identified (Westbrook 2011). 
 K-Space 2.2.2.17
The raw data is acquired (then digitized by the receiver) and stored in a 
temporal domain commonly called ‘k-space’.  K-space is an array of complex 
numbers of signal intensities encoded by the gradients discussed above. 
Storage in k-space is determined by the matrices of the frequency and 
phase-encoding gradients. Low frequency information in the centre of k-
space stores information on contrast and larger structures, whereas higher 
frequency information located at the edges of k-space represents finer detail 
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and smaller structures. Fourier transformation mathematics, which transform 
the spatially encoded frequencies stored in k-space allow us to reconstruct 
the data into the ‘image space’ with contrast determined by our choice of 
scanning parameters (Bracewell 1986, Gallagher, Nemeth et al. 2008) 
 Statistical analysis 2.3
 Statistical Parametric Mapping (Spm)  2.3.1
Statistical Parametric Mapping (SPM) refers to the construction of spatially 
extended statistical processes used to test hypotheses about regional 
specific effects in imaging data (Friston, Frith et al. 1991). In this thesis, SPM 
refers to the implementation of these voxelwise statistical processes using 
‘SPM’ software (http://www/fil.ion.ucl.ac.uk/spm), however alternative 
software packages for example the ‘FMRIB Software Library (FSL)’ and 
‘Analysis of Functional Neuroimages (AFNI)’ are built upon similar spatial 
statistical frameworks. SPMs can be used to examine volumetric, and 
functional activation differences between groups or experimental states 
within-group using voxelwise (mass-univariate) independent statistical tests 
on every single voxel to produce probability density function maps under the 
null hypothesis (T- or F-maps) that are fashioned into an image or ‘map’. 
SPM maps are often interpreted by referring to the probabilistic behaviour of 
Gaussian random fields (Worsley and Friston 1995).  
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 The General Linear Model 2.3.2
The General Linear Model (GLM) is a statistical model used in the analysis of 
MRI data, which attempts to model the scanner data into components of 
interest, confound and error. The GLM encompasses common statistical 
tests used in MRI such as t-test, analysis of variance (ANOVA) and multiple 
regression analysis. It makes inferences about the effects of interest in 
relation to the error variance, in order to arrive at an F statistic or similar 
estimate of probability (for a review, see http://www.fil.ion.ucl.ac.uk/spm and 
(Smith 2004)).  
The GLM can be expressed as a formula (employed at every voxel): 
Y = Xβ + c + e 
Y is the observed data from the scanner (dependent variable), measured as 
intensity at every voxel. X are regressors (dependent or predictor variable), 
which represent the experiment design variable. Regressors of interest are 
variables expected to explain the data (ie the experimental manipulation). 
Regressors of no interest (nuisance variables) are confounding variables that 
are not part of the experimental design or variables beyond reasonable 
experimental control (for example, head motion, age, gender). β is the 
estimated parameter value (i.e. the optimal value required to make X fit to Y, 
such that the error e is minimised). The error or ‘residual’ term, e is the 
difference between the observed data, Y, and that predicted by the model, 
Xβ. c is a constant term that expresses the value of the intercept.The optimal 
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parameter estimates, β, are found by minimising the sums of squared 
differences between the predicted model and the observed data. To put it 
simply, the best estimates β are those that minimise the amount of 
unexplained data in the model.  
In standard MRI analysis the GLM is represented by a design matrix 
expressed as a series of columns, each containing a regressor (explanatory 




Figure 13: VBM design matrix. 
The X axis describes the three groups in the study and two regressors (age and gender). The Y-axis 
relates to each individual subject’s scan. The relative contributions of the regressor of each subject are 
expressed by the intensity of shading. For instance, relative age is from light grey to black whereas 
gender is expressed in tow tones only.  
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Parameter estimates β are compared with the uncertainty in their estimation 
in order to arrive a T value for each voxel. The T value is the parameter 
estimate (PE) divided by the standard error (SE). High or low values of the 
PE in relation to its estimated uncertainty will give high or low T values 
respectively. In the simplest case of a one-sample t-test, the value of T is an 
indicator of how likely the PE is to be significantly different from zero (i.e. 
whether there is significant activation in an fMRI task, CBF change in an ASL 
investigation or a tissue volume difference in a VBM study). 
 Creation Of Contrasts 2.3.3
Parameter estimates can be used to test the relevant contributions of one 
regressor in a model compared to another by simple subtraction of one 
regressor to another compared to their combined standard error. These ‘so-
named’ ‘contrasts of parameter estimates’ or ‘contrasts’ are expressed in 
SPM as a simple [-1, +1]. A T-statistical map is then generated, which 
graphically represents the distribution of differences between regressor 1 
and regressor 2 across the volume of interest (Smith 2004). 
 Inference  2.3.4
Having obtained a statistical T map composed of scores for every voxel in 
the brain, it is then necessary to set a statistical threshold, at a given level of 
significance (Z or p-value), in order to make inferences as to which parts of 
the brain show significant activation (or in VBM, which voxels show 
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significant GM loss or gain). An inference is made that voxels with T scores 
above a stated threshold will reject the null hypothesis.  
Three levels of inference are available for whole brain MRI analysis: set-
level, voxel-level and cluster-level (Poldrack 2011). Set-level inference 
merely states if there are clusters in the T map that pass significance 
according to the p-value. Cluster-level significance is determined by the 
number of contiguously activated voxels in an area (spatial extent) and to 
some extent the peak height, and therefore gives sensitivity to spatially 
extended signals (Friston, Holmes et al. 1996, Poline, Worsley et al. 1997) 
compared to voxel-level inference, where the peak height alone is the 




Figure 14: Voxel-level versus cluster-level inference.  
The above image illustrates voxel-level inference - two voxels are identified above a significance 
threshold and both are marked as significant. The image below illustrates cluster-level inference  - a 
series of voxels is identified as a significant cluster although none would pass significance based on 
height threshold alone (adapted from (Poldrack 2011). 
 
 Multiple Comparisons Correction  2.3.5
Conventionally, the statistical significance level is set at 5% (p value of 0. 
05). Setting a p-value of 0 05 assumes that there is 5% probability that the 
same result could happen by chance, giving a false positive result (Type-1 
error). Therefore, a T score with an associated significance level of 0.05 %, 
applied to a mass-univariate statistical analysis of MRI data involving 
100,000 voxels, is liable to introduce approximately 5000 false positive 
voxels (even if the null hypothesis is accepted). With an abundance of false 
positive data, how can a threshold be set that allows confidence that the 
suprathreshold voxels are not merely due to chance? Statistical correction is 
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therefore necessary to account for Type-1 error when dealing with multiple 
statistical comparisons in MRI analysis (Bennett, Wolford et al. 2009, 
Poldrack 2011). 
 Bonferroni Correction 2.3.5.1
The standard statistical approach to multiple testing is to correct the p-
thresholds to account for how many tests are being done. For instance, 
Bonferroni correction works by dividing the desired p value by the number of 
comparisons. For analysis of 100,000 voxels, this arrives at 0.05/100,000 = p 
< 0.0000005 at every single voxel. The Z score associated with this p-value, 
which we would use as a threshold, would be very large. Whilst this 
undoubtedly controls the occurrence of false positives, it is far too stringent 
(conservative) and is liable to result in type II errors (false negatives) with 
loss of significant data (Jezzzard 2001, Smith 2004, Lindquist 2008).  
 Spatial Correlation Of Data  2.3.5.2
Bonferroni correction requires data (voxels) to be independent of each other 
(and therefore that tests performed and resulting z scores are independent of 
each other). Spatial correlation of MRI data violates this assumption. MRI 
data is frequently spatially correlated, in that data from one voxel will tend to 
be similar to data from nearby voxels. This is due to several factors including: 
(i) spatial smoothing of data, which reduces the number of independent data 
points by averaging across voxels; (ii), the likelihood that contiguous voxels 
frequently work together in group activation; (iii) partial voluming effects due 
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to re-slicing of images during pre-processing causing smoothing across 
voxels  
 Gaussian Random Field Theory (GRF) And Family-Wise Error: 2.3.5.3
Bonferroni correction is calculated based on the number of truly independent 
voxels. If one were able to calculate the true number of independent voxels, 
it would be possible to use Bonferroni.  However it is not possible to work out 
how many independent observations there are in smoothed data. Commonly 
in analysis of neuroimaging data an alternative method, named Gaussian 
Random Field theory (GRF) is adopted as an approach to overcome the 
multiple comparisons problem (Worsley, Evans et al. 1992).  
GRF estimates the number of resolution elements (resels) in smoothed data. 
A resel is essentially a cube of voxels of the same size as the full width half 
maximum (FWHM) Gaussian kernel used to smooth the data. The resel 
count is used to estimate how many significant clusters should be found 
according to chance at a given statistical threshold; this is known as the 
expected Euler characteristic (EC). When the statistical threshold is set high, 
the EC will be correspondingly low. The expected EC is a good 
approximation of the probability of observing one or more clusters at a 
certain threshold. For instance, a Z score of x that gives an EC of 0.05, 
indicates that any clusters passing threshold will have a probability of less 
than or equal to 0.05 of having occurred by chance. Although GRF can be 
thought of as a Bonferroni-type correction that allows for multiple non-
independent tests due to spatial correlation (smoothness) it is not the same 
and GRF produces corrections that are more liberal.  
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 Non-Stationary Cluster Extent Correction 2.3.5.4
Gaussian Random Field theory performs statistical corrections based on the 
assumption that data is uniformly smooth across the whole brain in a 
Gaussian distribution. GRF theory is valid for corrections based on peak 
heights (voxel-wise) but not for corrections based on cluster extents, due to 
anisotropic smoothness of the data, which is non-stationary (i.e. not the 
same) across regions of grey matter (GM) and white matter (WM).  
Assumptions of stationary smoothness produce invalid cluster-level statistics 
- cluster sizes will be overestimated in smooth areas (type 1 error) and 
underestimated in rough areas (type 2 error) (Worsley and Friston 1995, 
Hayasaka and Nichols 2004). This has lead to recommendations to abandon 
the use of cluster-size tests in VBM (Ashburner and Friston 2000). In fact, 
the assumption of stationarity in fMRI data has also been questioned 
(Hayasaka, Phan et al. 2004). 
Therefore, in order to arrive at valid cluster size statistics, we have adopted 
the method proposed by Hayasaka et al (Hayasaka, Phan et al. 2004) to 
correct for issues of non-stationarity, using the toolbox developed for the 




Chapter 3 CHARACTERISATION OF 
CHRONIC LOW BACK PAIN: BEHAVIOURAL 
EVALUATION AND SENSORY EXAMINATION 
 Introduction 3.1
I will adopt a model of pain throughout this thesis which is centred not only 
on the sensory-discriminative experience of the patient but also on cognitive-
evaluative, and affective-motivational mechanisms, rather on pathological 
mechanisms alone. The experience of pain is more than purely sensory; pain 
incorporates cognitive and emotional aspects, which mediate the distress felt 
by sufferers of chronic pain. This distress, which includes psychological 
components of increased anxiety, bodily awareness, and depression, may in 
itself, increase and perpetuate chronic pain (Lumley, Cohen et al. 2011).  
 Body Identity And CLBP 3.1.1
It has been claimed, however, that the study of the psychology of pain has 
neglected the body, preferring to concentrate on the mind as a ‘disembodied’ 
abstract concept (Kelly and Field 1996). Unlike other forms of sensory 
stimuli, which are experienced externally, pain is experienced within the 
body: embodiment.is central to notions of self-identity, self-agency and self-
worth (Corbin 2003, Osborn and Smith 2006) - “The body is the embodiment 
of who we are” (Corbin 2003). In a study asking patients to describe their 
experience of CLBP, subjects contrasted a ‘previous’ body associated with 
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their ‘original’ healthy self, with a ‘new’ dsyfunctioning body associated with 
their present identity as a sufferer of CLBP. Previously, when pain free and 
fully functional, patients reported being largely unaware of, and uninterested 
in, the internal workings of the body. However, the painful ‘new’ body had to 
be constantly assessed and monitored; activities of daily living had gone 
from being effortless and thoughtless to “planned, fearful and threatening” 
(Osborn and Smith 2006). The authors suggested patients’ experience was 
akin to Pincus and Morley’s concept of “enmeshment”, in which pain in the 
body became entangled with a rejected and negative view of the self, 
forming an “enmeshment” from which the patient could not free themselves 
(Pincus and Morley 2001). 
 CLBP Sufferers Experience A Fundamental Change In 3.1.2
Relationship With Their Body 
CLBP sufferers experience a fundamental change in relationship with the 
“new” body. In spite of the novel attention to the workings of the body, 
patients paradoxically report feeling alienated from the ‘new’ body. The 
painful back feels different to the rest of their body, as if it was not working 
for them, even that it no longer felt part of them. Patients had a concept of 
their ’best/preferred self’ from which they were alienated or excluded. 
Alienation from, or rejection of, certain body parts (neglect) is a common 
symptom of overt neurological damage such as stroke. Patients demonstrate 
little appreciation of the shape, contour and position in space of their own 
bodies (Husain 2008). Neglect-like symptoms have also been reported in 
other chronic pain conditions (Galer and Jensen 1999, Schwoebel, Friedman 
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et al. 2001, Flor, Nikolajsen et al. 2006, Frettloh, Huppe et al. 2006, Lewis, 
Kersten et al. 2007, Vartiainen, Kirveskari et al. 2009, Lewis, Kersten et al. 
2010, Foell, Bekrater-Bodmann et al. 2013) including LBP (Moseley 2008, 
Moseley, Gallagher et al. 2012).  
 Altered Body Schema And Disruption Of Cortical Maps 3.1.3
Are Seen In CRPS, PLP And CLBP 
Neglect-type symptoms and changes in perceptual disorders imply 
accompanying neuroplastic changes to the central nervous system. Normal 
body schema is dependent on both regular somatosensory and 
proprioceptive input and motor output. In CRPS and PLP, altered afferent 
input, both painful and non-painful, is linked to disruption of motor (M1) and 
sensory (S1) cortical representational maps (Moseley and Flor 2012). Similar 
disruption of cortical representational maps are seen in CLBP using 
magnetoencephalography (MEG) (Flor, Braun et al. 1997) and fMRI (Lloyd, 
Findlay et al. 2008). Both studies show a medial shift in the representation of 
the back in the somatosensory cortex suggesting a functional neuroplastic 
alteration. 
 Changes In Body Schema Are Associated With 3.1.4
Alterations In Two-Point Discrimination (2PD) In CRPS, 
PLP And CLBP  
Changes in tactile acuity (defined as “the keenness or sharpness of the 
sense of touch, usually measured by the two-point threshold” (Colman 
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2008)) have been demonstrated in patients with a variety of chronic pain 
conditions (Flor, Denke et al. 2001, Wand, Di Pietro et al. 2010, Stanton, Lin 
et al. 2013). Studies, using a variety of methods (MEG, EEG 
(electroencephalography) and fMRI show that alterations in 2PD are 
associated with changes in representational maps in the motor and 
somatosensory cortex, in patients with CRPS (Flor 1995, Juottonen, Gockel 
et al. 2002, Maihofner, Handwerker et al. 2003, Pleger, Tegenthoff et al. 
2004, Maihofner, Forster et al. 2005) and PLP (Flor, Elbert et al. 1995, Lotze, 
Flor et al. 2001).  
Two-point discrimination (2PD) is the most widely used test in the 
assessment of tactile acuity. Traditionally, the test is thought to measure the 
density of nerve fibre regeneration after injury (Weinstein 1993) in particular 
the concentration of slowly adapting type 1 fibres, which are selectively 
sensitive to spatial discontinuities (Johnson and Hsiao 1992). However, 
advances in the understanding of supraspinal plasticity in relation to 
somatosensory cortical representation have suggested alternative uses for 
2PD testing. It has been noted that in normal subjects, there is a wide 
variation of normative values for 2PD discrimination throughout the body, 
from 2-4mm on the fingertips to 50mm or more on the trunk (Nolan 
1985).These variations reflect not only peripheral innervation density but also 
representational maps in the somatosensory cortex; areas with reduced 
innervation density (and therefore large 2PD thresholds) also demonstrate 
reduced representation of the body part in the S1 somatosensory cortex 
(Kandel 2012). Furthermore, 2PD thresholds are sensitive to training effects. 
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Healthy individuals demonstrate decreases in 2PD thresholds after only a 
few hours of training (Godde, Stauffenberg et al. 2000). It is therefore highly 
unlikely that observed changes in sensory thresholds are due to in changes 
in sensory receptive field density due to neurogenesis. Rather, it has been 
suggested that changes in 2PD thresholds are more likely due to central 
nervous system neuroplasticity of cortical representational maps. 
Enlargement of cortical representation of the index finger has been shown 
after a short period of 2PD training (Pleger, Dinse et al. 2001, Godde, 
Ehrhardt et al. 2003). Pharmacological modulation with both memantine and 
methamphetamine (NMDA receptor agonist and anatagonist respectively) 
correlates with representational changes in the S1 cortex, suggesting a 
synaptic basis for the change in these receptive fields (Dinse, Ragert et al. 
2003). Furthermore, reorganisation of S1 representational maps correlates 
not only with the intensity of pain (Flor, Elbert et al. 1995, Maihofner, 
Handwerker et al. 2003, Maihofner, Forster et al. 2005) but has also been 
shown to correlate with alterations in tactile acuity (Pleger, Tegenthoff et al. 
2005, Pleger, Ragert et al. 2006).  
Chronic low back pain is also associated with disturbances of sensory 
perception. Initial data suggest that CLBP patients report significantly larger 
2PD thresholds than controls on the lumbar spine, although normal 2PD 
thresholds are found elsewhere on the trunk and tactile thresholds are 
unaltered (Moseley 2008, Wand, Di Pietro et al. 2010, Luomajoki and 
Moseley 2011). As yet there is no data directly linking alterations in sensory 
discrimination in CLBP with altered cortical representation. I have therefore 
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chosen to use 2PD as a methodology to assess the impact of CLBP on 
supraspinal somatosensory representation. Later chapters in this thesis will 
assess the neural correlates of these examination findings utilising 
neuroimaging methodologies. 
 Proprioceptive And Motor Control Disorders Are Also 3.1.5
Associated With Altered Two-Point Discrimination In 
CLBP 
Proprioceptive deficits and motor control disorders are frequently seen in 
patients with CRPS and PLP (Anderson-Barnes, McAuliffe et al. 2009, van 
Rijn, van Hilten et al. 2009). It has been suggested that these deficits are 
related to altered central processing of proprioceptive information (Bank, 
Peper et al. 2013). Deficits in motor control, muscle activation and poor 
proprioceptive acuity of the lumbo-pelvic region, frequently seen clinically in 
CLBP patients, (for a review see (Hodges and Moseley 2003)) also show a 
close association with increased 2PD thresholds on the back (Moseley 2008, 
Wand, Di Pietro et al. 2010, Luomajoki and Moseley 2011). These changes 
have been linked to changes to M1 representational maps (Tsao, Galea et 
al. 2008, Tsao, Danneels et al. 2011, Wand, Parkitny et al. 2011). As yet 
there is no data directly linking proprioception and motor dysfunction in CLBP 
with altered cortical representation.  
Furthermore, not only are CLBP patients unable to perform proprioceptive 
tasks skillfully, they also demonstrate less skill than controls in recognising 
the movement orientation of others, in common with patients with CRPS. 
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CRPS patients perform poorly on a hand laterality recognition task, which 
has been proposed to be related to disrupted body schema, and altered 
cortical networks (Moseley 2004). In a similar experiment with CLBP 
patients, subjects were unable to accurately judge the direction of trunk 
rotation (left or right) adopted by a model. The degree of accuracy was 
related to the spread of patients’ lower back pain. In patients, accuracy for 
left/right trunk rotation judgment was 53.4% (44.5% to 62.3%) and 67.2% 
(60.2% to 74.1%) for those with bilateral and unilateral presentations 
respectively. Pain-free control participants were able to distinguish left and 
right with an accuracy of 87% (75-98%). All three groups were highly 
accurate in a left/right-hand identification task (“about 83% of the time”), 
which indicates that disruption of the body schema is most likely specific to 
the condition and to the area of dysfunction (Bray and Moseley 2011). 
 Perceptual Challenges In CLBP 3.1.6
In addition to perceptual difficulties in recognising the movement orientation 
of others, there is evidence that CLBP patients may face perceptual 
challenges related to their own bodies. Many patients who have suffered 
overt neurological damage such as stroke (and frequently conditions such as 
CRPS and PLP) demonstrate little appreciation of the shape, contour and 
position in space of their own bodies (Moseley 2008) Some CLBP patients 
also report similar symptoms, in not being able to recognise their back as a 
part of themselves - “not me” (Osborn and Smith 2006).Some CLBP patients 
are also unable to clearly delineate the outline of their own back when asked 
to draw it. Importantly, association was found with poor tactile acuity 
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measured using two point discrimination supporting the potential importance 
of this sensory testing modality to reveal supraspinal representational 
change (Moseley 2008).  
It has been proposed, therefore, that the changes outlined above, provide 
evidence that CLBP is linked to disruption of the virtual representation of the 
body in the motor and sensory cortex, and that CRPS and CLBP may 
therefore share similar neural mechanisms (Luomajoki and Moseley 2011). 
 What Factors Underlie Alterations In 2PD And 3.1.7
Representational Change? 
It, is unclear, however, what factors underlie representational change. It 
appears unlikely that the mechanism for 2PD is due to disrupted or delayed 
transmission along the neuraxis, as transmission of normal cutaneous input 
to S1 in CLBP patients is unaffected (Flor 2003). Tactile thresholds are also 
normal (Moseley 2008, Wand, Di Pietro et al. 2010). It has been suggested 
that poor 2PD performance may be due to central sensitization mechanisms 
causing spinally-evoked noxious input to result in supraspinal noise and a 
loss of normal inhibition (Luomajoki and Moseley 2011). Therefore, I suggest 
that increased 2PD thresholds on the trunk in CLBP are most likely linked to 
reorganization of representational maps that have been shown in CLBP and 
also in PLP and CRPS. 
Relationships between 2PD, representational change and components such 
as pain intensity, chronicity, emotions, cognitions, medication or lifestyle 
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changes are difficult to establish and there is a lack of consistency amongst 
studies in reporting these relations. For instance, although representational 
change in below-level spinal cord injury (SCI) injury pain correlates with pain 
intensity (Wrigley, Press et al. 2009) others studies have found that changes 
relate not to pain intensity but to chronicity instead (Lotze, Laubis-Herrmann 
et al. 2006). Similarly, studies have shown that alterations in S1 
representation of the affected limb in CRPS (Maihofner, Handwerker et al. 
2003, Pleger, Tegenthoff et al. 2004) and PLP (Flor, Elbert et al. 1998, 
Grusser, Winter et al. 2001, Karl, Birbaumer et al. 2001) are associated with 
pain intensity. Furthermore, normalisation of the cortical representation of the 
1st and 5th fingers in CRPS (Maihofner, Forster et al. 2005) and of the lip and 
hand areas in PLP is associated with reduction of pain in fMRI studies 
(Lotze, Flor et al. 2001). In CLBP, however, the medial shift of the trunk, 
reported by Flor in 1997 was associated with pain duration and not intensity 
(Flor, Braun et al. 1997). Further analysis of the neural mechanisms 
underlying CLBP and relationships with psychological and sensory 
discriminative examination variables is needed. 
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 Chapter Summary 3.1.8
The purpose of this chapter is to quantify the emotional-motivational, 
cognitive-evaluative and sensory-discriminative characteristics of CLBP 
patients compared to controls and, in particular, NuLBP and MLBP 
subgroups using questionnaire-based evaluation and clinical examination of 
tactile acuity. There are five main hypotheses to be tested in this study: 
1) Patients with CLBP exhibit greater psychological distress compared to 
controls 
2) Patients with NuLBP complain of greater pain and psychological distress 
compared to MLBP patients 
3) CLBP patients demonstrate altered two-point sensory discrimination 
thresholds and tactile thresholds of the lower back compared to controls 
4) NuLBP exhibit altered two-point sensory discrimination thresholds and 
tactile thresholds compared to MLBP patients  
5) Deficits in sensory discrimination are related to the severity and/or 




 Methods  3.2
 Psychometric And Behavioural Data 3.2.1
The following questionnaires were administered in order to assess pain and 
psycho-physical status: Numeric rating scale (NRS) for pain, Short Form 
McGill Pain Questionnaire (SFMPQ) (Melzack 1987), RAND Medical 
Outcomes 36-Item Short Form Survey Instrument (SF-36) (Ware and 
Sherbourne 1992), Centre for Epidemiologic Studies Depression Scale 
Questionnaire (CES-D) (Radloff 1977); State Trait Anxiety Inventory (STAI) 
(Spielberger 1983), Revised Symptom Checklist 90 Questionnaire (SCL-90-
R) (Derogatis and Unger 2010), Eysenck Personality Questionnaire (revised 
version) (EPQ-R) (Eysenck, Eysenck et al. 1985), painDETECT 
Questionnaire (Freynhagen, Baron et al. 2006). 
 Numeric Rating Scale (NRS) For Pain 3.2.1.1
All patients had LBP for at least 12 months. Patients rated their pain on a 
numerical rating scale (NRS) at screening and on the day of scanning. The 
NRS is an 11 point numeric version of the visual analog scale (VAS) in which 
a subject chooses a whole number between 0 -10 that corresponds to the 
intensity of their pain. The numbers are arranged along a horizontal line and 
anchored by the terms 0=“no pain” to 10 “maximum pain”. The NRS is used 
widely in chronic pain studies due to its brevity and ease of use for patients 
(Farrar, Young Jr et al. 2001).  
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 Short Form Mcgill Pain Questionnaire (SFMPQ) 3.2.1.2
The SFMPQ is a multidimensional measure of pain, which has been modified 
from the original version of the McGill Pain Questionnaire (Melzack 1987). It 
is composed of eleven sensory and four affective pain descriptors, rated on 
an intensity scale from 0 (none) to 4 (severe). The two-factor structure has 
been cross-validated in a large sample of CLBP patients (Beattie, Dowda et 
al. 2004). It also includes a 10-cm visual analogue scale (VAS) and a five-
item present pain intensity scale (PPI) to describe overall pain intensity (Turk 
and Melzack 2011). It has had widespread use in adult chronic pain 
populations, including CLBP (Ruoff, Rosenthal et al. 2003) and has modest 
predictability in discrimination of neuropathic and musculoskeletal pain of 
spinal cord injury (Putzke, Richards et al. 2002).  
 Rand Medical Outcomes 36-Item Short Form Survey Instrument 3.2.1.3
(SF-36) 
The SF-36 uses 36 questions to assess eight health concepts (Ware and 
Sherbourne 1992): 1) limitations in physical activities because of health 
problems (SF-36 Physical Function); 2) limitations in social activities because 
of physical or emotional problems (SF-36 Social Function); 3) limitations in 
usual role activities because of physical health problems (SF-36 Role-
Physical); 4) bodily pain (SF-36 Pain); 5) psychological distress and 
emotional well-being (SF-36 General Mental Health); 6) limitations in usual 
role activities because of emotional problems (SF-36 Role-Emotional); 7) 
energy and fatigue (SF-36 Vitality); 8) general health perceptions (SF-36 
General Health). For each of the eight domains an aggregate percentage 
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score is produced. The percentage scores range from 0% (lowest or worst 
possible level of functioning) to 100% (highest or best possible level of 
functioning). Two summary scores of physical quality of life (Physical 
Component Summary; PCS) and psychological well-being and general 
health perception (Mental Component summary; MCS) can also be obtained 
by combining physical and mental domains respectively (Ware, Kosinski et 
al. 1995). PCS and MCS scales are scored to have the same average (50) 
and standard deviation (10) (norm-based scores). Therefore scores below 
and above 50 represent above and below average values of physical and 
mental health and functioning with increasingly low scores represent 
increasing degrees of psychological distress and disability (Ware 1993). A 
cut off score of 35 or less on the MCS is able to identify depressive 
symptoms (as measured by the CES-D) in LBP patients (Walsh, Homa et al. 
2006). 
 Centre For Epidemiologic Studies Depression Scale 3.2.1.4
Questionnaire (CES-D) Questionnaire  
The CES-D is a 20-item questionnaire of symptoms associated with 
depression (Radloff 1977) that demonstrates good sensitivity and specificity 
and high internal consistency (McDowell 2006). Scores range from 0 to 60, 
with high scores indicating greater depressive symptoms. It cannot be used 
to diagnose depression in itself. However, scores of 16 or greater can be 
used to identify individuals at risk for clinical depression in primary care and 
19 or greater in the chronic pain population (Turk and Okifuji 1994).  
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 State Trait Anxiety Inventory (STAI) 3.2.1.5
The STAI is a 40-item questionnaire that measures two components of 
anxiety: Anxiety in the present moment (“state”) and anxiety as a general, 
ongoing personal characteristic (“trait”). Twenty questions are each scored 
on a four point Likert scale and higher scores are associated with higher 
levels of anxiety. The STAI has good reliability, validity, and sensitivity 
(Quek, Low et al. 2004). CLBP subjects have previously demonstrated 
increased trait anxiety levels compared to acute LBP subjects (Newcomer, 
Shelerud et al. 2010). Fear avoidance beliefs have also been associated with 
anxiety and CLBP (Gatchel, Polatin et al. 1995, da, Maher et al. 2012). 
 Revised Symptom Checklist 90 Questionnaire (SCL-90-R) 3.2.1.6
The SCL-90-R is a 90-item questionnaire designed to assess a broad range 
of psychological problems and the current psychopathology of subjects along 
nine symptom constructs; Somatization, Obsessive-Compulsive Symptoms, 
Interpersonal Sensitivity, Depression, Anxiety, Hostility, Phobic-Anxiety, 
Paranoid Ideation and Psychoticism). Three additional scales have also been 
developed; the Positive Symptom Total (PST) measuring the total number of 
self reported symptoms, the Positive Symptom Distress Index (PSDI) 
measuring intensity of symptoms and the Global Severity Index (GSI), 
designed to measure overall psychological distress which can be used as a 
summary of the test (http://www.pearsonassess.ca).  The SCL-90-R has 
been widely used in CLBP (Bernstein, Jaremko et al. 1994, Viniol, Jegan et 
al. 2013). 
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 Eysenck Personality Questionnaire (EPQ) 3.2.1.7
The Eysenck Personality Questionnaire  (revised) (EPQ-R) is a one hundred 
yes/no question scale that measures personality in three dimensions; 
extraversion/introversion, neuroticism/stability, psychoticism/socialization 
(Eysenck, Eysenck et al. 1985). It has been widely used in a variety of 
medical and psychiatric settings. The neuroticism and extraversion scales of 
the EPQ-R show very good internal consistency and consistency over time 
although the psychoticism scale is characterized by a somewhat lower 
internal consistency (Irving B. Weiner 2010) 
Extraverted individuals with high EPQ-R-E scores tend to be outgoing, 
impulsive and uninhibited. They enjoy socialising and dislike solitary pursuits. 
They tend to be active, seek out excitement and enjoy group activities. 
Individuals with high neuroticism scores (EPQ-R-N) tend towards emotional 
lability and often complain of generalised anxiety and worries and negative 
emotions. They may complain of ongoing somatic symptoms. Individuals with 
high psychoticism scores tend towards hostility and aggression towards 
others with a lack of empathy. However high scores do not in themselves 
imply that the individual is psychotic in the full-blown psychiatric sense of the 
term, solely that the individual has tendencies in that direction and therefore, 
the term “tough-mindedness” is often substituted. The neuroticism and 
extraversion scale s of the EPQ-R show very good internal consistency and 
consistency over time although the psychoticism scale is characterized by 
lower internal consistency.  
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 Clinical Examination: Sensory Testing 3.2.2
2PD and TTD (Tactile threshold discrimination) testing was carried out on all 
subjects. Participants were positioned comfortably in prone lying with a pillow 
underneath the stomach to standardise lumbar position. Using a common 
palpation procedure, the examiner marked the spine in line with the spinous 
processes of L1, L3 and L5 bilaterally in line with the inferior angle of the 
scapula. 
The same assessor (the author) examined all subjects in order to reduce the 
inter-rater variability inherent in these techniques (see (Catley, Tabor et al. 
2013). Testing was undertaken separately on left and right sides of the back 
and the order of testing was randomised, as was the order of levels tested. 
 Tactile Threshold Discrimination  3.2.2.1
Tactile threshold discrimination (TTD) (touch detection) uses Semmes-
Weinstein monofilaments (North Coast Medical, Morgan Hill, CA, USA) of 
varying diameter and stiffness to assess sensory nerve functioning in an 
area of skin. It is used in a wide variety of contexts, most notably to assess 
nerve regeneration after injury and in neuropathy (Bell-Krotoski, Weinstein et 
al. 1993, Weinstein 1993, Rosen 1996). Intra-rater reliability is good to 
excellent (Novak, Mackinnon et al. 1993, Mawdsley, Behm-Pugh et al. 2004, 
Collins, Visscher et al. 2010, Auld, Boyd et al. 2011).  
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 Method: Tactile Threshold Discrimination (TTD) 3.2.2.2
Semmes-Weinstein monofilaments of varying thickness with corresponding 
target forces (1.65, 0.008g; 2.83, 0.07g; 3.61, 0.4g; 4.31, 2g; 4.56, 4g; 6.65, 
300g) were employed to measure sensory thresholds at L1, L3 and L5 
levels. Following a standardised, brief explanation of what the filaments 
were, each filament was applied perpendicular to the skin with enough force 
to create a visible bend in the filament. Subjects were instructed to “say 
TOUCH every time you feel the filament on your skin”. A standardised 
protocol for all subjects was carried out beginning with a 1.65, 0.008g 
filament. Filaments were applied 5 times with a 2 second delay between 
each repetition. For a positive result, subjects had to report that 3 out of 5 
applications elicited a response for each filament. Threshold was established 
by the method of limits, where stimuli were increased stepwise in filament 
strength until a response was elicited. The filament with a bending pressure 
immediately below the established threshold filament was then reapplied to 
confirm the exact threshold (Yarnitsky 1997).The threshold for each level 
(L1, L3, L5) was recorded on a standardised body chart. 
 Two-Point Discrimination 3.2.2.3
I have discussed the use of 2PD as an assessment tool in chronic pain in 
section 3.1.4. 
 Method: Two-Point Discrimination 3.2.2.4
TPD threshold testing followed the principles of the down-up-down method 
described by Moberg (Moberg 1990) and Seltzer and Seltzer (Seltzer and 
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Seltzer 1986). A set of electronic digital callipers (Precision Gold®) with a 
precision of 1mm was lightly applied until the first blanching of the skin. 
Testing was undertaken bilaterally at each level, and the order of the side of 
testing was randomised. Based on normative data for TPD threshold (Nolan, 
1985), testing was commenced with 70mm between the two points of the 
callipers. The distance between the points was increased in 5mm increments 
until the subject was able to perceive only one point instead of two. Each 
participant was instructed to say ‘one’ when they felt one point and ‘two’ 
when they felt two points. This was confirmed by descending 5mm below this 
point. An ascending sequence was then applied in 2mm increments until the 
patient reported two points. Testing continued around these initial values 
using ascending and descending sequences in 1mm increments until a 
consistent response was obtained. Catch trials were used to verify that 
participants were not guessing.  
 Data Analysis 3.2.3
 Psychometric And Behavioural Data 3.2.3.1
Independent samples t-tests were used to identify differences between 
MLBP and NuLBP groups with data relating primarily to pain intensity and 
discrimination (pain on day of scanning numerical rating scale (NRS), 
SFMPQ). We chose not to assess differences between CLBP subjects and 
controls with these questionnaires, as our controls were pain-free). 
One-way between groups analysis of variance (ANOVA) was used to identify 
differences between all three groups (controls, MLBP, and NuLBP) in 
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psychometric questionnaire data (SCL-90-R, EPQ-R, STAI) and pain-related 
quality of life data (SF-36). Planned comparisons were then used to test the 
primary hypotheses that CLBP subjects suffer greater psychological distress 
and poorer quality of life compared to controls and that NuLBP patients 
suffer greater psychological distress and poorer quality of life compared to 
MLBP patients. Homogeneity of variance across groups was tested for using 
Levene’s test. Post-hoc and t-tests and planned contrast results were 
adjusted if homogeneity of variance was violated. All tests were undertaken 
with a significance level set at p=<0.05.  
In the secondary analyses, a Pearson product-moment correlation test was 
used to investigate relationships between pain and psychometric variables. 
The relationship strength of the correlation coefficient was determined 
according to guidelines set out in (Cohen 1988). Significance was set at 0.05 
(p < 0.05) for all tests. 
 Clinical Examination Data 3.2.3.2
All analyses were completed using SPSS 20 (IBM SPSS Statistics for 
Windows, Version 20.0. Armonk, NY: IBM Corp.).  
One-way analysis of variance testing (ANOVA) was used to examine group 
differences in 2PD and TTD examination scores. Planned comparisons were 
then used to test the primary hypothesis that 2PD is disrupted in CLBP 
participants compared to control subjects, and also in NuLBP compared to 
MLBP patients. The same planned comparisons were then applied to the 
TTD data. ANOVAs were also used to examine if there were mean TTD and 
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2PD differences in different locations of the back and also to see if there 
were mean TTD and 2PD differences in subjects with differing presentations 
of back and leg pain, in order to examine whether differences in scores were 
driven by pain location and/or pain phenotype.  
The relationship between 2PD and pain characteristics (pain intensity, pain 
duration and painDETECT scores) was investigated using Pearson product-
moment correlation coefficient. Relationships between TTP and 2PD sensory 
testing thresholds with pain duration and intensity were explored as both pain 
intensity and pain duration have been implicated in changes to tactile acuity 
and cortical representation in chronic pain conditions (Lotze and Moseley 
2007). The relationship strength of the correlation coefficient was determined 
according to guidelines set out in (Cohen 1988). Significance was set at 0.05 
(p < 0.05) for all tests. 
 Subject Demographics  3.3
 Characterisation By painDETECT 3.3.1
After recruitment patients were classified into MLBP and NULBP subgroups 
using the painDETECT questionnaire. painDETECT is a highly sensitive, 
specific and positively predictive accurate questionnaire designed to identify 
neuropathic components in LBP (Freynhagen 2006). Patients scoring less 
than 19 were classified as most likely to have mechanical low back pain 
(MLBP); subjects scoring 19 or more were classified as likely to have a 
significant neuropathic component to their pain (NuLBP). Based on the 
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painDETECT questionnaire, 24 NuLBP, 26 MLBP and 20 control subjects 
completed the study. Mean painDETECT scores for the MLBP group were 
9.00, (SD 5.15) and 23.92, (SD 4.36) for the NuLBP group (see Figure 15). 
 
 
Figure 15: painDETECT scores across groups. 
We showed two discrete groups (MLBP M =9.00, SD =5.15; NuLBP M =23.92, SD = 4.36) based on 
pain phenotype. 
 
1.1.1 There Was No Significant Difference In Age Across 
Groups. 
Table 1: Age and gender across groups. 
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There was no significant difference in age across groups (ANOVA F (2, 65) = 2.4, p= .102. 
 
 
Subjects varied from 21-59 years in age. There was no significant difference 
in age across groups (ANOVA F (2, 65) = 2.4, p= .102) (see Table 1, Figure 
16). 
 
Control 20 9 11 25 59 35.9 9.63
MLBP 26 8 18 21 54 38.15 9.23
NuLBP 24 9 15 25 57 42.71 10.09
Total 70 26 44 : : 39.07 9.91
Std.=deviationN M F Minimum Maximum Mean
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Figure 16:Participant ages by group. 
There were no significant differences in age across groups (ANOVA F (2, 65) = 2.4, p= .102. 
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1.1.2 There Was No Significant Difference In Duration Of Pain 
Symptoms Between NuLBP And MLBP. 
 
Table 2: Duration of LBP across groups.  




Duration of LBP across subjects varied from 12-360 months. We used an 
independent samples t-test to compare duration of pain symptoms between 
groups. There was no significant difference in duration of pain symptoms for 
MLBP (mean = 102.15, SD = 100.78) and NuLBP (mean = 98.25, SD = 
80.58) (t (48) =.150, p = .881) (see Table 2, Figure 17)  
 
Duration)(months) Control 20 3 3 3 3
MLBP 26 102.15 100.78 12 360
NuLBP 24 98.25 80.58 12 284
N Mean Std.)Deviation Minimum Maximum
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Figure 17: Pain duration MLBP & NuLBP.  
Circle represents ID and scores for outliers. 
 
 Results: Questionnaire Evaluation 3.4
The results of this characterisation chapter encompass all three categories of 
Melzack’s three-dimensional model of pain (1) cognitive-evaluative 2) 
affective-motivational and 3) sensory-discriminative). I have chosen to 
discuss the results of the pain-related questionnaires first (NRS, SF-36, 
SFMPQ), which relate primarily to cognitive evaluation of the sensory and 
affective components of pain and health-related quality of life. Thereafter, I 
describe the results of the psychometric questionnaire data (CES-D, SCL-90-
R, STAI and EPQ-R), which relate primarily to affective-motivational and 
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cognitive-evaluative aspects of living with pain. The results of the sensory 
discrimination tests relate primarily to the sensory-discriminative aspects of 
the model (however, it may also be argued that processing of sensory 
discrimination includes significant cognitive-evaluative and affective-
motivational components). Importantly, the categories are not mutually 
exclusive; rather, that to all intents and purposes, they are interdependent.  
 Pain-Related Characterisation Across Groups 3.4.1
 
 NuLBP Patients Demonstrate Significantly Higher Pain On The 3.4.1.1
Day Of Scanning NRS Scores Than MLBP Patients. 
 
Table 3: Pain intensity on the day of scanning across groups. 
  
 
An independent samples t-test identified a significant difference in pain 
scores between the mechanical and neuropathic back pain groups, 
measured by a numerical rating scale on the day of scanning. Pain ratings 
were significantly higher (t (48) = -4.03, p=<0.001) in NuLBP patients (mean= 
6.88, SD: 1.70) than in MLBP patients (mean = 4.62, SD: 2.06) (Table 3, 
Figure 18). 
Pain%Intensity Control 20 1 1 1 1
MLBP 26 4.62 2.06 0 8
NuLBP 24 6.88 1.70 3 10




Figure 18: NRS pain on the day of scanning scores across groups. 
Significant difference in pain scores identified between the mechanical and neuropathic back pain 
groups (t (48) = -4.03, p=<0.0001). 
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 Middle And Older Patients Show Significantly Higher Pain NRS 3.4.1.2
Scores Compared To Younger Subjects. 
 
Table 4: NRS pain intensity on the day of scanning scores across age groups. 
 
 
I used a one-way between subjects analysis of variance (ANOVA) to explore 
the impact of age on pain intensity, measured by numerical rating scale 
(NRS) scores on the day of scanning. CLBP patients were grouped into 3 
age categories: younger (20-30yrs), middle (31-45yrs) and older (>45yrs). 
Group means and standard deviations are presented in Table 4. 
There was a statistically significant difference in pain NRS scores for the 
three age groups: F (2,45) = 4.40, p = .018. Post-hoc comparisons using the 
Tukey HSD test showed that younger and older groups significantly differed 
in pain. Younger patients (20-30) demonstrate significantly lower mean pain 
NRS scores than middle (p = .05) or older subjects (p = .017). The middle 
and older subjects did not significantly differ in pain (p =.902) (see Figure 
19). 
 
20#30 11 4.09 2.34
31#45 18 6 2.22
>-45 21 6.29 1.74
Total 50 5.7 2.20
Age-group N Pain-intensity Std.-Deviation
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Figure 19: NRS pain intensity on the day of scanning across age groups.  
Younger patients (20-30) show significantly lower mean pain NRS scores than middle aged (p = .05) or 
older subjects (p = .017). Middle and older subjects did not significantly differ in pain (p =.902). Circles 
represent ID and scores for outliers. Asterisks represent ID and scores for extreme values. 
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 Short Form Mcgill Pain Questionnaire (SFMPQ) 3.4.2
 
 NuLBP Patients Show Significantly Higher SFMPQ Visual 3.4.2.1
Analogue Scale (VAS) Pain Scores Than MLBP Patients. 
 
Table 5: SFMPQ domain scores. 
 
 
Using an independent samples t-test, NuLBP patients demonstrated 
significantly (t (46) = 3.99, p = < 0.001) greater VAS pain scores (M = 80.68, 
SD = 12.75) than patients with MLBP (M = 61.77, SD =18.89) (see Table 5, 
Figure 20). 
  
VAS MLBP 26 61.77 18.89
NuLBP 22 80.68 12.75
Sensory9Pain9Descriptors MLBP 26 10.19 5.87
NuLBP 22 19.77 7.53
Affective9Pain9Descriptors MLBP 20 3.45 2.33
NuLBP 15 4.93 2.66
Present9Pain9Intensity MLBP 26 2.46 0.81
NuLBP 21 3.71 1.19




Figure 20: SFMPQ visual analogue scale scores 
NuLBP patients had significantly greater VAS pain scores (M = 80.68, SD = 12.75) than patients with 
MLBP (M = 61.77, SD =18.89); t (46) = 3.99, p = < 0.001). 
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 NuLBP Patients Show Significantly Higher SFMPQ Sensory 3.4.2.2
Pain Scale Descriptor Scores Than MLBP Patients. 
 
Using an independent samples t-test, NuLBP patients demonstrated 
significantly greater (t (46) = 4.95, p = < 0.001) SFMPQ Sensory Pain 
Descriptor Scale scores (M = 19.77, SD = 7.53) than patients with MLBP   (M 
= 10.19, SD = 5.86) (see Table 5, Figure 21). 
 
 
Figure 21: SFMPQ Sensory pain descriptor scores. 
NuLBP patients demonstrate significantly greater SFMPQ sensory pain descriptor pain scale scores 
(M = 19.77, SD = 7.53) than patients with MLBP (M = 10.19, SD =5.86); t (46) = 4.95, p = < 0.001). 
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 NuLBP Patients Show Significantly Higher SFMPQ Present Pain 3.4.2.3
Intensity Scale Scores Than MLBP Patients. 
 
Using an independent samples t-test, NuLBP patients demonstrated 
significantly greater SFMPQ Present Pain Intensity scale scores (M = 3.71, 
SD = 1.19) than patients with MLBP (M = 10.19, SD =5.86); (t (46) = 4.95, p 
= < 0.001) (Table 5, Figure 22). 
 
 
Figure 22: SFMPQ PPI scores across groups. 
 NuLBP patients demonstrated significantly greater SFMPQ	  Present Pain Intensity scale scores (M = 
3.71, SD = 1.19) than patients with MLBP (M = 10.19, SD =5.86); t (46) = 4.95, p = < 0.001). 
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 No Significant Difference Was Seen In SFMPQ Affective Pain 3.4.2.4
Descriptor Scores Between MLBP And NuLBP Groups. 
 
There was no significant difference in McGill Affective Pain Scores Between 
MLBP (M =3.45, SD 2.33) And NuLBP Groups (M=4.93, SD=2.66); T (33)=     
-1.76, P= 0.88). However, Only 35 Scores Were Completed (MLBP N= 20, 
NuLBP  N= 15) (Table 5). 
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 Rand Medical Outcomes 36-Item Short Form Survey 3.4.3
Instrument (SF-36) 
 There Were Significant Differences Between Groups Across All 3.4.3.1
Domains Of The SF-36. 
Using one-way analysis of variance (ANOVA), we identified significant 
differences between groups across all domains of the SF-36 (see Figure 23). 
See Table 6 for F and significance values and Table 7, Table 8 for mean 
domain scores). 




Physical)Functioning 2,)65 76.78 <0.001
Social)Functioning 2,)65 40.21 <0.001
Role>Physical 2,)65 28.93 <0.001
Bodily)Pain 2,)65 130.38 <0.001
General)Mental)health 2,)65 10.95 <0.001
Role>Emotional 2,)65 8.96 <0.001
Vitality 2,)65 20.79 <0.001
General)Health)Perception 2,)65 21.29 <0.001
Physical)Component)Summary 2,)65 84.08 <0.001
Mental)Component)Summary 2,)65 27.98 <0.001
Domain df F Sig.
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Table 7: RAND Medical Outcomes 36-Item Short Form Survey Instrument (SF-36).  
Physical domains: mean values across groups. 
 
 
Physical)Functioning Control 19 100.00 0.00
MLBP 26 55.38 20.64
NuLBP 23 35.43 19.42
RoleBPhysical Control 19 100.00 0.00
MLBP 26 36.54 40.76
NuLBP 23 26.09 38.05
Bodily)Pain Control 19 98.95 3.15
MLBP 26 41.54 19.08
NuLBP 23 24.13 16.95
General)Health)Perception Control 19 85.53 10.39
MLBP 26 52.88 19.86
NuLBP 23 47.61 25.67
PCS Control 19 96.12 2.60
MLBP 26 46.59 19.12
NuLBP 23 33.32 19.10
Domain Group N Mean Std.)Deviation
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Table 8: RAND Medical Outcomes 36-Item Short Form Survey Instrument (SF-36). 




Vitality Control 19 73.95 14.20
MLBP 26 48.08 22.45
NuLBP 23 36.30 18.48
Social>Functioning Control 19 96.71 11.67
MLBP 26 65.38 23.53
NuLBP 23 42.93 19.15
RoleCEmotional Control 19 94.74 12.49
MLBP 26 70.51 40.36
NuLBP 23 47.83 42.43
General>Mental>health Control 19 81.68 10.27
MLBP 26 71.23 16.93
NuLBP 23 58.96 17.94
MCS Control 19 86.77 7.51
MLBP 26 63.80 21.10
NuLBP 23 46.51 18.41
Group N Mean Std.>DeviationDomain
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Figure 23: SF-36: Mean scores across groups. 
Scores are expressed a percentages. Error bars show 1 standard deviation. One way analysis of 
variance (ANOVA) shows significant differences between subject groups in all SF-36 domains 
(physical functioning F (2,65) = 76.78, p = <0.001; Role-physical F (2,65) = 28.93, p = <0.001; Bodily 
pain F (2,65) = 130.38, p = <0.001; General Health perception F (2,65) = 21.29, p = <0.001; Role-
emotional F (2,65) = 8.96, p = <0.001; Vitality F (2,65) = 20.79, p = <0.001; Social functioning F (2,65) 
= 40.21, p = <0.001; General Mental Health F (2,65) = 10.95, p = <0.001; Physical component 
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 CLBP Patients Experience Significantly Poorer Physical And 3.4.3.2
Mental Health Related Quality Of Life Across All Domains Of 
The SF-36 Compared To Controls. 
Using ANOVA planned comparisons; we observed reduced scores 
(indicating poorer physical and mental health related quality of life) in CLBP 
patients compared to controls in all SF-36 domains (see Figure 23). Mean 
scores are listed in Table 7,Table 8; degrees of freedom, t and significance 
values are listed in Table 9. 




Physical)Functioning 19.07 46.81 <0.001
Role;Physical 12.20 46.85 <0.001
Bodily)Pain 24.73 53.84 <0.001
General)Health)Perception 8.65 58.88 <0.001
PCS 20.07 50.49 <0.001
Vitality 6.15 65.00 <0.001
Social)Functioning 10.48 57.66 <0.001
Role;Emotional 5.40 60.94 <0.001
General)Mental)health 4.83 54.19 <0.001
MCS 9.56 64.98 <0.001
Domain t)value df Sig.)value
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 NuLBP Patients Experience Significantly Poorer Physical And 3.4.3.3
Mental Health Related Quality Of Life Across Several Domains 
Of The SF-36 Compared To MLBP Patients. 
Using ANOVA planned comparisons, we observed reduced scores 
(indicating poorer physical and mental health related quality of life) in NuLBP 
patients compared to MLBP in the following SF-36 physical domains: 
physical functioning, bodily pain and physical component summary (see 
Figure 23). Mean scores are listed in Table 7; degrees of freedom, t and 
significance values are listed in Table 10. 
We also saw reduced scores in NuLBP patients compared to MLBP in the 
following SF-36 mental domains: Vitality, social functioning, general mental 
health and mental component summary. Mean scores are listed in Table 8; 
degrees of freedom, t and significance values are listed in Table 10.  
Table 10: SF-36 ANOVA planned comparisons: NuLBP compared to MLBP. 
Domains with significant p values at <0.05. 
 
Physical)Functioning 3.49 46.81 0.001
Bodily)Pain 3.38 47.00 0.001
PCS 2.43 46.28 0.019
Vitality 2.15 65.00 0.035
Social)Functioning 3.68 46.70 0.001
General)Mental)health 2.45 45.48 0.018
MCS 3.06 46.99 0.004
Domain t)value df Sig.)value
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 No Statistically Significant Difference In SF-36 Scores Were 3.4.3.4
Identified Between Mechanical And Neuropathic Back Pain 
Groups In The Following Domains. 
Using ANOVA planned comparisons, we did not observe statistically 
significant differences between NuLBP and MLBP groups in the following 
SF-36 domains: Role-Physical (limitations in usual role activities because of 
physical health problems), General Health (general health perceptions) and 
Role-Emotional (limitations in usual role activities because of emotional 
problems) (see Figure 23). Mean scores are listed in Table 7, Table 8; 
degrees of freedom, t and significance values are listed in Table 11. 
Table 11: SF-36 ANOVA planned comparisons: NuLBP compared to MLBP 




Role%Physical 0.93 46.85 0.358
General8Health8Perception 0.80 41.28 0.43
Role%Emotional 1.91 45.60 0.062
Domain t8value df Sig.8value
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 Group Psychometric Evaluation  3.4.4
 Revised Symptom Checklist 90 Questionnaire (SCL-90-3.4.5
R). 
Table 12: SCL-90-R Group mean values. 
 
Somatisation Control 19 42.68 9.10
MLBP 26 62.69 9.12
NuLBP 24 69.58 9.38
Obsessive@Compulsive Control 19 50 10.29
MLBP 26 59.77 10.45
NuLBP 24 65.21 9.97
InterpersonalDSensitivity Control 19 46.63 6.33
MLBP 26 53.12 12.43
NuLBP 24 61.38 12.36
Depression Control 19 47.32 10.61
MLBP 26 56.92 11.29
NuLBP 23 62.48 12.91
Anxiety Control 19 42.53 8.26
MLBP 26 51.85 11.98
NuLBP 24 60.46 14.23
Hostility Control 19 44.79 7.42
MLBP 26 53.27 11.33
NuLBP 24 55.38 13.86
Domain Group N Mean Std.DDeviation
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Table 13: SCL-90-R Group mean values. 
 
 
Phobic'Anxiety Control 19 46.89 7.98
MLBP 26 50.54 11.17
NuLBP 24 58.96 13.08
Paranoid'Ideation Control 19 46.21 7.71
MLBP 26 49.62 10.23
NuLBP 24 54.04 15.00
Psychoticism Control 19 45.63 4.55
MLBP 26 55.85 11.38
NuLBP 24 62.25 13.39
Global'Severity'Index Control 19 43.84 11.21
MLBP 26 58.27 9.99
NuLBP 24 65.17 10.45
Positive'Symptom'Total Control 19 43.89 9.36
MLBP 26 54.85 10.02
NuLBP 23 63.26 8.97
Positive'Symptom'Distress'Index Control 19 46.58 8.58
MLBP 26 61.31 9.95
NuLBP 24 62.42 10.48
Domain Group N Mean Std.'Deviation
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Figure 24: Mean SCL-90-R scores across groups.  
Scores are expressed a percentages. Error bars show 1 standard deviation. One way analysis of 
variance (ANOVA) shows significant differences between subject groups in all SCL-90-R domains  
except paranoid ideation (Somatisation F (2,66) = 47.61,  p = <0.001; Obsessive-Compulsive F (2,66) 
= 11.82, p=<0.001; Depression F (2,65) =9.60, p = <0.001; Interpersonal Sensitivity F(2,66) =8.86, 
p=<0.001; Anxiety F 2,66 = 11.91, p = <0.001; Hostility F (2,66) = 4.96, p=0.01; Psychoticism F (2,66) 
= 12.56, p = <0.0001; Global Severity Index F (2,66) = 22.35, p = <0.0001; Positive Symptom Total F 


























 There Were Significant Differences Between Subject Groups In 3.4.5.1
All SCL-90-R Domains Except Paranoid Ideation. 
We used one–way analysis of variance (ANOVA) to identify differences 
between subject groups. We observed significant differences between 
subject groups in all SCL-90-R domains except Paranoid Ideation (see 
Figure 24). Mean scores are listed in Table 12, Table 13; F and significance 
values are listed in Table 14. 
Table 14: SCL-90-R ANOVA, F and significance values. 
 
 CLBP Patients Show Greater Psychological Distress Compared 3.4.5.2
To Controls In All SCL-90-R Domains. 
Using ANOVA planned comparisons; we observed increased scores 















controls in all SCL-90-R domains (see Figure 24). Mean scores are listed in 
(see Table 12 and Table 13); degrees of freedom, t and significance values 
are listed in Table 15. 




 NuLBP Patients Show Greater Psychological Distress 3.4.5.3
Compared To MLBP Patients In Several SCL-90-R Domains.  
Using ANOVA planned comparisons; we observed increased scores 
(indicating greater psychological distress) in NuLBP patients compared to 
MLBP patients in several SCL-90-R domains (see Figure 24). Mean scores 
are listed in (see Table 12 and Table 13); t and significance values are listed 
in (see Table 16).  
Somatisation 9.45 66 p/=/<0.001
Obsessive8Compulsive 4.52 66 p/=/<0.001
Interpersonal/Sensitivity 4.66 60.39 p/=/<0.001
Depression 3.92 65 p/=/<0.001
Anxiety 5.12 50.86 p/=/0.013
Hostility 3.85 53.63 p/=/<0.001
Phobic/anxiety 3.12 48.95 p/=/0.03
Psychoticism 6.55 63.15 p/=/0.001
Paranoid/ideation 2.21 50.97 p/=/0.032/
Global/Severity/Index 6.32 66 p/=/<0.001
Positive/Symptom/Total 5.91 65 p/=/<0.001/
Positive/Symptom/Distress/Index 5.79 66 p/=/<0.001
Domain t/value Sig./valuedf
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 CES-D  3.4.6
 
 There Were Significant Differences Between Subject Groups In 3.4.6.1
CES-D Scores. 
Using one–way analysis of variance (ANOVA), we were able to identify 
significant differences between subject groups in CES-D scores, F (2,67) = 
27.12, p = <0.001 (see Table 17 and Figure 26). 
Table 17: CES-D scores across groups. 
 
 
Somatisation 2.65 66 p.=.0.01
Interpersonal.Sensitivity 2.35 47.72 p.=.0.023
Anxiety 2.31 45.17 p.=.0.026
Psychoticism 6.55 45.35 p.=.<0.001
Phobic.anxiety 2.44 45.45 p.=.0.019
Global.Severity.Index 2.32 66 p.=.0.023
Positive.Symptom.Total 3.1 65 p.=.0.003
Domain t.value Sig..valuedf
Control 20 4.55 5.69
MLBP 26 11.42 8.37
NuLBP 24 23.33 10.67
Group N Mean Std.>Deviation
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 CLBP Subjects Report Significantly Greater Depressive 3.4.6.2
Symptoms Than Controls.  
Using ANOVA planned comparisons, we observed that CLBP patients 
reported significantly greater depressive symptoms compared to controls, t 
(55.70) = 6.88, p = <0.001 (see Table 17, Figure 25). 
 
 
Figure 25: CES-D scores: ANOVA planned comparisons, CLBP compared to controls.  
CLBP patients report significantly greater depressive symptoms compared to controls, t (55.70) = 6.88, 
p = <0.001. Asterisks represent ID and scores for extreme values. 
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 NuLBP Subjects Report Significantly Greater Depressive 3.4.6.3
Symptoms Than MLBP Subjects.  
Using ANOVA planned comparisons, we observed that NuLBP patients 
reported significantly greater depressive symptoms compared to MLBP 
subjects, t (55.70) = 6.88, p = <0.001 (see Table 17, Figure 26) 
 
Figure 26: Mean CES-D scores across groups.  
There are significant differences between subject groups in CES-D scores, F (2,67) = 27.12, p = 
<0.001. CLBP patients report significantly greater depressive symptoms compared to controls, t 
(55.70) = 6.88, p = <0.001. NuLBP patients report significantly greater depressive symptoms 
compared to MLBP subjects, t (55.70) = 6.88, p = <0.001. Circles represent ID and scores for outliers. 





 STAI State And Trait Anxiety  3.4.7
 There Were Significant Differences Between Subject Groups In 3.4.7.1
STAI State Scores And STAI Trait Scores. 
Using one–way analysis of variance (ANOVA), we were able to identify 
significant differences between subject groups in STAI state scores, F (2,66) 
= 9.02, p = <0.001 and STAI trait scores, F (2,67) = 10.77, p = <0.001 (see 
Table 18 and Figure 27). 





STAI%State Control 19 29.53 9.65
MLBP 26 36.42 8.02
NuLBP 24 43.83 14.34
STAI%Trait Control 20 32.8 8.08
MLBP 26 42.31 10.13
NuLBP 24 46.63 11.18
Domain Group N Mean Std.%Deviation
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Figure 27: Mean STAI state and trait scores across groups.  
Scores are expressed as arbitrary units. Error bars show 1 standard deviation. One-way analysis of 
variance (ANOVA) shows significant differences between subject groups in STAI state scores (F (2,66) 
























 STAI State Scores Are Greater In CLBP Patients Than Controls. 3.4.7.2
Using planned comparisons, we observed greater state anxiety in CLBP 




Figure 28: Mean STAI state scores. 
CLBP patients report greater state anxiety compared to controls (t (37.88) = 3.83, p = <0.001). Circles 
represent ID and scores for outliers. 
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 STAI Trait Anxiety Scores Are Greater In CLBP Patients Than 3.4.7.3
Controls. 
Using planned comparisons, we observed greater trait anxiety in CLBP 




Figure 29: Mean STAI trait scores.  
CLBP patients report greater trait anxiety in CLBP patients compared to controls (t (67) = 4.42, p = 
<0.001). Circles represent ID and scores for outliers 
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 NuLBP Subjects Report Greater STAI State Anxiety Scores 3.4.7.4
Compared To MLBP Subjects. 
Using planned comparisons, we observed greater STAI state anxiety scores 
in NuLBP patients compared to MLBP patients (t (35.49) = 2.23, p = 0.032) 
(Table 18, Figure 30).  
 
Figure 30: Mean STAI state scores across groups.  
NuLBP subjects report greater STAI state anxiety scores compared to MLBP patients. (t (35.49) = 
2.23, p = 0.032). Circles represent ID and scores for outliers. 
  
 141 
There were no significant differences between NuLBP patients and MLBP 




Figure 31: Mean STAI trait scores across groups. 
There are no significant differences between NuLBP patients and MLBP patients (t (67) = 1.53, p = 




 EPQ-R  3.4.8
 There Were Significant Differences Between Subject Groups In 3.4.8.1
EPQ-R-P Scores.  
Significant group differences in EPQ-R-P (psychoticism) scores were 
identified using one-way analysis of variance (ANOVA), F (2,66) = 3.79, p = 
0.028. There were no statistically significant differences between groups on 
EPQ-R-E, F (2,66) = 2.62, p = 0.081 and EPQ-R-N, F (2,66) = 2.09, p = 
0.131 scales (see Table 19 and Figure 32). 
 
Table 19: EPQ-R scores across groups. 
 
 
EPQ$R$E Control 20 15.2 3.85
MLBP 26 11.96 5.11
NuLBP 23 13 5.17
EPQ$R$N Control 20 8.4 5.37
MLBP 26 10.19 5.61
NuLBP 23 12 6.23
EPQ$R$P Control 20 3.8 2.73
MLBP 26 4.46 2.53
NuLBP 23 6.13 3.39
Domain Group N Mean Std.EDeviation
 Figure 32: Mean EPQ-R scores across groups.  
Scores are expressed as arbritrary units. Error bars show 1 standard deviation. One-way analysis of 
variance (ANOVA) shows significant differences between subject groups in in EPQ-R-P (psychoticism) 
scores (F (2,66) = 3.79, p = 0.028) but not in EPQ-R-E (extraversion) (F (2,66) = 2.62, p = 0.081) and 
EPQ-R-N (neuroticism) (F (2,66) = 2.09, p = 0.131) scores.  
 
 EPQ-R-E Scores Are Greater In Controls Than CLBP Patients.  3.4.8.2
Using planned comparisons, we observed greater EPQ-R-E scores in 
controls compared to CLBP patients, t (66) = 2.13, p = 0.037, indicating that 
CLBP patients display fewer characteristics associated with extraversion, 
such as sociability, out-goingness and impulsivity (see Table 19). 
 EPQ-R-P scores are greater in NuLBP compared to MLBP 3.4.8.3
subjects  
Using planned comparisons, we observed greater EPQ-R-P scores in 
NuLBP patients compared to MLBP, t (66) = 2.01, p = 0.048, indicating 
greater characteristics associated with psychoticism (aggressiveness, 


























scored greater compared to controls on the EPQ-R-P scale but this narrowly 
missed statistical significance, t (66) = 1.94, p = 0.056 (see Table 19). 
 PainDETECT Correlations 3.4.9
The relationship between painDETECT scores and other variables were 
investigated using Pearson product-moment correlation coefficient. 
Table 20: painDETECT correlations with pain intensity, pain duration and CES-D scores. 
 
 There Was A Strong, Significant Correlation Between 3.4.9.1
PainDETECT And Pain Intensity. 
There was a strong, significant correlation between painDETECT and pain 
intensity, measured by NRS, on the day of scanning (see Table 20 for r and 
significance values). 
 There Was A Strong, Significant Correlation Between 3.4.9.2
PainDETECT And CES-D Scores. 
There was a strong, significant correlation between painDETECT and CES-D 
scores (see Table 20 for r and significance values).  
Pearson(Correlation 1 .636** 0.079 .592**
Sig.((2:tailed) <0.001 0.588 <0.001




There was no significant relationship between painDETECT and pain 
duration (see Table 20 for r and significance values).  
 PainDETECT And SF-36  3.4.9.3
 
Table 21: painDETECT and SF-36 correlations.  
There are strong to moderate, signifiicant correlations with all domains of the SF-36. 
 
 
 There Were Strong, Significant Correlations Between 3.4.9.4
PainDETECT And Physical Functioning And Mental Component 
Summary SF-36 Domains.  
There were strong, significant correlations between painDETECT and the 
SF-36 domains of Physical Functioning and Mental Component Summary 
(see Table 21 for r and significance values). 
 
 There Were Moderate, Significant Correlations Between 3.4.9.5
PainDETECT And The Following SF-36 Domains.  
There were moderate, significant correlations between painDETECT and the 
following SF-36 domains: Social Functioning, Bodily Pain, Role-Emotional, 
Mental Health, Vitality, General Health perception and the Physical 
Component Summary (see Table 21 for r and significance values). 
PainDETECT Physical Social 0Role3Physical Bodily0Pain Mental Role3Emotional Vitality General0Health0 PCS MCS
Function 0Function Health Perception
Pearson0Correlation 1 3.555** 3.490** 30.132 3.463** 3.417** 3.402** 3.427** 3.377** 3.441** 3.530**
Sig.0(23tailed) <0.001 <0.001 0.367 0.001 0.003 0.004 0.002 0.008 0.002 <0.001




 PainDETECT And SFMPQ  3.4.9.6
 
Table 22: painDETECT and SFMPQ correlations. 
 
 
 There Was A Strong, Significant Correlation Between 3.4.9.7
PainDETECT And The SFMPQ Sensory Pain Descriptor Scale 
And SFMPQ Visual Analogue Scale (VAS). 
There was a strong, significant correlation between painDETECT and the 
SFMPQ sensory pain descriptor scale and SFMPQ VAS (see Table 22 for r 
and significance values). 
 There Were Moderate, Significant Correlations Between 3.4.9.8
PainDETECT And SFMPQ Affective Pain Scale Scores And 
SFMPQ Present Pain Intensity Scale Scores. 
There were moderate, significant correlations between painDETECT and 
SFMPQ affective pain scale scores and SFMPQ present pain intensity scale 
scores (see Table 22 for r and significance values). 
PainDETECT Sensory/Pain Affective/Pain/ VAS Present/
/Descriptors Descriptors Pain/Intensity
Pearson/Correlation 1 .623** .490** .552** .493**
Sig./(2Etailed) <0.001 0.003 <0.001 <0.001
N 50 48 35 48 47
**/Correlation/is/significant/at/the/0.01/level/(2Etailed).
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 PainDETECT And SCL-90-R 3.4.9.9
 
Table 23: painDETECT and SCL-90-R correlations. 
There was a strong, significant correlation with the SCL-90-R Somatisation scale and moderate, 
significant correlations with Obsessive-Compulsive Symptoms, Interpersonal Sensitivity, Depression, 
Anxiety, Phobic-Anxiety, Paranoid Ideation, Psychoticism, Positive Symptom Total and Global Severity 
Index scales 
 
 There Was A Strong, Significant Correlation Between 3.4.9.10
PainDETECT And The SCL-90-R Somatisation Domain.  
There was a strong, significant correlation between painDETECT and SCL-
90-R Somatisation scores (see Table 23 for r and significance values).   
 There Were Moderate, Significant Correlations Between 3.4.9.11
PainDETECT And The Following SCL-90-R Domains.  
There were moderate, significant correlations between painDETECT and the 
following domains of the SCL-90-R (see Table 23 for r and significance 
values):  Obsessive-Compulsive Symptoms, Interpersonal Sensitivity, 
Depression, Anxiety, Phobic-Anxiety, Paranoid Ideation, Psychoticism, 
Positive Symptom Total and the Global Severity Index.  
There were no significant relationships between painDETECT and SCL-90-R 
domains of Hostility and Positive Symptom Distress Index (see Table 23 for r 
and significance values). 
PainDETECT Somatisation Obsessive2 Interpersonal Depression Anxiety Hostility Phobic= Paranoid= Psychoticism Global=Severity Positive=Symptom Positive=Symptom=
Compulsive =Sensitivity Anxiety Ideation =Index =Total Distress=Index
Pearson=Correlation 1 .512** .404** .420** .334* .379** 0.255 .416** .290* .416** .456** .487** 0.177
Sig.=(22tailed) <0.001 0.004 0.002 0.019 0.007 0.073 0.003 0.041 0.003 0.001 <0.001 0.22




 PainDETECT And EPQ-R 3.4.9.12
 
Table 24: painDETECT and EPQ-R correlations. 
 
There was a weak, significant correlation between painDETECT and the 
EPQ-R-N domain only (see Table 24 for r and significance values). 
 PainDETECT And STAI  3.4.9.13
 
Table 25: painDETECT and STAI state and trait correlations. 
 
Pearson(Correlation 1 .0.15 .284* 0.181
Sig.((2.tailed) 0.303 0.048 0.213
N 50 49 49 49
*(Correlation(is(significant(at(the(0.05(level((2.tailed).
PainDETECT EPQ.R.E EPQ.R.N EPQ.R.P
Pearson(Correlation 1 .407** .318*
Sig.((29tailed) 0.003 0.024





 There Were Moderate, Significant Correlations Between 3.4.9.14
PainDETECT And Both STAI State And STAI Trait Domains.  
There were moderate, significant correlations between painDETECT and 
both STAI state and STAI trait domains (see Table 25 for r and significance 
values). 
 
 NRS Pain Scores On The Day Of Scanning 3.4.10
Correlations.  
 




 There Was A Moderate, Significant Correlation Between 3.4.10.1
Pain On The Day Of Scanning And Depression Scores.  
There was a moderate, significant correlation between pain on the day of 
scanning and depression scores (see Table 26 for r and significance values).  
Pearson(Correlation 1 0.041 .437**
Sig.((28tailed) 0.779 0.002
N 50 50 50
**(Correlation(is(significant(at(the(0.01(level((28tailed).
Pain8day Duration((months) CES8D
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 NRS Pain Scores On The Day Of Scanning And SF-36   3.4.10.2
 
Table 27: Pain on the day and SF-36 correlations. 
There were moderate, significant correlations with pain on the day of scanning and SF-36 




 There Were Moderate, Significant Correlations With 3.4.10.3
Pain On The Day Of Scanning And The Following SF-36 
Domains.  
There were moderate, significant correlations with pain on the day of 
scanning and the following SF-36 domains (see Table 27 for r and 
significance values): Social Functioning, Bodily Pain, Mental Health, 
Role-Emotional, Vitality and the Mental Component Summary. 
NRS Pain Scores On The Day Of Scanning And SFMPQ 
 
Table 28: Pain on the day and SFMPQ correlations. 
 
Pain%on Physical Social %Role/Physical Bodily%Pain Mental Role/Emotional Vitality General%Health% PCS MCS
scanning%day Function %Function Health Perception
Pearson%Correlation 1 /0.274 /.393** /0.118 /.314* /.375** /.320* /.340* /0.197 /0.268 /.432**
Sig.%(2/tailed) 0.056 0.005 0.42 0.028 0.008 0.025 0.017 0.176 0.063 0.002
N 50 49 49 49 49 49 49 49 49 49 49
**%Correlation%is%significant%at%the%0.01%level%(2/tailed).
*%Correlation%is%significant%at%the%0.05%level%(2/tailed).
Pain Sensory+Pain Affective+Pain+ VAS Present+
+on+scanning+day +Descriptors Descriptors Pain+Intensity
Pearson+Correlation 1 .342* 0.004 .543** 0.204
Sig.+(2Btailed) 0.017 0.983 <0.001 0.169
N 50 48 35 48 47
**+Correlation+is+significant+at+the+0.01+level+(2Btailed).
  151 
 There Was A Strong, Significant Correlation Between 3.4.10.4
Pain On The Day Of Scanning And SFMPQ VAS.  
There was a strong, significant correlation between pain on the day of 
scanning and SFMPQ VAS (see Table 28 for r and significance values). 
 
 There Was A Moderate, Significant Correlation Between 3.4.10.5
Pain On The Day Of Scanning And SFMPQ Sensory Pain 
Descriptors.  
There was a moderate, significant correlation between pain on the day of 
scanning and SFMPQ sensory pain descriptors (r = .342, n = 48, p = 
0.017) (see Table 28 for r and significance values). 
 
 NRS Pain Scores On The Day Of Scanning And SCL-90-3.4.10.6
R 
 
Table 29: Pain on the day and SCL-90-R correlations. 
There were moderate to weak, significant correlations between pain on the day of scanning and 
domains of Somatisation, Obsessive-Compulsive Symptoms, Interpersonal Sensitivity, 
Depression, Anxiety, Phobic-Anxiety, Paranoid Ideation, Psychoticism, Global Severity Index 
(GSI), Positive Symptom Total and  Positive Symptom Distress Index. 
Pain Somatisation Obsessive. Interpersonal Depression Anxiety Hostility Phobic: Paranoid: Psychoticism Global:Severity Positive:Symptom Positive:Symptom:
:on:scanning:day Compulsive :Sensitivity Anxiety Ideation :Index :Total Distress:Index
Pearson:Correlation 1 .462** .366** .335* .287* .381** 0.244 .296* .305* .352* .419** .400** .280*
Sig.:(2.tailed) 0.001 0.009 0.017 0.045 0.006 0.087 0.037 0.031 0.012 0.002 0.004 0.049
N 50 50 50 50 49 50 50 50 50 50 50 49 50
**:Correlation:is:significant:at:the:0.01:level:(2.tailed).
*:Correlation:is:significant:at:the:0.05:level:(2.tailed).
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 There Were Moderate To Weak, Significant Correlations 3.4.10.7
Between Pain On The Day Of Scanning And The Following 
Domains Of The SCL-90-R.  
There were moderate to weak, significant correlations between pain on 
the day of scanning and the following domains of the SCL-90-R (see 
Table 29 for r and significance values): Somatisation, Obsessive-
Compulsive Symptoms, Interpersonal Sensitivity, Depression, Anxiety, 
Phobic-Anxiety, Paranoid Ideation, Psychoticism, Global Severity Index 
(GSI), Positive Symptom Total, Positive Symptom Distress Index. There 
was no significant relationship with pain on the day of scanning and SCL-
90-R Hostility domain. 
 
 NRS Pain Scores On The Day Of Scanning And STAI 3.4.10.8
 





Pearson%Correlation 1 .309* 0.225
Sig.%(2;tailed) 0.029 0.116
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 There Was A Moderate, Significant Correlation Between 3.4.10.9
Pain On The Day Of Scanning And STAI State Scores.  
There was a moderate, significant correlation between pain on the day of 
scanning and STAI State scores but not with STAI trait scores (see Table 
30 for r and significance values). 
 CES-D Correlations 3.4.11
 CES-D And SF-36 3.4.11.1
 
Table 31: CES-D and SF-36 correlations. 
There were strong, significant correlations with pain on the day of scanning and domains of Social 
Functioning, Mental health, Vitality, Physical Component Summary, General Health, Mental 
Component Summary 
 
 There Were Strong, Significant Correlations With CES-D 3.4.11.2
Scores And The Following SF-36 Domains.  
There were strong, significant correlations with CES-D scores and the following SF-36 domains: 
Social Functioning, Mental health, Vitality, Physical Component Summary, General Health, Mental 
Component Summary (see  
Table 31 for r and significance values). 
 There Were Moderate, Significant Correlations With 3.4.11.3
CES-D Scores And The Following SF-36 Domains. 
There were moderate, significant correlations with CES-D Scores and the following SF-36 
domains:Physical Functioning, Role-Physical, Bodily Pain, Role-Emotional (see  
Table 31 for r and significance values). 
CES$D Physical Social /Role$Physical Bodily/Pain Mental Role$Emotional Vitality General/Health/ PCS MCS
Function /Function Health Perception
Pearson/Correlation 1 $.476** $.641** $.409** $.453** $.694** $.483** $.732** $.545** $.600** $.747**
Sig./(2$tailed) 0.001 <0.001 0.004 0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
N 50 49 49 49 49 49 49 49 49 49 49
**/Correlation/is/significant/at/the/0.01/level/(2$tailed).
*/Correlation/is/significant/at/the/0.05/level/(2$tailed).
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 CES-D And SFMPQ  3.4.11.4
 




 There Was A Strong, Significant Correlation Between 3.4.11.5
CES-D Scores And SFMPQ Sensory Pain Descriptors. 
There was a strong, significant correlation with CES-D Scores and 
SFMPQ sensory pain descriptors  (see Table 32 for r and significance 
values). 
 There Were Moderate, Significant Correlations Between 3.4.11.6
CES-D Scores And SFMPQ Affective Pain Descriptors And 
Between SFMPQ VAS.  
There were moderate, significant correlations between CES-D Scores 
and SFMPQ affective Pain Descriptors and between SFMPQ VAS (see 
Table 32 for r and significance values). CES-D And SCL-90-R  
Table 33: CES-D and SCL-90-R correlations. 
CES$D Sensory,Pain Affective,Pain, VAS Present,
,Descriptors Descriptors Pain,Intensity
Pearson,Correlation 1 .564** .457** .364* 0.194
Sig.,(2$tailed) <0.001 0.006 0.011 0.191
N 50 48 35 48 47
**,Correlation,is,significant,at,the,0.01,level,(2$tailed).
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There were strong, significant correlations between CES-D scores and the following domains of 
SCL-90-R: Somatisation, Obsessive-Compulsive Symptoms, Interpersonal Sensitivity, 
Depression, Anxiety, Hostility, Phobic-Anxiety, Paranoid Ideation, Psychoticism, Global Severity 
Index, and Positive Symptom Total and a moderate, significant correlation with the Positive 
Symptom Distress Index 
 
 
 There Were Strong, Significant Correlations Between 3.4.11.7
CES-D Scores And The Following Measures Of The SCL-90-
R.  
There were strong, significant correlations between CES-D scores and 
the following measures of the SCL-90-R: Somatisation, Obsessive-
Compulsive Symptoms, Interpersonal Sensitivity, Depression, Anxiety, 
Hostility, Phobic-Anxiety, Paranoid Ideation, Psychoticism, Global 
Severity Index and  Positive Symptom Total (see Table 33 for r and 
significance values). 
 There Was A Moderate, Significant Correlation Between 3.4.11.8
CES-D Scores And The SCL-90-R Positive Symptom Distress 
Index. 
There was a moderate, significant correlation between CES-D scores and 
the SCL-90-R Positive Symptom Distress Index (see Table 33 for r and 
significance values). CES-D And STAI 
 
CES$D Somatisation Obsessive$ Interpersonal Depression Anxiety Hostility Phobic< Paranoid< Psychoticism Global<Severity Positive<Symptom Positive<Symptom<
Compulsive <Sensitivity Anxiety Ideation <Index <Total Distress<Index
Pearson<Correlation 1 .663** .758** .696** .739** .726** .572** .709** .557** .705** .805** .714** .489**
Sig.<(2$tailed) <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
N 50 50 50 50 49 50 50 50 50 50 50 49 50
**<Correlation<is<significant<at<the<0.01<level<(2$tailed).
*<Correlation<is<significant<at<the<0.05<level<(2$tailed).
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 There Were Strong, Significant Correlations Between 3.4.11.9
CES-D Scores And Both STAI State And STAI Trait Domains. 
There were strong, significant correlations between CES-D scores and 




Pearson(Correlation 1 .692** .668**
Sig.((27tailed) <0.001 <0.001
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 CES-D And EPQ-R 3.4.11.10
 
 There Was A Strong, Significant Correlation Between 3.4.11.11
CES-D Scores And EPQ-R Neuroticism Domain 
Questionnaire. 
Table 35: CES-D and EPQ-R correlations. 
 
There was a strong, significant correlation between CES-D scores and 
the neuroticism domain of the EPQ-R questionnaire (see Table 35 for r 




Pearson(Correlation 1 .0.269 .653** 0.235
Sig.((2.tailed) 0.062 <0.001 0.104
N 50 49 49 49
*(Correlation(is(significant(at(the(0.05(level((2.tailed).
CES.D EPQ.R.E EPQ.R.N EPQ.R.P
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 Results: Clinical examination 3.5
 
 TTD Examination Scores 3.5.1
A one-way between groups analysis of variance (ANOVA) was used to 
explore differences between groups in TTD examination scores. There 
was a statistically significant difference in TTD examination scores 
between groups (F (2,62) = 6.45, p=.003) (see Table 36) 
 




Controls 18 2.70 0.67
MLBP 24 2.85 0.78
NuLBP 23 3.48 0.78
Group N TTD<Mean Std.<Deviation
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 CLBP Demonstrate An Increase In TTD Compared To 3.5.2
Controls. 
 
Using planned comparisons, we observed that TTD examination scores 
revealed significantly increased sensory thresholds to tactile stimulation 
in CLBP patients compared to controls (t (62) = 2.23, p = .029) (see Table 
36, Figure 33). 
 
 
Figure 33: TTD values, LBP & Controls 
Circles represent ID and scores for outliers.  
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 NuLBP Demonstrate An Increase In TTD Compared 3.5.3
To MLBP. 
Using planned comparisons, we observed that TTD examination scores 
revealed significantly increased sensory thresholds to tactile stimulation 
in NuLBP compared to MLBP patients (t (62) = -2.84, p = .006) (see 
Table 36, Figure 34). In order to examine the relative influence of each 
LBP sub-group, we also analysed the ANOVA post hoc comparisons 
(Tukey HSD). We found significant differences between the Controls and 
the NuLBP group (p = .005) but not between Controls and the MLBP 
subjects (p =.79). These data suggest that the observed differences 
between the Controls and CLBP subjects are primarily driven by the 
increased sensory thresholds observed in NuLBP patients. 
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Figure 34: Mean TTD scores, MLBP & NuLBP groups. 
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 2PD Examination Scores 3.5.4
 
Using a one-way analysis of variance (ANOVA) we were able to show 
significant statistical differences in 2PD examination scores between 
groups (F (2,62) = 5.37, p=.007) (see Figure 35, Table 37). 
 





Controls 18 4.98 0.65
MLBP 24 6.43 1.81
NuLBP 23 6.46 1.89
Group N 2PD;Mean Std.;Deviation
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Figure 35: Mean 2PD scores for Controls, MLBP and NuLBP groups. 
Circles represent ID and scores for outliers. Asterisks represent ID and scores for extreme values. 
 
 CLBP Demonstrate An Increase In 2PD Thresholds 3.5.5
Compared To Controls 
 
Using planned comparisons, we observed significantly increased 
thresholds to two-point discrimination in CLBP patients compared to 
controls (t (62) = -3.28, p = .002) (see Figure 36). Our results for 2PD are 
consistent with previous studies (Moseley 2008, Wand, Di Pietro et al. 
2010, Luomajoki and Moseley 2011). 
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Figure 36: 2PD values, LBP & Controls. 
Circles represent ID and scores for outliers. Asterisks represent ID and scores for extreme values. 
 
In order to examine the relative influence of each LBP sub-group, we 
analysed the ANOVA post hoc comparisons (Tukey HSD). We found 
significant differences (p =. 014) between both the Controls (M = 4.98, SD 
= .65) and the NuLBP (M = 6.46, SD = 1.89, group and between Controls 
and the MLBP subjects (M = 6.43, SD = 1.81) (p =. 015), which suggests 
a relatively even contribution to the observed differences between the 
Controls and CLBP. 
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 There Are No Differences In 2PD Thresholds 3.5.6
Between NuLBP And MLBP. 
Using planned comparisons, we observed no significant differences 
between NuLBP and MLBP groups in 2PD examination scores (t (62) = -
.06, p =.952). 
 
 Location Of LBP Has No Effect On TTD Scores. 3.5.7
 
Table 38: Mean TTD scores according to LBP location. 
 
 
We used a one-way analysis of variance (ANOVA) to examine whether 
mean TTD scores varied according to subjects’ location of low back pain. 
We found no statistical differences in TTD examination scores between 
subjects’ locations of low back pain: F (3,43) = .1.753, p=.171 (see Table 
38) 
Central 13 3.29 0.67
Left 4 3.32 1.06
Right 4 3.89 0.32
L8&8R 26 2.96 0.89
Total 47 3.16 0.83
LBP8location N TTD8Mean Std.8Deviation
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 Location Of LBP Has No Effect On 2PD Scores 3.5.8
 




We used a one-way analysis of variance (ANOVA) to examine whether 
2PD scores varied according to subjects’ location of low back pain. We 
found no statistical differences in 2PD examination scores between 
subjects’ locations of low back pain: F (3,43) = .221, p = .881 (see Table 
39).  
  
Central 13 6.21 0.89
Left 4 6.65 1.37
Right 4 5.99 1.48
L9&9R 26 6.60 2.28
Total 47 6.44 1.83
LBP9location N 2PD9Mean Std.9Deviation
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 Location Of Referred Leg Pain Has No Effect On TTD 3.5.9
Scores.  
 
Table 40: Mean TTD scores according to leg pain location 
 
We used a one-way analysis of variance (ANOVA) to examine whether 
mean TTD scores varied according to location of subjects’ leg pain. We 
found no statistical differences in mean TTD examination scores between 
locations of subjects’ leg pain (F (3,43) = .1.670, p=.188) (see Table 40). 
  
LBP$only 14 3.01 0.81
Above$Knee 13 2.88 1.04
Below$knee$unilateral 12 3.56 0.44
Below$knee$bilateral 8 3.28 0.85
Total 47 3.16 0.83
LBP$location N 2PD$Mean Std.$Deviation
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 Location Of Referred Leg Pain Has No Effect 3.5.10
On 2PD Scores  
 
Table 41: Mean 2PD scores according to leg pain location 
 
We used a one-way analysis of variance (ANOVA) to examine whether 
mean 2PD scores varied according to location of subjects’ leg pain. We 
found no statistical differences in mean TTD examination scores between 
locations of subjects’ leg pain (F (3,43) = .187, p=.904) (see Table 41). 
  
LBP$only 14 6.16 1.04
Above$Knee 13 6.70 2.25
Below$knee$unilateral 12 6.48 2.51
Below$knee$bilateral 8 6.45 1.06
Total 47 6.44 1.83
LBP$location N 2PD$Mean Std.$Deviation
  169 
 Correlation Analysis: Tactile Threshold 3.5.11
Discrimination  
 
 CLBP Patients Demonstrate Moderate Relationships 3.5.11.1
Between TTD Scores And Pain Phenotype And TTD Scores 
And Pain Intensity. 
 
Table 42: Correlations between TTD scores and pain intensity, pain duration and painDETECT 
scores 
 
We found a moderate relationship between TTD scores and numerical 
rating scale pain intensity measured on the day of scanning (r = 354, n = 
47, p < .05) and also between TTD scores and pain phenotype 
(PainDETECT) (r = .390, n = 47, p = <. 01). There was no significant 
relationship between pain duration and TTD scores (r = .002, n = 47, p = 
.987) (see Table 42). 
Pearson(Correlation 1 .354* 30.002 .390**
Sig.((2(tailed) 0.015 0.987 0.007
N 47 47 47 47
*(Correlation(is(significant(at(the(<(0.05(level((23tailed).
**(Correlation(is(significant(at(the(<(0.01(level((23tailed).
TTD pain(intensity pain(duration( painDETECT
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 CLBP Patients Demonstrate A Moderate Relationship 3.5.11.2
Between TTD Scores And STAI State Scores And TTD 
Scores And CES-D Scores. 
 
Table 43: TTD correlations with STAI State & Trait & CES-D scores in CLBP patients. 
 
 
We chose to investigate relationships between sensory testing thresholds 
with measures of anxiety and depression as these are important 
psychological variables implicated in the maintenance and augmentation 
of chronic pain states (Linton 2000, Linton 2011). We found a moderate 
relationship between TTD scores and CES-D scores (r = 327, n = 47, p < 
.05) and also between TTD scores and STAI state scores (r = .417, n = 
47, p =.0004). There was no significant relationship between TTD scores 
and STAI trait scores (r = .15, n = 47, p =.314) (see Table 43).    
  
Pearson(Correlation 1 .327* .417** 0.15
Sig.((29tailed) 0.025 0.004 0.314
N 47 47 47 47
*(Correlation(is(significant(at(the(0.05(level((29tailed).
**(Correlation(is(significant(at(the(0.01(level((29tailed).
TTD CES9D STAI(state STAI(trait
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 Correlation Analysis: Two-Point Discrimination 3.5.12
 
 CLBP Patients Demonstrate No Significant 3.5.12.1
Relationships Between 2PD Scores And Pain Phenotype, 
Pain Intensity Or Pain Duration. 
 




There were no significant relationships between 2PD scores and pain 
intensity (r = .148, n = 47, p = .32), pain duration (r = .135, n = 47, p = 
.366)., or pain phenotype (r = .018, n = 47, p = .902) ( see Table 44).  
  
Pearson(Correlation 1 0.148 0.135 40.018
Sig.((24tailed) 0.32 0.366 0.902
N 47 47 47 47
2PD pain(intensity pain(duration( painDETECT
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 CLBP Patients Demonstrate A Moderate Relationship 3.5.12.2
Between 2PD Scores And STAI State Scores. 
 
Table 45: 2PD correlation with STAI State & Trait & CES-D scores in CLBP patients. 
 
We found a moderate relationship between 2PD scores and STAI state 
scores (r = .348, n = 47, p = .017). There was no significant relationship 
between 2PD scores and STAI trait scores (r = .122, n = 47, p = .414). or 
2PD scores and CES_D scores (r = .252, n = 47, p = .087) (see Table 
45).  
  
Pearson(Correlation 1 0.252 .348* 0.122
Sig.((29tailed) 0.087 0.017 0.414
N 47 47 47 47
*(Correlation(is(significant(at(the(0.05(level((29tailed).
**(Correlation(is(significant(at(the(0.01(level((29tailed).
2PD CES9D STAI(state STAI(trait
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 Summary: Pain and Psychometric 3.6
Questionnaire data 
The questionnaire data used in this study can be broadly divided in to 
three main dimensions: 
1) Measures of the sensory discriminative dimensions of pain - bodily 
pain and intensity  
2) Self-reported functional measures – how pain interferes with normal 
physical and social functioning 
3) Measures of psychological well-being and distress 
We hypothesised that patients with CLBP would exhibit:  
1) Poorer quality of life and 2) greater psychological distress compared to 
controls (We chose not to assess differences in pain intensity and pain 
description between CLBP subjects and controls, as our controls were 
pain-free).  
In addition, we hypothesised that patients with NuLBP would complain of 
1) greater pain, 2) poorer quality of life and 3) greater psychological 
distress compared to MLBP patients.  
Our data show that all these hypotheses are correct. 
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 CLBP Results Summary 3.6.1
We saw significant differences in between CLBP subjects and controls in 
health related quality of life, as measured by all domains of the SF-36 
(see section 3.4.3.2) Interestingly, although we chose CLBP patients with 
no self-report of psychological problems or mental illness, both physical 
and mental domains of the questionnaire were equally affected. CLBP 
patients obviously perceived their bodily pain to worse than controls. 
They also thought that their general health was significantly poorer. 
Functional ability (being able to take part in usual role and social 
activities) was affected by both physical and mental domains (SF-36 
Physical Function; SF-36 Social Function; SF-36 Role-Physical; SF-36 
Role-Emotional). All mental domains of the questionnaire showed 
significant poorer results for back pain sufferers with significantly poorer 
perceptions of mental well-being and psychological distress, in addition to 
restrictions in function being caused by emotional problems. Overall 
physical and mental summary scores showed highly significant 
differences between groups indicating a significantly poorer physical and 
emotional quality of life. 
We also used a broad range of questionnaires to examine if CLBP 
patients exhibit greater psychological distress across a broad range of 
psychological domains. These data show a large range of psychological 
sequelae to CLBP, with scores showing significantly greater 
psychological distress in almost all domains of the psychometric 
questionnaires we employed, even in domains that, at first glance, would 
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not particularly be associated with LBP such as SCL-90-R Obsessive-
Compulsive Symptoms, Interpersonal Sensitivity, Hostility, Phobic-
Anxiety, and Psychoticism, as well as SCL-90-R and CES-D Depression 
domains and SCL-90-R and STAI Anxiety domains. In fact, out of all 
questionnaire domains, only SCL-90-R paranoid ideation and EPQ-R 
Neuroticism and Psychoticism domains did not show any significant 
differences between controls and CLBP patients.  
 NuLBP Results Summary 3.6.2
1) NuLBP patients complain of significantly greater pain intensity and 
decrease in quality of life (see Table 46) 
2) Reduced ability to engage in normal physical and social functioning 
(see Table 47) and  
3) Significantly greater psychological distress compared to MLBP patients 
(see Table 48). 
NuLBP patients demonstrate greater pain intensity and bodily symptoms 
in the following questionnaire domains: 
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Table 46: Questionnaire domains showing increased pain intensity and bodily symptoms in 
NuLBP patients compared to MLBP. 
 
Secondly, NuLBP patients demonstrate reduced ability to engage in 
normal physical and social functioning in the following questionnaire 
domains of the SF-36: 
Table 47: SF-36 domains showing reduced ability to engage in normal physical and social 
functioning in NuLBP patients compared to MLBP. 
 
Lastly, NuLBP patients showed greater psychological distress and 
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Table 48: Questionnaire domains showing greater psychological distress and reduced well-being 
in NuLBP patients compared to MLBP. 
 
We were also able to demonstrate relationships between pain and 
psychological domains. We saw moderate to strong correlations with 
most psychological domains and pain intensity and painDETECT. In 
particular, we observed strong correlations between CES-D scores and 
both measures of pain and pain related function and affect but also with 
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 Discussion: Pain and Psychometric 3.7
Questionnaire data 
 Patients With CLBP, Especially Patients With NuLBP, 3.7.1
Report Greater Depression Scores  
There is a significant difference between CLBP subjects and controls on 
the Global Severity Index (GSI), which is a summary of overall 
psychological distress across all domains of the SCL-90-R. These data 
show that CLBP has a significant negative impact on well-being and 
quality of life. Chronic pain patients have higher rates of generalised 
anxiety, post-traumatic stress disorder and alcohol abuse and depression 
than the general population (Demyttenaere, Bruffaerts et al. 2007). In 
fact, depression is second only to low back pain as a leading global 
cause of disability (Ferrari, Charlson et al. 2013, Hoy, March et al. 2014). 
This study has shown that CLBP subjects score significantly higher than 
controls in depressive symptomology and neuropathic back pain patients 
scored significantly higher again than patients with MLBP. In fact, NuLBP 
patients scored significantly above the cut off zone of the CES-D 
questionnaire (>/= 19) identifying individuals at risk of depression.  
Depression is a common comorbidity for patients with CLBP (Atkinson, 
Slater et al. 1991, Sullivan, Reesor et al. 1992, Walsh, Homa et al. 2006). 
In Canada CLBP patients are three to four times more likely to suffer from 
major depression than the pain-free population (5.9% vs 19.8%) and the 
rate of major depression in CLBP patients increases in a linear fashion 
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with pain severity (Currie and Wang 2004). In fact, back pain has been 
identified as the strongest predictor of major depression after adjusting for 
demographics and other medical comorbidity (Currie and Wang 2004).  
We observed significant correlations between pain intensity and CES-D 
scores, as well as CES-D and painDETECT scores, which suggests that 
a negative affective response is a feature of the increasing severity and 
neuropathic component of CLBP. Interestingly, we did not identify any 
relationship between pain chronicity and low mood, suggesting that the 
development of the affective component of CLBP is not an inevitable 
consequence of pain duration but rather of pain intensity. Similarly, we 
did not identify any relationship between duration of symptoms and 
painDETECT scores, suggesting that the development of the neuropathic 
component of CLBP is not an inevitable consequence of pain duration 
from mechanical towards neuropathic but that MLBP and NULBP involve 
different mechanisms. Other studies of mechanical and neuropathic back 
pain agree with our findings. Freynhagen et al. found a significantly 
greater depression scores in a large group (n=717) of NuLBP patients. 
Furthermore, a strong relationship was found between severity of 
depression and painDETECT scores (Freynhagen, Baron et al. 2006).  
The question of whether depressive symptoms arise as a consequence of 
pain or whether patients develop pain due to underlying depression is 
unresolved. There has been extensive research on depression in chronic 
pain patients yet relatively little on pain in patients with a primary 
diagnosis of depression. A major review identified 59 studies on 
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depression in patients’ with chronic pain compared to only 14 on pain in 
depressive patients (Bair, Robinson et al. 2003). We excluded patients 
from our study that reported any psychological or mental health issues. It 
is possible, however, that the findings we observed of increased levels of 
depression in back pain patients actually relate to underlying levels of 
depression prevalent in the general population. Patients with depression 
are twice as likely to have low back pain than those without (Croft, 
Papageorgiou et al. 1995). It has been suggested that treatment failures 
in CLBP may occur because depression has either not been diagnosed 
or else has been ignored in the treatment regime. Studies suggest that 
depression is drastically under reported in CLBP (Spitzer, Williams et al. 
1994, Grevitt, Pande et al. 1998, Haggman, Maher et al. 2004). 
Importantly, the problem of pain and depression comorbidity may be 
significantly under-reported in the majority of patients that have 
subclinical or milder forms of depression who are likely to present to GPs 
and primary care providers (Bair, Robinson et al. 2003). Depressed 
patients may therefore be treated the same as non-depressed with 
negative consequences (Sullivan, Reesor et al. 1992). It has been 
suggested that depression has a greater impact on treatment outcomes 
than any other factor (Linton 2000). 
Conversely, it has also been stated that the reporting of pain and its 
importance in the diagnosis of depression is underreported, certainly at 
least in relation to the attention given to psychological symptoms in 
patients with chronic pain (Katona, Peveler et al. 2005). In fact, more than 
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50% of patients with depression report somatic symptoms alone, and of 
those, at least 60% are pain related (Bair, Robinson et al. 2003). These 
patients may end up having treatment addressed at their physical 
symptoms alone. At the same time, patients with depression may be 
diagnosed with ‘Somatization disorder’ and run the risk of having their 
physical symptoms dismissed as ‘non-organic’, in other words, not 
genuine (Katona, Peveler et al. 2005). The DSM IV (Diagnostic and 
Statistical Manual of Mental Disorders) diagnostic criteria for 
Somatization disorder state “the physical complaints or resulting social or 
occupational impairment are in excess of what would be expected from 
the history, physical examination, or laboratory findings”. Unfortunately, 
such a description renders around 85% of CLBP patients diagnosed with 
a psychiatric disorder! Despite widespread recognition of the 
biopsychosocial model, this is old-fashioned biomedical dualism of the 
highest order. The new DSM V (Association 2013) has attempted to 
address this with a new diagnostic category called “Somatic Symptom 
and Related Disorders”.  The common feature of this disorder category is 
that individuals have “somatic symptoms associated with significant 
distress and impairment.” The introduction to this new disorder includes 
the description of the diagnosis is to be made “on the basis of positive 
symptoms and signs (distressing somatic symptoms plus abnormal 
thoughts, feelings, and behaviors in response to these symptoms) rather 
than the absence of a medical explanation for somatic complaints” 
thereby acknowledging that just because the cause of symptoms is 
unknown does not mean that they are made up. Ultimately, the dual 
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prevalence of CLBP and depression in society present a challenge to 
those of us seeking to explore the mechanisms of either. Writing in 1992, 
Sullivan et al. stated “At this time, the strongest statement that can be 
made about the relation between pain and depression is that the two 
conditions frequently coexist” (Sullivan, Reesor et al. 1992). Further work 
is necessary to explore the mechanisms and underlying relationships of 
each condition.  
I suggest that there is a fundamental conceptual issue with a dualistic 
approach to the problem of pain and depression. Indeed, there may need 
to be a fundamental reconceptualisation of the view that depression is 
solely a consequence of the burden of pain. Pain and depression, in fact, 
share common neurobiological supraspinal pathways involving serotonin 
(von Knorring and Ekselius 1994) and noradrenaline (Max, Lynch et al. 
1992) and both conditions may involve lower levels of monoamine 
oxidase activity (von Knorring, Perris et al. 1984). Neural dysregulation of 
serotonin and noradrenaline may help to explain pain and depression 
comorbidities and may account for the success of anti-depressant 
medication in treating both conditions (Fishbain 2005)(Trivedi) . 
Furthermore, there is also increasing evidence that neuroimmune 
mechanisms may underlie depressive and pain comorbidities, via the 
direct effect of immune cells and cytokines within the CNS or via indirect 
mechanisms involving the vagus nerve and/or gut brain axis (Walker, 
Kavelaars et al. 2014).  
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In later sections of this thesis we use neuroimaging to examine the neural 
correlates of the pain and psychological symptoms we have observed in 
order to examine whether patients with CLBP show changes in brain 
areas associated with dysegulation of mood and/or pain processing.  
Our findings of widespread psychological distress in CLBP patients show 
the importance of psychological factors in CLBP. Although pain and 
disability are most frequently measured in chronic back pain trials (Froud, 
Patterson et al. 2014) recent recommendations for outcome measures in 
chronic pain suggest that ‘emotional functioning’ should be assessed as a 
core domain (Turk, Dworkin et al. 2003, Dworkin, Turk et al. 2005). We 
have evidence here of a broad range of psychological distress in CLBP. 
CLBP patients and medical professionals may have different treatment 
goals and expectations (Georgy, Carr et al. 2009) It is important that as 
well as a proper physical examination, the psychological well being of 
patients is adequately assessed. Our data suggest that in addition to 
sensory-discriminative aspects of pain and disability, psychological 
distress may be a vitally important component of CLBP sufferers’ quality 
of life. Further chapters of this thesis will examine functional and 
structural neuroimaging correlates of the pain experience. 
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 Neuropathic Pain Patients Present With Not Only 3.7.2
Greater Pain Intensity But Also Poorer Quality Of Life 
Across A Number Of Mental And Physical Domains. 
This study reports fundamental differences in pain intensity, function and 
psychological comorbidities between patients and controls and between 
NuLBP and MLBP. These data are in accordance with several studies 
comparing neuropathic with non-neuropathic patients. Neuropathic 
patients with a variety of chronic pain conditions report significantly higher 
pain and disability scores, reduced quality of life and higher psychological 
co-morbidities compared to non-neuropathic pain patients (Rowbotham 
2002, Freynhagen, Baron et al. 2006, Torrance, Smith et al. 2006, 
Jensen, Chodroff et al. 2007, Smith, Torrance et al. 2007, O'Connor 
2009, Smith and Torrance 2012).  
These data clearly show that the impact of neuropathic pain on the 
individual sufferer is far greater than the sensory-discriminative 
characteristics of the pain alone. Subjects with neuropathic pain generally 
respond poorly to treatment (Baron, Binder et al. 2010). These data 
suggest that therapies must be aimed at alleviating not only the sensory 
dimensions of the pain but also alleviating its psychological sequelae and 
restoring functional quality of life.  
Studies show that the impact of neuropathic pain varies according to the 
condition and also to the method of evaluation of health related quality of 
life (Jensen, Chodroff et al. 2007). The CLBP data from this study are 
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consistent with Freynhagen et al. who showed the biopsychosocial 
impact of NuLBP compared to MLBP (Freynhagen, Baron et al. 2006). 
Our data also show similar findings to studies using the SF-36 to explore 
differences between neuropathic and non-neuropathic pain conditions in 
the general population (Smith, Torrance et al. 2007). However, compared 
to the findings of this study, our data show greatly reduced scores across 
nearly all SF-36 domains (only role limitations due emotional problems 
(SF-36 Role-Emotional) and general mental health (SF-36 Emotional 
well-being) had reasonably similar, albeit still lower, results) indicating 
more severe pain, disability and affect in all SF-36 measures in both our 
neuropathic and non-neuropathic population. The reason for the reduced 
scores in our population is unclear. Our results may demonstrate the 
significant burden of CLBP compared to other chronic pain conditions.  In 
addition, our patient group was recruited in an inner city London hospital. 
The substantial impact across a broad range of quality of life domains 
may also reflect a patient population not only struggling to cope with on-
going pain but also having to negotiate this burden in harsh economic 
and social inner-city environment. Unfortunately, this remains 
speculation, as I did not collect extensive socio-economic data. However, 
there is an extensive body of literature that suggests that the adversity of 
chronic pain is associated with socio-economic and educational status 
(Dorner, Muckenhuber et al. 2011). This could be a useful avenue for 
further study. 
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 Why Do Neuropathic Pain Patients Present With Not 3.7.3
Only Greater Pain Intensity But Also Poorer Quality 
Of Life? 
It may be that poorer quality of life in patients with neuropathic pain is 
nothing more than a consequence of increased pain intensity. However, 
the psychological comorbidities we have shown may be an intrinsic result 
of the underlying disease mechanisms of neuropathic pain, which in the 
case of CLBP may only be loosely connected, if at all to peripheral 
mechanisms. For instance, it has been suggested that neuropathic pain 
may cause maladaptive reorganisation of higher brain centres, which are 
involved in multidimensional processing of mood and affect (Smith, 
Torrance et al. 2007).  
Perhaps it is useful to question whether it is helpful to view NuLBP as a 
binary phenomenon, an all or nothing concept (Attal and Bouhassira 
2004, Bennett, Smith et al. 2006). Perhaps a more flexible approach is 
required, where neuropathic pain is seen as a continuum of signs and 
symptoms, whose peripheral mechanisms may or may not be seen as 
neuropathic, rather than a fixed, all or nothing, lesion-based pathological 
definition. This definition therefore allows patients with supposedly non-
neuropathic such as osteoarthritis (and low back pain) to be reclassified 
as having a significant neuropathic component regardless of the origin of 
their symptoms. I suggest that mechanisms may be of extreme 
importance in chronic neuropathic pain and differences that have been 
identified between groups in both sensory-discriminative examination and 
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questionnaire evaluation may show supraspinal neural correlates. The 
next sections therefore show the results of structural and functional 
neuroimaging of CLBP in order to highlight differences between groups to 
show the neural correlates of both non-neuropathic and neuropathic 
CLBP. 
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 Discussion: TTD and 2PD Examination Data 3.8
 Summary Of Main Findings 3.8.1
We aimed to discover whether CLBP patients demonstrated deficits in 
tactile threshold testing of the lower back, in order to examine the 
relationship of tactile acuity and CLBP and, in particular, whether deficits 
in tactile threshold testing of the lower back were worse in patients with 
NULBP compared to MLBP. We also wished to examine the relationship 
of pain and psychometric variables to our examination data. We found 
significantly higher 2PD and TTD thresholds in CLBP patients than 
controls. NuLBP patients had significantly higher mean TTD threshold 
scores than MLBP patients. There were no differences in 2PD thresholds 
between the NuLBP and MLBP patients. Location of LBP or referred leg 
pain had no bearing on 2PD or TTD scores. Moderate relationships were 
seen between TTD thresholds and both pain severity and pain phenotype 
(as measured by painDETECT) but not pain duration. Moderate 
relationships were also seen between TTD examination data and STAI 
State and depression scores. No relationships were seen between 2PD 
scores and pain severity, phenotype or duration. 2PD data showed a 
moderate relationship with STAI State scores only. 
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 What Mechanisms Underlie Both The Hyposensitivity 3.8.2
To Tactile Stimuli And Also The Increased 2PD 
Thresholds Seen In CLBP Patients Compared To 
Controls? 
These tactile data may be explained by changes to the peripheral or 
central nervous system, or, indeed, a combination of both. Tactile 
threshold and 2PD testing have traditionally been used to assess the 
integrity of the peripheral nervous system. However, we chose these 
tests principally as a marker of central nervous system plasticity, in 
accord with other chronic pain studies (see section 3.2.2.3). 
Nevertheless, it is possible that the changes we observed may be driven 
by peripheral mechanisms. For instance, peripheral neuropathy of lumbar 
dorsal rami could account for both tactile hyposensitivity and also 
increased 2PD thresholds. However, studies on the sequelae of a 
compressive lesion to a mixed peripheral nerve show an order of events 
governed by nerve diameter size (Rydevik, Brown et al. 1984, Nygaard 
and Mellgren 1998, Yamashita, Kanaya et al. 2002). The first nerves to 
be affected by a compressive lesion are large diameter Aα fibres and the 
largest Aβ fibres. Damage to these fibres, which mediate vibration sense, 
proprioception and 2PD, may therefore be responsible for increases in 
2PD thresholds. Thereafter, with increasing compression, smaller 
diameter Aβ fibres transducing light touch may be compromised, resulting 
in increases to tactile thresholds.  
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However, the examination data show that although NuLBP patients 
demonstrated increased tactile thresholds compared to MLBP patients, 
2PD thresholds were unaffected, making a diagnosis of compressive 
neuropathy unlikely to be the cause, as one would expect a pattern of 
loss of 2PD first then alterations in light touch. Therefore, I suggest that 
involvement of central nervous system mechanisms is a more likely 
reason for these changes. The question that arises is what sort of 
involvement? In a clinical setting, increases in tactile thresholds, but not 
2PD thresholds in an individual patient might suggest unwelcome 
pathology of the CNS, perhaps affecting transmission of sensory input via 
the dorsal columns. However, this is extremely unlikely to be the cause in 
a group of 24 patients who, apart from a diagnosis of CLBP are otherwise 
healthy. I suggest, therefore, that a more likely explanation is that these 
findings most likely reflect neuroplastic alterations to representational 
areas in the somatosensory cortex that were discussed in section 3.1.4 
and are consistent with work showing changes in representational fields 
associated with alterations in.2PD thresholds (Flor 1995, Flor, Elbert et al. 
1995, Lotze, Flor et al. 2001, Juottonen, Gockel et al. 2002, Maihofner, 
Handwerker et al. 2003, Pleger, Tegenthoff et al. 2004, Maihofner, 
Forster et al. 2005).    
Additional supraspinal mechanisms may also explain the tactile 
hyposensitivity we observed. Similar results have also been 
demonstrated both experimentally (Nathan 1960, Apkarian, Stea et al. 
1994, Moriwaki and Yuge 1999, Geber, Magerl et al. 2008, Agostinho, 
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Scherens et al. 2009) and also in clinical studies (Leffler, Kosek et al. 
2000, Leffler, Hansson et al. 2003), including CLBP (Puta, Schulz et al. 
2013). It has been suggested (Agostinho, Scherens et al. 2009) that that 
chronic pain causes a centrally-mediated impairment of non-painful 
stimuli. Patients in chronic pain may divert attentional and working 
memory resources to painful stimuli (Legrain, Crombez et al. 2011, 
Romero, Straube et al. 2013). I suggest that hyposensitivity may be part 
of a general coping strategy employed by the CNS that has parallels with 
neglect-type phenomena that are seen in CLBP and other chronic pain 
conditions. As pain increases, CNS resources are directed towards the 
painful area to deal with the situation. However, if pain persists, then the 
CNS may adapt by decreasing attentional mechanisms devoted to the 
body part in question, in an effort to distance oneself from the source of 
pain. I propose that grey matter increases (Teutsch, Herken et al. 2008) 
and decreases (Apkarian, Sosa et al. 2004, Schmidt-Wilcke, Leinisch et 
al. 2006, Ivo, Nicklas et al. 2013, Wu, Inman et al. 2013) observed in the 
somatosensory cortex and elsewhere in the brain in acute and chronic 
pain respectively may be the neural correlates of this process. However, 
in chronic pain conditions it appears that this adaptive strategy does not 
lead to pain reduction. In fact, I hypothesise that grey matter loss may, in 
itself, cause dysregulation of pain processing and inhibitory modulatory 
systems. The following chapters in this thesis will use neuroimaging to 
identify neuroplastic changes associated with group differences in both 
our questionnaire and clinical examination data in an attempt to test these 
hypotheses. 
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Chapter 4 EVALUATION OF STRUCTURAL 
CHANGES IN GREY MATTER IN CLBP 
USING VOXEL BASED MORPHOMETRY 
(VBM)  
 Introduction 4.1
Conventional methods of clinical assessment, structural imaging and 
diagnostic testing have failed to adequately explain the causes and 
underlying mechanisms for either mechanical or neuropathic CLBP 
(Waddell 2005, Krismer and van Tulder 2007). In the previous chapter we 
identified clear differences in behavioural data and sensory testing 
between CLBP patients and controls and between NuLBP and MLBP 
patients. We interpreted these findings in terms of the potential for 
supraspinal neuroplastic adaptions to pain. It has been claimed that 
functional and structural brain imaging may have utility as a diagnostic 
marker for CLBP, as an adjunct to conventional methods of 
evaluation(Apkarian, Baliki et al. 2009). This chapter will investigate this 
claim, using structural brain imaging, namely voxel based morphometry, 
to identify differences between CLBP patients and controls and 
differences between CLBP subgroups. 
Voxel based morphometry (VBM) is a fully automatic unbiased technique 
which statistically analyses the volume of gray and white matter between 
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differing groups on a voxel to voxel basis across the whole brain using 
normalised, modulated data to correct for differences in brain size 
(Ashburner and Friston 2000).  This makes it an ideal tool to assess the 
potential for structural neuroplastic change associated with CLBP. Both 
increases and decreases in grey matter have been identified in clinical 
populations suffering from a wide range of chronic pain conditions (May 
2011, Smallwood, Laird et al. 2013). However, the exact mechanisms 
behind grey matter changes are as yet unknown. 
 What Do Volume Changes Represent? 4.1.1
In 2004 Apkarian et al. described findings of GM reductions in the 
dorsolateral prefrontal cortex and thalamus as brain atrophy, caused by 
neuronal cell death (Apkarian, Sosa et al. 2004). However, studies 
emerging over the last 5 years, showing restoration of grey matter deficits 
after successful treatment in a variety of conditions, including CLBP, 
suggest that cell death is unlikely to be the mechanism behind GM 
reductions in neuroimaging studies (Obermann, Nebel et al. 2009, 
Rodriguez-Raecke, Niemeier et al. 2009, Gwilym, Filippini et al. 2010, 
Seminowicz, Wideman et al. 2011). Furthermore, as some density 
changes appear to be reversible, this suggests that grey matter changes 
are also likely to be a consequence of pain, rather than a causative 
factor. 
Most chronic pain studies show reduced GM volume, yet increases are 
also consistently reported (Smallwood, Laird et al. 2013). Recent 
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evidence shows that structural plasticity is temporally dynamic; increases 
in volume in brain areas associated with learning increase occur within 
hours both in human and animal models (Sagi, Tavor et al. 2012). In 
animal models, increased volume is associated with changes in the 
morphology of astrocytes and neurons, primarily involving enhancement 
of tissue organisation and reshaping of neuronal or glial processes and 
concomitant increased levels of brain derived neurotrophic factor (BDNF), 
which may be a marker of synaptic long term potentiation (Blumenfeld-
Katzir, Pasternak et al. 2011, Sagi, Tavor et al. 2012). Similar synaptic 
mechanisms may be involved in chronic pain as well as in memory and 
learning (Sandkuhler 2000, Sandkuhler 2007). Peripheral nerve injury 
and C fibre stimulation in rodents causes increased permeability of the 
blood-brain and blood-spinal cord barrier after 24 hours, causing plasma 
extravasation throughout the spinal cord and brain, which may be another 
possible mechanism for initial volume increase (and possible later 
decrease) (Beggs, Liu et al. 2010). In humans, grey matter density 
increase in response to painful stimulation in areas associated with 
somatosensory processing has been reported after only eight days 
(Teutsch, Herken et al. 2008). Grey matter increases and reductions 
could be caused by a wide variety of possible mechanisms - a decrease 
in glial or neuronal cell size, changes to synaptic architecture, axonal or 
dendritic density or structure, local blood flow or relative levels of 
hydration (May and Gaser 2006, Zatorre, Fields et al. 2012). Therefore, 
non-neuronal mechanisms, rather than neurogenesis or cell death, are 
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arguably more likely to account for the increases and decreases in GM 
witnessed in structural imaging studies. 
Similarly, it is not known what factors influence the mechanisms behind 
GM volume alterations in chronic pain. These may include pain intensity, 
pain duration, mood and cognitions, activity and lifestyle changes, co-
morbidities, medication and social, cultural and environmental factors. 
The relevance and importance of possible causal factors to underlying 
mechanisms is, as yet, unknown (Tracey and Bushnell 2009).  
 Structural Neuroimaging Studies Of CLBP  4.1.2
The results of CLBP structural neuroimaging studies are varied, showing 
a mixed picture of both increases and decreases in grey matter in patient 
groups that vary both in size and clinical characteristics. Apkarian’s study 
of 2004 described 26 individuals diagnosed with CLBP (15 
‘musculoskeletal’, 5 radicular and 6 ‘mixed picture’). They reported an 
overall reduction in brain grey matter in the region of 5-11%. The 
decreased volume was related to pain duration, indicating a 1.3-cm3 loss 
of grey matter for every year of chronic pain. Pain characteristics were 
important. A combination of sensory and negative-affective dimensions of 
pain (assessed by the short form McGill pain questionnaire (Melzack 
1987) strongly predicted dorso-lateral prefrontal cortex (DLPFC) gray 
matter changes. Grey matter density was reduced in the bilateral DLPFC 
and right thalamus and was significantly dependent on the duration. 
Despite uneven groups with small sample sizes, inferences were made 
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regarding the presence and type (neuropathic or non-neuropathic) of 
chronic back pain. Neuropathic chronic back pain patients with 
radiculopathy were described as suffering significantly greater grey 
matter change than non-neuropathic back pain patients. Apkarian 
proposed that the decrease in grey matter density in the DLPFC was the 
reason that neuropathic pain conditions are more clinically more 
debilitating. 
In a similar study, Schmidt-Wilcke et al in 2006 (Schmidt-Wilcke, Leinisch 
et al. 2006) in a study of 18 CLBP patients also found reductions in grey 
matter in the right somatosensory cortex, brainstem (dorsolateral pons) 
and right DLPFC with increases in the left thalamus and basal ganglia. 
Grey matter losses correlated with the extent of pain intensity and 
unpleasantness (measured by the SES, pain experience scale (Geissner 
1995) but unlike Apkarian’s study not with pain duration. In common with 
other studies previously mentioned, this suggests that distress and 
negative effect may have a neurobiological substrate in chronic pain 
states. At first, the reductions in brain morphology appear to contradict 
the earlier work of Flor (using MEG), which showed an increase in 
representational fields related to chronicity (Flor, Braun et al. 1997). 
However, neuroimaging studies of CRPS and PLP demonstrate that 
shrinking of representational fields correlates highly with intensity of pain 
and hyperalgesia (Flor 2003, Moseley 2007). Schmidt-Wilke et al. 
suggested that grey matter loss represents structural reorganization and 
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that Flor’s MEG data represents functional reorganization; essentially two 
different measurements with different mechanisms.  
 Another study also shows reduced grey matter volume in elderly CLBP 
patients (Buckalew, Haut et al. 2008). Grey matter volume decreases 
have also been demonstrated in other chronic pain conditions such as 
headache, IBS (irritable bowel syndrome), FMS (fibromyalgia syndrome), 
CRPS and pelvic pain. Each type of pain condition appears to have its 
own unique characteristics in relation to activity and atrophy (May 2008). 
VBM has also shown that many clinical pain conditions are also 
associated with increases as well as decreases in grey matter brain 
volume (FMS (Schmidt-Wilcke, Luerding et al. 2007) (IBS (Blankstein, 
Chen et al. 2010) (Pelvic pain (Schweinhardt, Kuchinad et al. 2008). As 
well as the reductions previously mentioned, CLBP patients have also 
shown an increase in thalamic and basal ganglia grey matter volume 
(Schmidt-Wilcke, Leinisch et al. 2006). The authors offered no 
explanation for the increase in grey matter, other than noting that their 
group only included patients with axial pain, without radiating pain or 
radiculopathy, whereas Apkarian’s group in 2004 studied a mixture of 
patients with and without neurological manifestations, as well as patients 
with pain outside of the lower back. To the best of this author’s 
knowledge, no studies have yet correlated clinical profiles of axial and 
radiating back pain patients with functional and structural brain imaging.   
While previous studies have suggested that clinical phenotypes may have 
discrete and distinguishable cerebral fingerprints, these studies show a 
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wide diversity of results, most likely reflecting diversity in patient 
demographics, image pre-processing and methods of data analysis 
(Apkarian, Sosa et al. 2004, Schmidt-Wilcke, Leinisch et al. 2006, 
Schmidt-Wilcke, Luerding et al. 2007, Buckalew, Haut et al. 2008, 
Seminowicz, Wideman et al. 2011, Kong, Spaeth et al. 2013, Wu, Inman 
et al. 2013).  
 In particular, structural neuroimaging studies have inconsistently 
addressed the issue of characterisation of study populations into 
mechanical and neuropathic phenotypic subgroups. Some studies have 
included both mechanical and neuropathic cohorts (Apkarian, Sosa et al. 
2004); others have excluded patients with neuropathic symptoms 
(Schmidt-Wilcke, Leinisch et al. 2006, Ivo, Nicklas et al. 2013, Kong, 
Spaeth et al. 2013). Other studies have not attempted to sub-categorise 
their CLBP populations at all, other than to list a structural diagnosis 
(Buckalew, Haut et al. 2008, Seminowicz, Wideman et al. 2011). It is 
therefore uncertain whether the GM changes observed in these studies 
are applicable to all subjects with CLBP or specific to either mechanical 
or neuropathic phenotypes of the study population. Better differentiation 
and characterisation of mechanical and neuropathic subgroups in CLBP 
will help to develop appropriate treatment strategies in order to improve 
patient outcomes. 
Furthermore, a recent paper has also cast doubt on the significance of 
the reporting of grey matter density changes in mental health research, 
citing selective reporting of significant results and omission of negative 
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results, resulting in “excess significance bias” of published results 
(Ioannidis 2011). As many of the published papers in pain brain research 
involve small sample sizes, similar biases may also occur. There is a 
continuing need to test the hypothesis that brain volume changes occur in 
chronic low back pain and to investigate the underlying mechanisms. 
Therefore, the purpose of this chapter was to test the following 
hypotheses:  
1. CLBP patients demonstrate brain morphological differences 
compared to controls  
2. NuLBP patients demonstrate specific alterations in GM volume 
compared to MLBP patients. 
  Image Acquisition 4.2
All participants were scanned in a 3T GE Signa HDX MRI scanner 
(General Electric Healthcare, Milwaukee, USA) using an 8-channel 
receive only head coil. A high-resolution T1 weighted structural image 
was acquired for each subject using a spoiled gradient-recalled echo 
(SPGR) sequence (number slices = 196, slice thickness = 1.1mm, slice 
gap = 1.1mm, Repetition Time (TR) 7.012, Echo Time (TE) 2.812 (TR/TE 
=7/2.82 ms), Flip angle = 20°, FOV = 280 mm, matrix = 256 × 256). An 
additional highly detailed structural T2 fast spin-echo (FSE) scan was 
also acquired (Slice thickness = 2mm, Slice Gap = 2mm, Spatial positions 
= 72, Flip angle = 90º, FOV = 240mm2, Repetition Time (TR) 4380, Echo 
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Time (TE) = 65.28 (TR/TE = 4380/65.28), Matrix = 320x320). A fast spin 
echo fluid-attenuated inversion-recovery (FLAIR FSE) scan was 
performed and subjects were radiologically assessed to exclude gross 
pathology. 
 Data Pre-processing 4.3
Image pre-processing and analysis were carried out using Statistical 
Parametric Mapping software 8 (SPM 8) (Wellcome Department of 
Cognitive Neurology, London, UK, 2008; www.fil.ion.ucl.ac.uk/spm), 
running under Matlab 7.12 (MathWorks, Natick, MA, USA). The pre-
processing pipeline consisted of segmentation, normalization, and 
smoothing prior to statistical analysis using the Diffeomorphic Anatomical 
Registration Using Exponentiated Lie algebra (DARTEL) technique 
(Ashburner 2007). DARTEL was used as it offers optimal registration 
across subjects (Klein, Andersson et al. 2009). We followed the pre-
processing strategy as detailed by Ashburner 
(http://www.fil.ion.ucl.ac.uk/%7Ejohn/misc/VBMclass10.pdf.).  
Initial segmentation into grey, white and CSF (GM/WM/CSF) tissue 
classes was performed in native space using the Unified Segmentation 
Procedure developed by Ashburner and Friston (Ashburner and Friston 
2005). “DARTEL imported” versions, used for DARTEL registration in the 
next step, were concurrently produced in order to make study-specific 
templates (see Figure 37) for illustration of pre-processing states detailed 
here and below). Next, an average of all native space grey and white 
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matter images from all subjects was created using both the segmented 
native space and DARTEL imported GM/WM/CSF files.  
 
 
Figure 37: DARTEL pre-processing steps. 
The pipeline incorporates segmentation, normalisation, modulation and smoothing (taken from 
(Bergouignan, Chupin et al. 2009). 
 
An original template is generated by computing the average of all the 
aligned data. Each subject is then registered to the template. This creates 
the first iterative template. The second iteration begins with each subject 
registered to the first iterative template to create a second iterative 
template. After six iterations, the final template is generated, which is the 
average of the DARTEL registered data. DARTEL employs more 
realignment parameters (6 million as opposed to 1000 in normal VBM) to 
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create an optimally refined group specific template for realignment of all 
scans. The final template image (template 6) produced in the last 
sequence is the most accurate template. During iterations, all images are 
warped to the template, to provide a series of flow fields that 
parameterize deformations. These parameters are used in the 
normalisation and modulation step.  
The final template was then registered to MNI (Montreal Neurological 
Institiute) space, initially using a linear affine transformation. Information 
from the flow fields derived from the previous iterations and the grey 
matter images were then applied in order to produce individual spatially 
normalised scans to MNI space. At this stage images were modulated to 
preserve local tissue volume information. Modulation accounts for 
variations in global and local anatomy across subjects. Without 
modulation, VBM is able only to compare the relative concentration or 
density of tissues with in area rather than absolute volume. Modulation 
has the effect of preserving the total amount of grey matter signal in the 
normalised partitions, allowing comparison of absolute volumes (ie the 
volume of GM is the same before and after normalization) in one area 
compared with another. Modulation therefore enables comparison of grey 
matter volume across groups.  
Finally, images were spatially smoothed using an isotropic gaussian 
kernel (10mm Full Width at Half Maximum (FWHM)). This results in the 
intensity in each voxel of the smoothed data being a locally weighted 
average of grey and white matter density from a region of surrounding 
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voxels, the size of the region being defined by the size of the smoothing 
kernel (Ashburner and Friston 2000). There are several reasons for 
smoothing the data. Firstly, smoothing increases the signal to noise ratio 
by decreasing the intensity of isolated random-noise voxels, which 
otherwise may be counted as significant data. However, genuinely 
significant clusters, with surrounding activated voxels, will maintain their 
intensity signal with smoothing and still be counted as significant. 
Importantly, the width of the smoothing kernel should be approximately 
equivalent to the expected size of the expected change in brain 
structure/activity according to the matched filter theorem (Jones, Symms 
et al. 2005). Secondly, smoothing aids spatial normalisation by smoothing 
out anatomical differences and variations in structural anatomy to allow 
better registration. Consequently, smoothing compensates for the inexact 
nature of spatial normalisation and helps adjust for registration errors. 
Lastly, smoothing renders the data more normally distributed and 
increases the validity of parametric statistics, allowing SPM to make 
inferences about the data. Smoothing with a Gaussian kernel fulfils the 
prerequisites underpinning correction for multiple comparisons according 
to Gaussian Random Field theory (GRF) (Ashburner and Friston 2000). 
 Statistical Analyses 4.4
Group-level statistical analysis was performed using the general linear 
model (GLM) (Friston, Holmes et al. 1995, Worsley and Friston 1995). 
Comparisons between the 3 groups (controls, MLBP, and NuLBP) were 
conducted using voxelwise univariate analysis of covariance (ANCOVA) 
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with age and gender included as covariates of no interest in the model. 
Planned contrasts were used to examine group differences between the 
following groups: CLBP and controls; MLBP and controls; NuLBP and 
controls; MLBP and NuLBP. Total Intra-Cranial Volume (TIV) was 
included in the SPM global calculations to account for global brain 
volumes of different subjects (Good, Johnsrude et al. 2001, Resnick, 
Pham et al. 2003, Barnes, Ridgway et al. 2010, Pail, Brazdil et al. 2010).  
Significant groupwise differences in GM volumes were identified following 
an initial height threshold of p < 0.01 and corrected for multiple 
comparisons using non-stationary cluster extent correction at threshold of 
p<0.05. Non-stationary cluster extent correction corrects for 
heterogeneity in the smoothness of the height thresholded corrected t-
statistic and allows for valid cluster-level inference (Hayasaka and 
Nichols 2004). Use of Non-stationary cluster extent correction has 
already been discussed in the Statistical Analysis section in Chapter 4. 
The behavioural data detailed in chapter 3 show significant differences 
between CLBP and controls and between MLBP and NuLBP groups. Our 
data show differences in CES-D and STAI-state scores between all 
groups (there were no differences in STAI-trait scores between NuLBP 
and MLBP groups, however).  
In order to examine the question of whether VBM group differences could 
be attributed to these psychological variables rather than underlying pain 
mechanisms, I carefully considered the statistical methods that would 
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allow an answer to this question. Whole-brain regression analysis of both 
our VBM and ASL data with CES-D and STAI-state scores was chosen, 
in order to examine the relationship between depression and anxiety 
scores and structural group differences. Whole-brain regression analysis 
was used, rather than post-hoc analysis of significant regions of interest, 
in order to avoid the pitfalls of circular data analysis (so-called “double 
dipping”) in which false positive results can be obtained by first obtaining 
data to select a subset and then undertaking further analysis of this data 
to obtain artificially inflated false positive results (for a full discussion of 
this topic see (Kriegeskorte, Simmons et al. 2009, Kriegeskorte, Lindquist 
et al. 2010).  
I also considered using CES-D and STAI-state scores as an additional 
covariate in an ANCOVA analysis to “correct” and “control” for the 
influence of these variables in our analysis. However, as the CES-D and 
STAI-state scores differed between groups it was not possible to include 
them in an ANCOVA, as an ANCOVA cannot be used when groups differ 
on a covariate, as stated in Miller and Chapman’s seminal paper of 2001 
(Miller and Chapman 2001).  
Whole brain regression analysis of the structural data with depression 
and anxiety variables was performed separately for the MLBP and 
NuLBP groups.  The results of the regression analysis were then 
compared to the results of the between groups ANCOVA. It was 
reasoned that if the regression analysis showed significant structural 
alterations in areas in which we also observed significant ANOVA group 
differences, it could be argued that the group differences in areas 
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common to both groups were primarily driven by the psychological 
variables. 
 Results  4.5
 CLBP Patients Show Reduced GM Volume Compared 4.5.1
To Controls. 
LBP subjects demonstrated a widespread pattern of clusters with reduced 
grey matter (GM) volumes, compared to controls (see Table 49).  
CLBP subjects compared to controls demonstrated significantly reduced 
GM volumes in the superior frontal gyrus (SFG) in the right frontal pole 
and in the right dorsomedial prefrontal cortex extending anteriorly (see 
Figure 38 and Figure 39). We observed a large cluster that extended from 
the left dorsolateral prefrontal cortex (DLPFC) into the left and right 
pregenual anterior cingulate cortex (pACC). A cluster was also identified 
in the right DLPFC. Reduced volumes were also seen in the left pre and 
post central gyrus extending in to the parietal operculum; left 
hippocampus; left middle temporal gyrus and right rostral (inferior) 
precuneus extending in to the posterior cingulate gyrus. Posteriorly, GM 
reductions were seen in the left occipital pole, extending into the fusiform 
body area in the occipital fusiform gyrus in areas V3 & 4 and right 
fusiform body area in the occipital fusiform gyrus. There were also two 
centrally located clusters that traversed right and left hemispheres in the 
cuneus, one inferior and one superior. The superior cluster extended into 
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the right lateral occipital pole. We also identified a cluster in the left lateral 
occipital cortex that crossed from the inferior to superior divisions. 
  208 
Table 49: CLBP: GM reductions, compared to controls. 
 
* Region = brain region; Cluster size = number of voxels in the cluster; Left = left hemisphere, 
Right = right hemisphere; T-Stat local maxima = T value of peak voxels in the cluster; x, y, z  = 





Figure 38: Reduced GM volume in CLBP subjects compared to controls  
Clusters show reduced GM volume in CLBP subjects compared to controls in the right superior 
frontal gyrus (SFG), right dorsomedial prefrontal cortex, left and right dorsolateral prefrontal cortex 
(DLPFC), left and right pregenual anterior cingulate cortex (pACC), left primary motor cortex (M1), 
left primary sensory cortex (S1), left hippocampus; left middle temporal gyrus, right rostral 
precuneus, left occipital pole, left and right occipital fusiform gyrus left and right cuneus, right 
lateral occipital pole and left lateral occipital cortex. 
* Results are height thresholded at p<0.01 (t=2.39), corrected for voxelwise multiple comparisons 
using non-stationary cluster extent correction at threshold of p<0.05.  Values of the t-statistic are 
colour coded, range is 2.39-4.83. The image is seen in neurological convention. 
T"Stat T"Stat
local)maxima local)maxima
Posterior)Cingulate) " " " " 2.94 15 "54 8
Cuneus) 2.75 "5 "87 36 3.03 2 "89 14
Occipital)Pole)(V1) 2.75 "12 "93 8 4.30 14 "86 38
Occipital)Pole)(V2) " " " " 2.90 23 "95 18
Occipital)Cortex)(lateral) " " " " 3.11 39 "75 15
Anterior)Cingulate)Cortex)(pregenual) 3.93 "5 47 14 " " " "
Anterior)mid)Cingulate)cortex 2.68 "11 29 18 3.29 14 26 20
Superior)Frontal)Gyrus:))Frontal)Pole 2.94 "29 53 30 " " " "
Dorsolateral)Prefrontal)Cortex) " " " " 3.63 29 35 39
3 Frontal)Pole) 3033 " " " " 4.51 21 65 23
4 Occipital)Fusiform)gyrus 2633 4.83 "30 "78 "14 " " " "
5 Middle)Temporal)Gyrus) 822 3.48 "53 "12 "18 " " " "
6 Hippocampus)) 783 3.87 "21 "21 "14 " " " "
7 Occipital)Cortex)(lateral) 667 4.08 "38 "78 15 " " " "
8 Postcentral)Gyrus) 605 3.81 "38 "15 27 " " " "








x y z x y z
t 2.39 4.83 
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Figure 39: Reduced GM volume in CLBP subjects compared to controls  
Clusters show reduced GM volume in CLBP subjects compared to controls in the right superior 
frontal gyrus (SFG), right dorsomedial prefrontal cortex, left and right dorsolateral prefrontal cortex 
(DLPFC), left and right pregenual anterior cingulate cortex (pACC), left primary motor cortex (M1), 
left primary sensory cortex (S1), left hippocampus; left middle temporal gyrus. 
* Results are height thresholded at p<0.01 (t=2.39), corrected for voxelwise multiple comparisons 
using non-stationary cluster extent correction at threshold of p<0.05.  Values of the t-statistic are 
colour coded, range is 2.39-4.83. The image is seen in neurological convention. 
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 CLBP Patients Show Increased GM Volume 4.5.2
Compared To Controls. 
We observed several clusters with increased GM volume (see Table 50). 
Anteriorly, we saw GM increases bilaterally in the lentiform nuclei, 
extending into the margin of the right thalamus and extending inferiorly 
into the nucleus accumbens (NAc) and orbitofrontal cortex (OFC) (see 
Figure 40 & Figure 41). We also saw a large central cluster in the 
brainstem extending superiorly from the upper medulla to the mid section 
of the pons. We observed a cluster traversing the right pre and post-
central gyrus from the primary motor cortex (M1) running inferiorly and 
laterally and posteriorly into the primary somatosensory cortex (S1). GM 
volume increases were seen in clusters bilaterally spanning the superior 
and inferior parietal lobules. On the left, the cluster originated superiorly 
on the edge of the primary somatosensory cortex (S1) and ran inferiorly 
into the superior parietal lobule / supramarginal gyrus / angular gyrus. 
Much of this cluster encompassed the intra-parietal sulcus (as did the 
cluster on the right). Posteriorly, we saw further bilateral clusters 
bilaterally in the superior/inferior parietal cortex. We also identified a 
cluster in the right dorsal/superior precuneus. 
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Table 50: CLBP: Increased GM compared to controls. 
 
* Region = brain region; Cluster size = number of voxels in the cluster; Left = left hemisphere, 
Right = right hemisphere; T-Stat local maxima = T value of peak voxels in the cluster; x, y, z  = 




Figure 40: Increased GM volume in CLBP subjects compared to controls  
Clusters show increased GM volume in CLBP subjects compared to controls bilaterally in the 
lentiform nuclei, nucleus accumbens (NAc) and orbitofrontal cortex (OFC).  
* Results are height thresholded at p<0.01 (t=2.39), corrected for voxelwise multiple comparisons 
using non-stationary cluster extent correction at threshold of p<0.05.  Values of the t-statistic are 




Primary*Motor*Cortex*(M1) " " " " 3.27 20 "23 56
1 Primary*Somatosensory*Cortex*(S1) " " " " 3.10 24 "30 51
Anterior*intra"Parietal** " " " " 3.86 29 "66 36
2 Anterior*intra"Parietal** 1735 3.81 "23 "56 47 " " " "
Orbitofrontal*cortex " " " " 3.26 9 5 "17
3 Thalamus* " " " " 4.46 18 "8 3
Lentiform*Nucleus*(putamen) " " " " 2.97 29 "15 "2
Nucleus*Accumbens* 2.60 "12 9 "12 " " " "
Lentiform*Nucleus*(pallidum)* 2.89 "23 "3 3 " " " "
Occipital*Cortex*(lateral) 3.30 "30 "68 20 " " " "
Superior*Parietal*Lobule* 3.05 "26 "72 47 " " " "
6 Precuneus* 303 3.40 3 "59 63 " " " "
7 Brainstem* 295 3.75 0 "33 "41 " " " "









t 2.39 4.46 
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Figure 41: Increased GM volume in CLBP subjects compared to controls  
Clusters show increased GM volume in CLBP subjects compared to controls in the right primary 
motor cortex (M1), and left and right primary somatosensory cortex (S1), superior and inferior 
parietal lobules and right dorsal/superior precuneus. 
* Results are height thresholded at p<0.01 (t=2.39), corrected for voxelwise multiple comparisons 
using non-stationary cluster extent correction at threshold of p<0.05.  Values of the t-statistic are 
colour coded, range is 2.39-4.46. The image is seen in neurological convention. 
.
t 2.39 4.46 
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 MLBP And NuLBP: Individual Subgroup Analyses 4.5.3
Compared To Controls. 
MLBP and NuLBP sub-groups showed clusters of GM increases and 
decreases when compared individually to controls.  
 MLBP And NuLBP Patient Groups Show Reduced GM 4.5.3.1
Volumes In Common Areas Compared To Controls.  
Both MLBP and NuLBP subjects compared to controls showed reductions 
in the left pACC, right SFG in the frontal pole, right superior cuneus, left 
occipital fusiform (V3/4 extra striatal body area), left inferior cuneus and 
left lateral occipital cortex (see Table 51, Table 52, Figure 42 & Figure 
43).  
Table 51: MLBP group GM reductions compared to controls 
 
* Region = brain region; Cluster size = number of voxels in the cluster; Left = left hemisphere, 
Right = right hemisphere; T-Stat local maxima = T value of peak voxels in the cluster; x, y, z  = 





Cuneus " " " " 2.86 3 "87 19
1 Occipital*Pole*(V1) " " " " 2.88 5 "93 6
Occipital*Pole*(V)2 " " " " 2.78 21 "95 18
2 Frontal*Pole 2859 " " " " 3.86 23 65 23
Precuneus " " " " 3.39 29 "54 17
Lateral*occipital*cortex " " " " 3.15 38 "71 14
Anterior*cingulate*Cortex*"*pregenual 1437 2.76 "5 47 14 " " " "
4 Dorsolateral*Prefrontal*Cortex 1437 5.40 "29 42 17 " " " "
Superior*Frontal*Gyrus:**Frontal*Pole 1437 2.62 "29 56 32 " " " "
5 Occipital*fusiform* 1264 4.33 "30 "78 "12 " " " "
6 Postcentral*Gyrus 567 3.69 "38 "15 27
7 Lateral*Occipital*Cortex 522 3.63 "38 "80 15 " " " "





x y z x y
2919
2776
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 Local Reductions In GM Volume Unique To MLBP Patients, 4.5.3.2
Compared To Controls.  
Only MLBP subjects, compared to controls, showed reductions in the left 
primary somatosensory cortex into the opercular cortex; left DLPFC into 
the frontal pole; right DLPFC, precuneus and right posterior cingulate into 
the inferior/ventral precuneus (Table 51, Figure 42).  
 
Figure 42: Reduced GM volume in MLBP subjects compared to controls.  
GM reductions are seen in the left primary somatosensory cortex into the opercular cortex; left 
DLPFC and frontal pole; right DLPFC, precuneus and right posterior cingulate and inferior/ventral 
precuneus. 
* Results are height thresholded at p<0.01 (t=2.39), corrected for voxelwise multiple comparisons 
using non-stationary cluster extent correction at threshold of p<0.05.  Values of the t-statistic are 
colour coded, range is 2.39-4.83. The image is seen in neurological convention. 
  
t 2.39 4.46 
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 Local Reductions In GM Volume Unique To NuLBP Patients, 4.5.3.3
Compared To Controls.  
Only NuLBP subjects, compared to controls, showed reductions in the left 
orbitofrontal cortex, hippocampus, left middle temporal gyrus, right 
anterior MCC and right inferior occipital pole (see Table 52, Figure 43).  
Table 52: NuLBP group GM reductions compared to controls. 
 
* Region = brain region; Cluster size = number of voxels in the cluster; Left = left hemisphere, 
Right = right hemisphere; T-Stat local maxima = T value of peak voxels in the cluster; x, y, z  = 




Figure 43: Reduced GM volume in NuLBP subjects compared to controls. 
Reductions are seen in the left orbitofrontal cortex, hippocampus, left middle temporal gyrus, right 
anterior MCC and right inferior occipital pole 
Results are height thresholded at p<0.01 (t=2.39), corrected for voxelwise multiple comparisons 
using non-stationary cluster extent correction at threshold of p<0.05.  Values of the t-statistic are 




Anterior*Cingulate*Cortex*(pregenual) 4.05 "5 47 12 " " " "
Mid*Cingulate*Cortex*(anterior) " " " " 3.11 15 29 33
2 Occipital*Fusiform*Gyrus 2339 4.14 "30 "78 "15 " " " "
Cuneus 2.52 "3 "89 15 " " " "
3 Occipital*Pole 2188 " " " " 3.17 24 "96 "2
Lateral*Occipital*cortex* " " " " 2.66 48 "78 "8
Hippocampus 3.72 "24 "21 "14 " " " "
Middle*Temporal*Gyrus 3.08 "53 0 "23 " " " "
4 Frontal*Pole 1401 " " " " 4.18 18 65 24
5 Cuneus 643 " " " " 3.71 14 "84 38
6 Orbitofrontal*Cortex 523 3.08 "21 32 "26 " " " "






x y z x y
4267
1716
t 2.39 4.18 
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 MLBP And NuLBP Patient Groups Show Increased GM 4.5.3.4
Volumes In Common Areas Compared To Controls.  
Both MLBP and NuLBP subjects, compared to controls, showed 
increases in the right and left superior parietal lobule and right pallidum 
(see Table 53, Table 54) 
Table 53: MLBP GM increases compared to controls 
 
* Region = brain region; Cluster size = number of voxels in the cluster; Left = left hemisphere, 
Right = right hemisphere; T-Stat local maxima = T value of peak voxels in the cluster; x, y, z  = 
orientation in MNI space. 
 
 
Table 54: NuLBP GM increases compared to controls. 
 
* Region = brain region; Cluster size = number of voxels in the cluster; Left = left hemisphere, 
Right = right hemisphere; T-Stat local maxima = T value of peak voxels in the cluster; x, y, z  = 




Lentiform*Nucleus*(Putamen) " " " " 4.01 14 14 "12
Lentiform*Nucleus*(Pallidum) " " " " 4.47 18 "6 2
Orbitofrontal*cortex 2.57 "14 8 "27 " " " "
2 Lentiform*Nucleus*(Putamen) 2.68 "24 15 "12 " " " "
Lentiform*Nucleus*(Pallidum) 2.84 "14 "2 "5 " " " "
Premotor*cortex " " " " 2.67 30 "17 54
Primary*motor*cortex " " " " 3.53 32 "30 51
4 Superior*parietal*lobule 1610 2.97 "20 "50 52 " " " "
5 Superior*parietal*lobule 1014 " " " " 3.35 33 "69 39












1 Superior*parietal*lobule 1378 " " " " 3.61 27 "65 36
2 Precuneus 945 " " " " 4.43 3 "57 65
3 Inferior*Parietal*Lobule 558 " " " " 3.47 44 "60 53
4 Superior*parietal*lobule 554 3.86 "23 "56 47 " " " "
5 Brainstem 175 3.51 0 "32 "39 " " " "




x y z x y
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 Local Increases In GM Volume Unique To The MLBP Group, 4.5.3.5
Compared To Controls. 
 MLBP subjects compared to controls alone showed increases in the right 
premotor cortex into M1/S1; in the right putamen (lentiform nucleus) and 
into the left pallidum and putamen (lentiform nucleus) extending into the 
nucleus accumbens and orbito-frontal cortex (see Table 53 & Figure 44).  
 
Figure 44: Increased GM volume in MLBP subjects compared to controls:  
MLBP subjects show increased GM in the right and left superior parietal lobule, right premotor 
cortex into M1/S1); in the right and left pallidum and putamen (lentiform nucleus) and left nucleus 
accumbens and orbito-frontal cortex. 
* Results are height thresholded at p<0.01 (t=2.39), corrected for voxelwise multiple comparisons 
using non-stationary cluster extent correction at threshold of p<0.05.  Values of the t-statistic are 
colour coded, range is 2.39-4.47. The image is seen in neurological convention. 
 
 Local Increases In GM Volume Unique To The NuLBP Group, 4.5.3.6
Compared To Controls. 
NuLBP subjects compared to controls alone showed increases in the 
brain stem and right thalamus just medial to the right lentiform nucleus, 
right superior precuneus just lateral to the midline and right inferior 
parietal lobule (see Table 54 & Figure 45). 
t 2.39 4.47 
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Figure 45: Increased GM volume in NuLBP subjects compared to controls. 
NuLBP subjects show increases in the brain stem and right thalamus just medial to the right 
lentiform nucleus, right superior precuneus, right inferior parietal lobule and right and left superior 
parietal lobule. 
* Results are height thresholded at p<0.01 (t=2.39), corrected for voxelwise multiple comparisons 
using non-stationary cluster extent correction at threshold of p<0.05.  Values of the t-statistic are 
colour coded, range is 2.39-4.43. The image is seen in neurological convention. 
  
t 2.39 4.43 
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 NuLBP Patients Show Relative Reductions In GM 4.5.4
Volume Compared To MLBP Patients. 
Compared to MLBP subjects, NuLBP subjects showed GM reductions 
bilaterally in the mid cingulate cortex (predominantly on the left) in a large 
cluster that encompassed both anterior and posterior parts of the mid 
cingulate cortex (MCC); in the left orbitofrontal cortex (OFC) extending 
laterally from the margins of the subcallosal cortex into the inferior aspect 
of the left insula cortex; left DLPFC and two clusters in the cerebellum, 
superiorly, centrally in the culmen and on the left, inferiorly in the 
cerebellar tonsil (see Table 55, Figure 46, Figure 47 & Figure 48). 
Table 55: NuLBP GM reductions compared to MLBP. 
 
* Region = brain region; Cluster size = number of voxels in the cluster; Left = left hemisphere, 
Right = right hemisphere; T-Stat local maxima = T value of peak voxels in the cluster; x, y, z  = 




1 *Cerebellum 2669 3.13 "32 "59 "51 " " " "
2 Orbitofrontal*Cortex 777 3.53 "18 30 "30 " " " "
3 Cerebellum 726 3.33 0 "62 "3 2.52 2 "42 "6
4 Mid"Cingulate*Cortex 573 2.85 0 0 30 " " " "
5 DLPFC 411 3.13 "26 9 27 " " " "
Left Right
x y z x y z
Cluster Region Cluster*Size
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Figure 46: GM reductions in NuLBP patients compared to MLBP patients.  
GM reductions are seen in the left OFC, anterior insula, DLPFC and cerebellum. 
* Results are height thresholded at p<0.01 (t=2.39), corrected for voxelwise multiple comparisons 
using non-stationary cluster extent correction at threshold of p<0.05.  Values of the t-statistic are 
colour coded, range is 2.39-3.58. The image is seen in neurological convention. 
 
 
Figure 47: GM reductions in NuLBP patients compared to MLBP patients. 
GM reductions are seen in the left DLPFC and bilateral mid cingulate. 
* Results are height thresholded at p<0.01 (t=2.39), corrected for voxelwise multiple comparisons 
using non-stationary cluster extent correction at threshold of p<0.05.  Values of the t-statistic are 
colour coded, range is 2.39-3.58. The image is seen in neurological convention. 
 
Figure 48: GM reductions in NuLBP patients compared to MLBP patients.  
GM reductions are seen in the bilateral mid cingulate, DLPFC and cerebellum 
* Results are height thresholded at p<0.01 (t=2.39), corrected for voxelwise multiple comparisons 
using non-stationary cluster extent correction at threshold of p<0.05.  Values of the t-statistic are 
colour coded, range is 2.39-3.58. The image is seen in neurological convention. 
 
t 2.39 3.58 
t 2.39 3.58 
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 NuLBP Patients Show Local Increases In GM Volume 4.5.5
Compared To MLBP Patients 
Compared to MLBP subjects, NuLBP subjects showed GM increases in a 
cluster superiorly just to the right of the midline in the right precuneus 
(see Table 56, Figure 49). 
Table 56: NuLBP GM increases compared to MLBP 
 
* Region = brain region; Cluster size = number of voxels in the cluster; Left = left hemisphere, 
Right = right hemisphere; T-Stat local maxima = T value of peak voxels in the cluster; x, y, z  = 




Figure 49: GM increases in NuLBP patients compared to MLBP.  
NuLBP subjects show GM increases in the right precuneus. 
• Results are height thresholded at p<0.01 (t=2.39), corrected for voxelwise multiple 
comparisons using non-stationary cluster extent correction at threshold of 
p<0.05.  Values of the t-statistic are colour coded, range is 2.39-3.83. The image is seen 




1 Precuneus 375 " " " " 3.83 3 "56 66
Left Right
x y z x y z
Cluster Region Cluster*Size
t 2.39 3.83 
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 Regression analysis 4.5.6
 CES-D 4.5.6.1
Comparison of regression analysis using CES-D with analysis of group 
differences (ANOVA) showed negligible overlap in areas in which GM 
alterations were observed.  
 
Figure 50: Composite image showing results of a) analysis of group differences (ANOVA) and b) 
CES-D regression analysis. 
Areas in green show all significant alterations in grey matter (increases or decreases) between 
groups (ANOVA: CLBP & controls, MLBP & NuLBP). Areas in red show significant relationships 
between alterations in grey matter (increases or decreases) and CES-D scores (Regression 
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 STAI-state 4.5.6.2
Comparison of regression analysis using STAI-state with analysis of 
group differences (ANOVA) showed negligible overlap in areas in which 
GM alterations were observed.  
 
Figure 51: Composite image showing results of a) analysis of group differences (ANOVA) and b) 
STAI-state regression analysis. 
Areas in green show all significant alterations in grey matter (increases or decreases) between 
groups (ANOVA: CLBP & controls, MLBP & NuLBP). Areas in red show significant relationships 
between alterations in grey matter (increases or decreases) and STAI-state scores (Regression 
analysis). Areas in yellow show areas of alterations in grey matter common to both analyses. 
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 Discussion  4.6
 Summary Of Results 4.6.1
The wide variations in patient demographics, pain intensity, duration, 
psychometrics and symptom profiles of our patients are an accurate 
representation of the heterogeneity of the CLBP clinical population. We 
attempted to account for these variations by including specific covariates 
in our analyses (Miller and Chapman 2001). Furthermore, we categorised 
these patients into diagnostic mechanical and neuropathic subgroups 
using a highly sensitive, specific and positively predictive accurate 
questionnaire (painDETECT) (Freynhagen 2006).  
Compared to controls, CLBP subjects demonstrated significantly reduced 
GM volumes in the following regions: right frontal pole, bilateral 
dorsolateral prefrontal cortex, bilateral pregenual anterior cingulate 
cortex, left M1, S1, hippocampus, middle temporal gyrus, right posterior 
cingulate gyrus, left extrastriatal body (occipital fusiform gyrus), bilateral 
superior and inferior cuneus, right occipital pole and right lateral occipital 
cortex.  
GM volume increases in CLBP compared to controls were seen in the 
following regions: bilateral superior and inferior parietal lobules, bilateral 
lentiform nucleus, bilateral nucleus accumbens, margin of the right 
thalamus, right orbitofrontal cortex, brainstem, right pre-motor cortex, M1, 
S1 and right dorsal/superior precuneus.  
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We were able to identify discrete morphological profiles for MLBP and 
NuLBP subgroups. NuLBP subjects showed GM reductions in the 
following regions: bilateral mid cingulate cortex (predominantly on the 
left), left orbitofrontal / inferior anterior insula, left DLPFC, left cerebellum. 
NuLBP subjects showed GM increases, compared to MLBP subjects, in 
the right precuneus only.   
In the following section I will discuss how these findings relate to the 
clinical picture of CLBP and, in particular, NuLBP. Throughout, I will make 
reference to where changes apply to all CLBP patients (CLBP compared 
to controls) and where changes apply to NuLBP and MLBP sub-groups 
(NuLBP compared to MLBP).  
I will show that clusters of GM volume alterations relate not only to the 
sensory discriminative experience of CLBP but also to areas devoted to 
cognitive-evaluative and affective-motivational aspects of the pain 
experience. I will show that the GM volume alterations that we have 
observed reflect neuroplastic changes that reflect the emotional and 
cognitive toll of living with persistent pain and suggest that these changes 
relate to concepts of disembodiment and even to a loss of self-identity. 
These changes have clinical importance as they strongly suggest that 
treatment of low back pain needs to not only target sensory aspects of 
pain but also cognitive and affective components, that may even cause 
an individual with CLBP to fundamentally re-evaluate their identity. The 
data suggest that that GM volume is altered in regions that are 
substantially involved with the following roles: 
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• Evaluation and assessment of internal and external stimulus 
saliency and decision making; 
• Regulation of mood and emotional response to pain; 
• Pain modulation; 
• Body image; 
Throughout, I discuss these themes in order of hypothesis 1 (CLBP 
patients demonstrate brain morphological differences compared to 
controls) and hypothesis 2 (NuLBP patients demonstrate specific 
alterations in GM volume compared to MLBP patients). Although these 
results show distinct differences in GM volume between NuLBP and 
MLBP patients, brain regions affected show considerable overlap with 
those observed in CLBP patients as a whole. The data suggest that all 
patients suffer in similar respects across all three dimensions of pain 
(using the model of Melzack and Casey (Melzack and Casey 1968). 
However, the data (and also in the behavioural data from the previous 
chapter) show a greater degree of suffering in patients with NuLBP. Many 
of the themes and brain regions are common to discussion of both 
hypotheses.  
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 CLBP Patients Compared To Controls, And In 4.6.2
Particular, NuLBP Patients Compared To MLBP 
Patients, Show GM Reductions In Areas Involved In 
Assessment And Evaluation Of The State Of The 
Body. 
 OFC And Insula GM Reductions In NuLBP Patients 4.6.2.1
Compared To MLBP Are Evidence Of Increased Evaluation 
And Scrutiny Of Internally And Externally Generated Input. 
I interpret GM reductions in the left orbitofrontal cortex (OFC) and anterior 
insula in NuLBP subjects (NuLBP compared to MLBP and NuLBP 
compared to controls) as a likely reflection of an ongoing state of 
assessment and evaluation of a hostile internal and external environment 
by an individual that feels under threat (physically, cognitively and 
emotionally). The scrutiny and evaluation of internally and externally 
generated inputs is central to the formulation of decisions relating to 
output generation and the choice of behaviours relating to the threat of 
low back pain. 
The OFC is involved in multiple roles in sensory integration, reward 
processing, decision making and hedonic processing (Kringelbach 2005). 
The OFC is involved in appraising the valence and reward value of multi-
sensory stimuli (O'Doherty 2004) and, in conjunction with the amygdala 
and ventral striatum, reward prediction, allowing behaviour to be 
organised in advance of stimuli. In particular, activity in the medial OFC is 
thought to encode the reward value of reinforcers, whereas activity in the 
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lateral OFC is thought to encode the reward value of punishers, leading 
to changes in behaviour. Ultimately, the OFC has a key role in the 
decision-making process itself (Bechara, Damasio et al. 2000, Bechara, 
Tranel et al. 2000). Patients with orbitofrontal lesions are impaired in 
everyday decision-making despite normal intellectual capacity (Bechara, 
Damasio et al. 2000, Kringelbach 2005).  
Our behavioural data provide ample evidence of the impact of CLBP and, 
in particular, NuLBP, on the quality of life of this cohort of patients; a 
finding consistent with a wide variety of pain related and psychometric 
domains. In particular, GM alterations in the OFC and insula cortex may 
particularly reflect the reduced decision-making capacity and consequent 
behavioural choices of CLBP patients with neuropathic, compared to non-
neuropathic symptoms. It would be of particular interest in future to 
examine variability in these regions using BOLD fMRI in these diagnostic 
groups in tasks designed to probe decision-making processes. 
 DLPFC GM Reductions In CLBP And NuLBP Patients May 4.6.2.2
Reflect Deficits In Decision-Making 
We also observed reductions in DLPFC GM volume in NuLBP compared 
to MLBP subjects and in CLBP subjects compared to controls.  
The DLPFC is involved in many higher-level cognitive processes, 
collectively termed executive function, including working memory, 
attention, set-shifting, reward evaluation and motor planning (Schmitz, 
Kawahara-Baccus et al. 2004, Murray and Ranganath 2007, Ardila 2008). 
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CLBP patients with altered levels of DLPFC metabolites and decreased 
GM volume perform poorly in tests designed to test “emotional decision 
making” (Iowa Gambling Task) and executive function (Grachev, 
Fredrickson et al. 2000, Apkarian, Sosa et al. 2004, Apkarian, Sosa et al. 
2004). I therefore suggest that the reductions in DLPFC GM volume we 
have observed may help to explain the cognitive deficits experienced by 
many CLBP and chronic pain patients (Keogh, Moore et al. 2013). 
Chronic pain patients frequently complain of cognitive deficits, such as 
reduced ability to concentrate when reading or watching a film, or of poor 
routine task performance. Clinicians may be inclined to dismiss such 
comments as irrelevant to the clinical picture of the patient. However, I 
suggest that the OFC reductions we have observed in NuLBP patients 
compared to controls, and DLPFC GM reductions in both groups, are 
linked to poor decision-making and subsequent maladaptive behavioural 
choices observed in CLBP patients.  
Both these areas are reduced significantly in NuLBP compared to MLBP 
patients and CLBP compared to controls. In particular, the DLPFC 
appears to be involved in evaluating long term versus short-term gain, via 
high level ‘neuroeconomic’ processing (Glimcher 2013) whereas by 
contrast, the OFC is involved with assessing the immediate reward value 
of a sensory stimulus (Kringelbach, de Araujo et al. 2004, Kringelbach 
2005). This suggests that higher order DLPFC processing inhibits 
immediate reward gratification. Local reductions in GM in these regions 
may reflect regulatory dysfunction between the OFC and DLPFC and also 
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reflect the greater behavioural costs of neuropathic back pain, as 
demonstrated in our behavioural data. Such behavioural sequelae are 
seen clinically in maladaptive cognitions and behavioural patterns, such 
as under and over activity, withdrawal from usual activities of daily living, 
social withdrawal, over-reliance on prescription and non-prescription 
medication, over-reliance on seeking treatments in spite of lack of 
success, negative appraisal, rumination and catastrophising.  
 GM Reductions In NuLBP Patients Compared To MLBP In 4.6.2.3
The ACC/OFC/Insula, May Reflect Increased Attentional 
Resources Devoted To Monitoring The Internal Environment 
And Stimulus Saliency. 
In NuLBP, compared to MLBP patients, we observed GM reductions in 
the anterior division of the mid cingulate and orbitofrontal insula. We also 
observed changes in the pregenual ACC in CLBP patients compared to 
controls. GM reductions in the cingulate/OFC /anterior insula may reflect 
perturbations in assessment of the salience of internally generated 
stimuli, resulting in in terms of their potential threat/reward value. I 
speculate that such alterations may play a role in altered decision-making 
processes observed in patients with CLBP.   
The anterior insula, in conjunction with the ACC and OFC, has been 
previously suggested as a site for integration of pain perception (Brooks 
and Tracey 2005), coding of pain intensity (Coghill, Sang et al. 1999) and 
where multimodal stimuli from the body, including pain) are 
estimated/surveyed (interoception) (Craig 2003) in order to evaluate the 
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state of the body and assess the need to take action, in order to maintain 
homeostasis. Moyaedi and Weissman-Fogel, however, (Moayedi and 
Weissman-Fogel 2009), citing the work of Moraux and Iannetti (Mouraux, 
Diukova et al. 2011) point out that it is as yet unknown whether the insula 
codes primarily for pain, rather than for stimulus saliency. The anterior 
insula and ACC have been posited as forming the core of a salience 
network that governs processing of hierarchical behavioural responses to 
stimuli including accessing attentional or working memory networks and 
coordinating autonomic and motor responses, as well as modulating 
contextual emotional and sensory inputs with other subcortical and 
cortical areas (Flor, Knost et al. 1997, Seeley, Menon et al. 2007, Menon 
and Uddin 2010). The anterior insula has also been implicated in 
Damasio’s “somatic marker” hypothesis in processing somatic and 
visceral input, in order to frame an emotional response on which decision-
making is predicated (Damasio, Grabowski et al. 2000, Damasio 2005). I 
suggest that reductions in these areas reflect the dysregulation of 
emotional control in decision-making that is seen clinically in CLBP 
patients whereby exaggerated emotional responses are associated with 
somatic markers such as the alterations in physiological behavioural 
responses (alterations in muscle tone/guarding, alterations in movement 
patterns) that are associated with an emotional response (e.g. 
fear/anxiety) in response to a behavioural challenge (e.g. walking, sitting 
to standing, lifting). Over time, the behavioural and corresponding 
emotional responses may become conditioned.  
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Furthermore, Changes in OFC/insula were seen primarily in the NuLBP 
population. I further speculate this finding may reflect the increased affect 
on salience of neuropathic pain due to increases in pain intensity, impact 
on quality of life and increased negative affect observed in our 
behavioural data; a reflection of the attentional resources increasingly 
devoted to maladaptive assessment and vigilance towards the ongoing 
nature of their pain by the NuLBP population. 
Our study also identified GM alterations in additional regions of the 
salience network in both NuLBP subjects (cingulate, anterior insula, 
DLPFC, cerebellum and precuneus) and in CLBP subjects (anterior 
cingulate, prefrontal cortex including the DLPFC and MFPC, 
hippocampus, parietal lobe, basal ganglia, precuneus, brainstem and 
temporal gyrus) (for a review of key areas associated with salience 
networks and pain see (Borsook, Edwards et al. 2013)). GM reductions in 
these regions may underpin heightened states of alertness and 
responsiveness to both painful and non-painful stimuli that are seen 
clinically in patients with CLBP; especially in NuLBP patients, who 
demonstrate higher levels of pain with greater negative affect as 
described in the previous chapter.  
Widespread dysregulation in sensory processing and lowering of 
thresholds for stimulus saliency that occurs in CLBP may be linked to the 
GM alterations and dysregulation seen in regions of salience networks in 
this study. For instance, CLBP patients describe sour taste stimuli as 
significantly more intense than normal controls (Small and Apkarian 
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2006) and are less able to disregard incoming auditory information (Fann, 
Preston et al. 2005). CLBP patients also demonstrate an enhanced EEG 
signal to pain-related words (Flor, Knost et al. 1997) and report increased 
pain when viewing images of painful events. It has been shown that the 
increased pain levels are associated with activation in the precuneus, 
cingulate and anterior insula, part of the salience network (Shimo, Ueno 
et al. 2011). Similar results are described for migraine sufferers reporting 
increased symptoms on viewing pain-related words (Eck, Richter et al. 
2011). Practical constraints limited the amount and spread of 
neuropsychological testing of our participants, but future studies should 
include more generalised assessment of stimulus saliency in individuals 
with CLBP. Such testing would facilitate understanding of potential 
relationships between stimulus saliency, local variability in GM and its 
interaction with clinical back phenotypes. 
 GM Increases In The Basal Ganglia In CLBP Patients 4.6.2.4
Compared To Controls: Might These Changes Relate To 
Increasing Demands Of Integrating Cortical And Sub-
Cortical Networks Involved In Pain Processing? 
In CLBP subjects compared to controls, largely driven by the MLBP 
group, we observed bilateral increases in the lentiform nuclei 
(incorporating medial and lateral globus pallidus and putamen) extending 
into the nucleus accumbens. I suggest that these GM increases are 
related to the involvement of the basal ganglia in integrating and 
modulating sensory, cognitive and affective elements of the pain 
experience via cortical and sub-cortical feedforward and feedback loops, 
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which incorporate multiple inputs from areas where we have also seen 
GM alterations (DLPFC, ACC, hippocampus, orbitofrontal, pre-motor, M 
1, S1 and parietal cortex) (Chudler and Dong 1995, Schweinhardt, 
Kuchinad et al. 2008, Borsook, Upadhyay et al. 2010). Furthermore, the 
nucleus accumbens (NAc), part of the dopaminergic mesolimbic pathway, 
encodes valuation of reward or punishment value ascribed to actions 
(O'Doherty 2004, Montague, King-Casas et al. 2006, Schultz 2006). 
Reports of functional connectivity analysis of resting-state fMRI data, 
using NAc as a seed, have reported inter-relationships between the NAc 
and brain areas where we have seen GM alterations associated with 
valuation, action selection and pain modulation such as the basal ganglia, 
amygdala, ACC, MPFC, OFC, thalamus and anterior insula. (Baliki, Geha 
et al. 2010).   
I therefore propose that the bilateral basal ganglia GM increases we have 
observed in CLBP patients (and that others have observed in CLBP 
(Schmidt-Wilcke, Leinisch et al. 2006) and in other clinical conditions 
(Schmidt-Wilcke, Luerding et al. 2007, Schweinhardt, Kuchinad et al. 
2008) reflect the on-going assessment of the threat and reward value of 
intended and actual behavioural decisions that have to be taken on a 
moment to moment basis, when actions and activities are no longer pain-
free and thoughtless due to LBP. A suitable BOLD (blood oxygen level 
dependent) fMRI decision-making experiment in individuals with CLBP 
and indeed other persistent pain phenotypes would prove to be an 
exciting avenue for future research to test such a working hypothesis. 
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 GM Increases In CLBP Patients Compared To Controls In 4.6.2.5
The Basal Ganglia Relate To Planning Motor Strategies And 
Adjusting To Altered Movement And Muscle Activation 
Patterns. 
The increased basal ganglia GM volume that we have observed may 
equally be an adaptive response to increased afferent and/or aberrant 
inputs, or may result from abnormalities in dopaminergic regulation due a 
combination of aberrant inputs and increased computational workload. 
Basal ganglia GM increases were identified in CLBP patients compared 
to controls and in MLBP (but not NuLBP) subjects compared to controls, 
which suggests that the increases reflect a population that are still 
actively involved in planning motor strategies (and concurrently adjusting 
to altered movement and muscle activation patterns frequently identified 
in CLBP populations (Hodges and Richardson 1999, Hodges, Moseley et 
al. 2003, Ferreira, Ferreira et al. 2004, MacDonald, Moseley et al. 2006, 
MacDonald, Moseley et al. 2009, Hodges and Tucker 2011). In addition, it 
is interesting to note that the GM increases and decreases we observed 
in the motor cortex were also seen in MLBP (and not NuLBP) subjects 
compared to controls. We observed GM increases in right premotor, M1 
and S1 areas that correspond to the homuncular representation of the 
trunk. However, we also saw GM reductions in left S1 and M1 regions 
that were more inferiorly located and extended into the parietal operculum 
(S2). These increases are therefore more likely associated with the 
integration of sensory (including proprioceptive and pain stimuli) and 
motor stimuli to coordinate motor activity (Proske and Gandevia 2009, 
Eickhoff, Jbabdi et al. 2010) which, I suggest, provides evidence in 
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support of a theory of individuals with LBP actively utilising motor 
strategies via feedforward and feedback loops between primary and 
secondary motor regions and the basal ganglia, to manage ongoing 
CLBP. Furthermore, the fact that these changes relate to the MLBP 
population may be related to increased dysregulation in sensory-
discriminative networks in the NuLBP population. Normal sensory-
discriminative processes will allow a measured and appropriate motor 
response to stimuli. I suggest that mechanical back pain retains its 
association with movement provocation and works to adopt appropriate 
motor strategies. However, neuropathic pain is characterised by a non- 
linear response to stimuli – pain out of proportion to the stimulus, latency, 
unusual pain perception – that may make an appropriate behavioural 
motor response challenging due to altered input mechanisms.  
One may also further speculate that the reason these increases are not 
seen in the NuLBP subjects is that the NuLBP population is directing 
ever-increasing resources towards vigilance and prevention of pain by 
reducing activity (as evidenced by our behavioural data) and less towards 
planning motor strategies to actively deal with ongoing back pain. I 
suggest that these results indicate that CLBP patients demonstrate a 
continuum, in which initial resources are directed at developing motor 
strategies, which, as the impact of CLBP increases, are either exhausted 
or extinguished. Therefore, the basal ganglia and motor cortex may be a 
key indicator (in some patients) of the transition from mechanical to 
neuropathic back pain. This is further evidence that mechanical and 
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neuropathic back pain may not depend as much on peripheral 
mechanisms as is widely believed but may rather be mediated by 
supraspinal mechanisms in the central nervous system. Admittedly such 
theories are highly speculative and ultimately are only testable within 
longitudinal study frameworks, for example, ‘at risk’ studies where 
individuals may be followed from their early acute presentations of 
episodes of back pain. 
 Fear Avoidance In CLBP May Be Related To GM Alterations 4.6.2.6
And Dysregulation Of Pain Saliency Networks. 
Knowledge of GM alterations in areas involved in saliency, executive 
function and motor planning, may force clinicians to reconsider long held 
beliefs about patients with CLBP. For instance, the somewhat pejorative 
term “fear avoidance”, used to describe the phenomenon in which 
patients with CLBP avoid activities or situations that trigger pain, may be 
less to do with psychological concepts of fear (and the implication that 
these patients are somehow cowardly and weak) and more to do with 
alterations and dysfunction in networks devoted to salience, executive 
function and motor planning. I suggest that fear avoidance is more to do 
with dysregulation in these networks, leading to increased vigilance 
towards, and on-going assessment of, stimuli related to persistent low 
back pain. Furthermore, failures in neuroeconomic decision making when 
faced with choices of action and inaction, linked to short-term gains (pain 
reduction) versus long-term benefits (participation in an active lifestyle), 
result in poor behavioural choices. Patients have the intellectual capacity 
to understand that excessive reduction in activity levels is harmful, 
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causing not only increased disability but paradoxically, increased pain 
intensity (Vlaeyen and Linton 2000, Leeuw, Goossens et al. 2007). These 
data, however, suggest that GM alterations in salience, executive function 
and motor planning networks may perturb the ability of CLBP patients to 
optimally evaluate sensorimotor stimuli and predict rewards and 
outcomes of normative functioning in their everyday lives. 
  GM Alterations In The Mid Cingulate Cortex In NuLBP 4.6.2.7
Patients Compared To MLBP Relate To Ongoing Behavioural 
Evaluation And Motivational Decision-Making Strategies 
Associated With NuLBP. 
We witnessed GM reductions in the anterior (aMCC) and posterior 
(pMCC) mid cingulate in NuLBP compared to MLBP patients (and in 
pregenual ACC / MPFC (medial prefrontal cortex) in CLBP patients, 
compared to controls).  
I suggest that GM alterations in the mid cingulate provide further 
evidence of perturbed ongoing behavioural evaluation and motivational 
decision-making strategies associated, in particular, with NuLBP.  A key 
role of the cingulate is to integrate pain, cognitions and emotions in order 
to ensure appropriate behavioural responses to pain and to coordinate 
pre-motor planning and skeletomotor orientation (Vogt 2005, Shackman, 
Salomons et al. 2011). Not all parts of the cingulate are equally involved 
in emotion, and studies suggest discrete parcellation of emotional 
processing (Vogt 2005) The anterior MCC, in particular, is associated 
with fear (Vogt and Pandya 1987) due to its cortical connections with the 
  239 
amygdala. In contrast, the pMCC is not associated with emotional 
processing but is involved with skeletomotor orientation in response to 
noxious stimulation (Vogt 2005). Shackman suggests the dorsal aspect of 
the anterior MCC is a hub where negative affect, pain and cognitive 
control overlap to direct goal-orientated behaviour, especially when 
outcomes are uncertain (Shackman, Salomons et al. 2011) (such as 
when a patient with CLBP is engaged in a difficult and painful functional 
task). As a result, increased anterior MCC activity is observed (along with 
other higher order centres, such as the DLPC) in individuals with high 
levels of fear avoidance (Vogt 2005, Shackman, Salomons et al. 2011). I 
suggest that GM alterations in the aMCC and pMCC in NuLBP patients 
may be a neuroplastic response to the emotional cost of on-going 
neuroeconomic decision making associated with CLBP and skeletomotor 
planning associated with behavioural responses. In future studies 
dedicated neuropsychological assessment of decision-making processes, 
in concert with structural MRI image analysis techniques, should be 
employed to better understand such potential relationships.  
 Pain Affect 4.6.3
We observed significant GM alterations in the DLPFC, orbitofrontal 
cortex, hippocampus, basal ganglia and ACC in CLBP and, in NuLBP, 
patients compared to controls. These areas, have previously been 
associated with processing the affective components of the pain 
experience and are also implicated in low mood and depression (Drevets 
2007, Egger, Schocke et al. 2008, Vasic, Walter et al. 2008, Cole, 
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Costafreda et al. 2011, Hamilton, Etkin et al. 2012, Grieve, Korgaonkar et 
al. 2013). 
The observed GM alterations suggest not only evidence of the neural 
correlates of the high cost of suffering experienced by CLBP patients (as 
evidenced by our behavioural data) but also possible dysfunction and 
dysregulation of mood, further augmenting the emotional content of 
CLBP. GM alterations in these areas may be an adaptive response to 
living with CLBP. However, dysregulation in these areas may equally 
heighten the emotional aspects of living with chronic pain in CLBP 
patients and in particular, in our NuLBP patients; a view, which is 
reflected in our behavioural data. 
The ACC is consistently implicated in functional pain imaging studies as a 
key area for processing the affective-motivational components of pain 
(Treede, Kenshalo et al. 1999, Vogt 2005, Etkin, Egner et al. 2011). In 
particular, the pregenual ACC mediates the feeling of unpleasantness in 
pain sensation (Hofbauer, Rainville et al. 2001, Vogt 2005). It is active 
during persistence of negative affect and in particular, during reflection on 
negative emotional states (Northoff, Richter et al. 2000, Schweinhardt 
and Bushnell 2010) and in detection of unfavourable outcomes 
(Ridderinkhof, Ullsperger et al. 2004). Studies have shown GM reductions 
in the ACC in numerous pain states (hip osteoarthritis (Rodriguez-
Raecke, Niemeier et al. 2009), headache (Rocca, Ceccarelli et al. 2006), 
idiopathic facial pain (Schmidt-Wilcke, Hierlmeier et al. 2010) and also in 
LBP patients with Ankylosing Spondylitis (Wu, Inman et al. 2013).  
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GM reductions in the pregenual ACC associated with processing pain 
unpleasantness may reflect the fundamental evolutionary importance of 
negative affect in the experience of pain. If ultimately the purpose of pain 
is motivational – to serve as a warning, a threat signalling danger, 
requiring action to prevent further harm, either by retreat away from an 
outside threat or, in the case of injury to the body, rest and recovery, then 
the unpleasantness of pain is key to motivating the individual to take 
action (Robinson and Riley III 1999). Pain without emotion lacks saliency 
and negative emotions in response to pain promote vigilance. Pain is a 
vital component of learning, enabling the individual to avoid future harm. 
Without emotional saliency, learning cannot take place. It is suggested 
that individuals with congenital insensitivity to pain are unable to learn 
from painful experiences, not because they do not experience the 
sensory-discriminative aspects of pain, but because their pain lacks 
emotional valence (Minde, Svensson et al. 2006). Consequently, these 
individuals do not develop protective responses to aversive stimuli and 
therefore suffer repeated injury with potentially fatal consequences.   
 Low Mood Is Associated With CLBP 4.6.3.1
I suggest that in addition to its role in sensorimotor evaluation and motor 
planning, the GM increases we have identified in CLBP subjects 
compared to controls may be associated with the incidence of low mood 
in our CLBP population. Reduction of dopaminergic activity in the 
mesolimbic pathway has been linked to depression and anhedonia 
(Nestler and Carlezon 2006, Nutt, Demyttenaere et al. 2007, Van den 
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Heuvel and Pasterkamp 2008, Tye, Mirzabekov et al. 2013). 
Furthermore, GM alterations may cause, or else be a consequence of 
dysregulation of functional connectivity between the nucleus accumbens 
and the ACC, leading to errors in affective pain processing (Baleydier and 
Mauguiere 1980). The alterations in these areas may reflect the low 
mood and exaggerated emotional responses seen clinically in patients 
with CLBP and demonstrated by both our behavioural data and also the 
work of others (Sullivan, Reesor et al. 1992, Bair, Robinson et al. 2003, 
Currie and Wang 2004, Katona, Peveler et al. 2005, Linton 2011, Walker, 
Kavelaars et al. 2014).  In this thesis regression analyses between 
psychometric variables and GM integrity were not attempted, but such 
additional investigations may provide insights into the relationship 
between morphometric and affective changes observed in individuals with 
CLBP. 
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 Pain Modulation  4.6.4
We observed alterations in GM in the ACC/MPFC, DLPFC, S1 and basal 
ganglia in CLBP patients compared to controls and also in the mid 
cingulate, OFC and DLPFC in NuLBP patients compared to MLBP.  
These areas are involved in multi-modal roles in pain processing, 
encompassing modulation (Tracey 2010), threat evaluation, cognitions, 
mood, emotions and behavioural decision-making. GM alterations in 
these areas may indicate a maladaptive response to on-going pain and 
low mood and a reduced capacity for both placebo and non-placebo 
endogenous pain modulation via cortico-subcortical and cortico-cortical 
pathways.  
Throughout this thesis I consider pain to be an amalgam of sensory-
discriminative, affective-motivational and cognitive-evaluative processes 
(Melzack and Casey 1968, Mollet and Harrison 2006, Wiech and Tracey 
2013). The GM reductions we have observed in frontal cortical areas are 
evidence of shared affective-motivational, cognitive-evaluative and 
sensory discrimination networks (NuLBP: DLPFC, orbitofrontal cortex, 
mid cingulate, insula; MLBP: DLPFC, hippocampus, basal ganglia, and 
pACC/MPFC, S1, insula). My findings are consistent with those of others 
(Bushnell, Kuchinad et al. 2007, Bingel and Tracey 2008, May 2008, 
Apkarian, Baliki et al. 2009, Henry, Chiodo et al. 2011, May 2011). These 
areas are frequently associated with pain intensity modulation (placebo 
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and non-placebo) mediated by emotions and mood, cognitions, 
expectation and context.  
 GM Volume Reductions We Observed In The Cingulate 4.6.4.1
Cortex In CLBP Patients Compared To Controls And Also 
NuLBP Patients Compared To MLBP Are Evidence Of 
Dysregulation In Pain Modulation. 
We identified significant bilateral anterior mid cingulate reductions in 
NuLBP patients and pregenual ACC and left MPFC volume in CLBP 
patients compared to controls. These areas have been implicated 
previously in processing of negative affect (Vogt 2005). GM changes in 
these regions may be associated with the modulation of ongoing pain, in 
conjunction with prefrontal and sub cortical networks. Supraspinal 
dysregulation of pain modulation has been suggested as a major reason 
for persistent clinical pain especially in the absence of, or out of 
proportion to, identifiable pathology, as is frequently seen in CLBP 
(Apkarian, Baliki et al. 2009, Tracey and Bushnell 2009, Apkarian 2011). 
The pregenual and subgenual rostral ACC (and also other areas in which 
we have shown GM alterations such as DLPFC, insula and nucleus 
accumbens) are crucially involved in pain modulation in both opioid and 
placebo analgesia (Petrovic, Kalso et al. 2002, Wager, Scott et al. 2007) 
and non-placebo modulation effects, such as in distraction (Bantick, Wise 
et al. 2002, Tracey, Ploghaus et al. 2002). Alterations in GM in these 
areas may reflect disrupted pain modulatory mechanisms, resulting in 
increased pain perception relative to stimulus intensity and increased 
duration of pain post-stimulus. These are frequently seen clinically and 
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unfortunately are often termed “exaggerated illness behaviours “ that are 
linked to a non-organic (i.e. made-up) presentation. In fact, tests have 
even been designed to catch-out patients with an increased pain 
presentation who are “faking” their symptoms (Waddell, McCulloch et al. 
1980, Blom, Taylor et al. 2002). Waddell’s signs are a series of tests 
designed to identify psychosomatic symptoms in CLBP patients. While 
Waddell’s signs may be an indicator of significant psychological distress, 
any suggestion they may be used to detect malingering patients is 
evidence of a misunderstanding of the mechanisms that underlie many, if 
not the majority, of chronic pain states and must be vigorously 
challenged. I suggest that the GM alterations in modulatory networks that 
this study has identified in the ACC and other areas provide evidence of 
dysfunctional inhibitory mechanisms that underlie the clinical 
manifestation and persistence of CLBP other clinical pain states and the 
failure of pharmacological, surgical and conservative treatment regimes 
that occur in the majority of CLBP patients.  
 GM Volume Reductions We Observed In The Orbitofrontal 4.6.4.2
Cortex In NuLBP Patients Compared To MLBP Are 
Associated With Alterations in Pain Modulation. 
We observed reductions in other areas associated with modulation of 
pain. I suggest that the reductions in the OFC GM that we observed in 
NuLBP compared to MLBP subjects, are associated with the increases in 
pain scores reported by our NuLBP patients. Reduced cortical thickness 
in the OFC (as well as mid cingulate and S1) is associated with reduced 
heat pain thresholds (Erpelding, Moayedi et al. 2012) and co-activation of 
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the OFC and ACC is observed in subjects that respond to placebo 
(Petrovic, Kalso et al. 2002). Furthermore, GM alterations related to the 
salience network that we observed in NuLBP patients (in particular, the 
ACC, OFC and anterior insula) have been linked to deficits in habituation 
to tonic pain stimuli seen in chronic pain patients (Seeley, Menon et al. 
2007). Reductions in OFC GM may reflect a failure of endogenous pain 
regulation in NuLBP cohort. 
 GM Volume Alterations We Observed In S1 In CLBP Patients 4.6.4.3
Compared To Controls May Relate To Reductions In Pain 
Thresholds. 
We observed a significant reduction in GM volumes in the S1 cortex. The 
S1 cortex may be involved in not only perception but also modulation of 
both painful and non-painful somatosensory sensation, although this has 
been the subject of some debate (Bushnell, Duncan et al. 1999). 
Recently, S1 reductions in cortical thickness have been shown to 
correlate with reductions in thresholds to pain sensitivity (Emerson, 
Zeidan et al. 2013). The GM reductions in the trunk area of S1 may also 
therefore be associated with dysregulation of pain modulation as well as 
with changes to cortical representation and is consistent with the 
implications of our behavioural data.  
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 GM Volume Reductions We Observed In The DLPFC In CLBP 4.6.4.4
Patients Compared To Controls And Also In NuLBP Patients 
Compared To MLBP Are Likely To Reflect Reductions In 
Inhibitory Pain Modulation. 
We found bilateral GM DLPFC reductions in CLBP subjects compared to 
controls and unilateral reductions in DLPFC GM in NuLBP patients 
compared to MLBP. The incidence of DLPFC GM reductions reported in 
the literature in CLBP studies is witness to the important role of the 
DLPFC in pain regulation (Apkarian, Sosa et al. 2004, Schmidt-Wilcke, 
Leinisch et al. 2006, Seminowicz, Wideman et al. 2011, Ivo, Nicklas et al. 
2013). Importantly, CLBP patients, whose symptoms improved after 
treatment, were shown to have normalization of DLPFC GM thickness 
(Seminowicz, Wideman et al. 2011). The DLPFC plays a key role in pain 
modulation via “top-down” cortical and subcortical pathways (Grachev, 
Fredrickson et al. 2002, Grachev, Ramachandran et al. 2003, Lorenz, 
Minoshima et al. 2003, Zubieta 2003, Giesecke, Gracely et al. 2004, 
Wager, Rilling et al. 2004, Schmahl, Bohus et al. 2006, Zubieta, Yau et al. 
2006, Fierro, De Tommaso et al. 2010, Krummenacher, Candia et al. 
2010). 
 GM Volume Increases In The Brainstem May Relate To 4.6.4.5
Compensatory Mechanism For GM Reductions In The 
DLPFC  
As well as DLPFC reductions, we also showed GM increases in the 
brainstem (from the upper medulla to the mid section of the pons) in 
CLBP subjects and, exclusively in NuLBP subjects compared to controls. 
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DLPFC mediated placebo is linked to activity in the periaqueductal grey 
matter in the brainstem (Wager, Rilling et al. 2004). A possible reason 
therefore, for GM volume increases in the brainstem may relate to 
compensatory mechanism for GM reductions in the DLPFC.  
GM reductions in the DLPFC in CLBP subjects compared to controls and 
also in NuLBP patients compared to MLBP may reflect dysregulation of 
inhibitory mechanisms on the MPFC.  
Similarly, the additional GM reductions we observed in CLBP subjects 
compared to controls in the MPFC may relate to top down dysregulation 
of MPFC activity by the DLPFC, which has been shown to negatively 
correlate with pain intensity (Lorenz, Minoshima et al. 2003, Baliki, 
Chialvo et al. 2006, Schmahl, Bohus et al. 2006) and appears to have an 
inverse relationship with the MPFC in spontaneous clinical pain (Baliki, 
Chialvo et al. 2006).  
GM volume reductions we observed in the DLPFC in CLBP patients 
compared to controls and also in NuLBP patients compared to MLBP 
may play a role in the maintenance and persistence of enhanced pain 
affect in addition to pain intensity. 
In addition, GM DLPFC reductions are implicated not only in the 
dysregulation of pain modulation but also of pain affect (Lorenz, 
Minoshima et al. 2003, Seminowicz and Davis 2006). Therefore, I 
suggest that the GM reductions we have observed in the DLPFC may 
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reflect a reduced ability of “top down” regulation on cortical centres 
regulating pain affect, resulting in the increased levels of pain intensity 
and of negative affect seen in CLBP patients and, in particular, the 
NuLBP population. A probable mechanism is failure of top down DLPFC 
regulation of the rACC and insula, both areas in which we have observed 
GM reductions in both CLBP patients compared to controls and NuLBP 
compared to MLBP patients. Low levels of DLPFC activity are associated 
with increased pain intensity and unpleasantness, which correspond with 
rACC (rostral anterior cingulate cortex) and anterior insular activity 
(Lorenz, Minoshima et al. 2003). Activity in the DLPFC is also reduced in 
distressed compared to less distressed axial CLBP patients (Lloyd, 
Findlay et al. 2008). Therefore, GM DLPFC reductions may play an 
important role in the maintenance and intensification of pain affect as well 
as pain intensity. Furthermore, GM increases in the thalamus in CLBP 
patients reflect dysregulation in pain processing networks. 
We observed GM increase in the lentiform nucleus, which extended into 
the margin of the right thalamus when comparing CLBP subjects with 
controls. Although GM alterations in the thalamus did not achieve 
statistical significance when comparing NULBP and MLBP groups, we 
saw GM increase in the right thalamus uniquely in NuLBP subjects when 
individually comparing LBP sub-groups to controls.  
The thalamus is one of the most frequently observed areas in 
experimental pain studies and is thought to be involved primarily in the 
sensory-discriminative aspects of pain processing, although it may also 
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be associated with general arousal patterns in relation to pain (Peyron, 
Laurent et al. 2000). The GM increase that we observed may therefore 
simply relate to ongoing nociceptive processing. However, there is 
evidence that the thalamus and brainstem comprise a pain modulatory 
network (Valet, Sprenger et al. 2004), and therefore GM thalamic 
increase may either be seen as an adaptive mechanism in pain 
modulation, to manage increased levels of nociception or conversely, 
representing maladaptive dysregulation of inhibitory modulation, resulting 
in the increased pain levels and temporal and spatial spontaneity of 
neuropathic pain. In fact, a substantial body of evidence points to the 
involvement of the thalamus in neuropathic pain both in animal (Paulson, 
Morrow et al. 2000, Paulson, Casey et al. 2002) and human models 
(Baron, Baron et al. 1999, Casey, Morrow et al. 2001, Casey, Lorenz et 
al. 2003, Lorenz and Casey 2005, Yen and Lu 2013). The thalamic GM 
increases we have seen may therefore instead point to the widespread 
dysregulation in sensory processing, hypersensitivity and non-
dermatomal pain patterns that are seen in neuropathic pain.  
 Body Image 4.6.5
 GM Alterations In The Pre-Central And Post-Central Gyri 4.6.5.1
Relate To Alterations In Sensory Processing In CLBP 
Patients Compared To Controls. 
We observed both increases and reductions in GM volume in separate 
regions of both pre-central and post-central gyri. GM increases were seen 
in right premotor, M1 and S1 areas that correspond to the homuncular 
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representation of the trunk. Patients with CLBP experience abnormal 
motor function and altered movement patterns, proprioceptive deficits and 
changes to body awareness and perception. The clinical examination 
data shows evidence of altered sensory processing of two-point and 
tactile threshold discrimination. There is substantial evidence that these 
changes are linked to functional and structural changes in 
representational maps in the motor (M1) and sensory (S1) cortex (Wand, 
Parkitny et al. 2011). I suggest that the GM increases in right premotor, 
M1 and S1 areas are evidence of cortical reorganisation in our CLBP 
cohort and that these changes are also relevant to not only pain intensity 
and motor function but even to concepts of self-image and bodily identity 
and further support our examination data. 
Generally, CLBP studies have shown reductions in GM volume or cortical 
thickness in the post-central gyrus (S1) (Apkarian, Sosa et al. 2004, 
Schmidt-Wilcke, Leinisch et al. 2006, Ivo, Nicklas et al. 2013, Wu, Inman 
et al. 2013) although one study has shown increased cortical thickness 
bilaterally in S1 (Kong, Spaeth et al. 2013). In a multivariate analysis 
employing a machine learning approach with Support Vector Machines 
(SVM) to identify areas of structural alteration that can be used to classify 
LBP, increases were also found in S1 and S2 although care must be 
taken in extrapolating results obtained by this different methodology (Ung, 
Brown et al. 2012). Surprisingly, given that patients with LBP demonstrate 
profound alterations in activity levels, movement patterns and muscle 
activation, there is a paucity of data available, I have been able to identify 
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only one study showing GM alterations in M1 (Ivo, Nicklas et al. 2013). 
This may be in part explained by methodological difficulties; differentiating 
S1 from M1 in spatially smooth data remains a technical challenge for 
VBM methodologies and cortical flattening techniques may be a suitable 
technology to assess issues of sensory-motor disambiguation (Fischl, 
Sereno et al. 1999).  
Normal body schemas are dependent on both regular somatosensory 
and proprioceptive input and motor output. In CRPS and PLP, altered 
afferent input, both painful and non-painful, is linked to disruption of motor 
(M1) and sensory (S1) cortical representational maps (Moseley and Flor 
2012). Similar disruption of cortical representational maps are seen in 
CLBP using MEG (Flor, Braun et al. 1997) and fMRI (Lloyd, Findlay et al. 
2008). Both studies show a medial shift in the representation of the back 
in the somatosensory cortex. Changes in body schema are associated 
with alterations in sensory function, in particular to tactile acuity (two point 
discrimination) and also pain intensity and are consistent with the 
examination and behavioural data from the cohort of patients in this 
thesis. This supports the findings of other groups who have demonstrated 
similar alterations in CRPS and PLP (Maihofner, Handwerker et al. 2003, 
Pleger, Tegenthoff et al. 2004, Maihofner, Forster et al. 2005) and also in 
CLBP (Wand, Di Pietro et al. 2010, Luomajoki and Moseley 2011).  
Proprioceptive deficits and motor control disorders in patients with CRPS 
and PLP are also associated with altered cortical representation 
(Anderson-Barnes, McAuliffe et al. 2009, van Rijn, van Hilten et al. 2009). 
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Deficits in motor control, muscle activation and poor proprioceptive acuity 
of the lumbo-pelvic region in CLBP patients also show a close association 
with increased 2PD thresholds on the back (for a review see (Hodges and 
Moseley 2003)) and changes to M1 representational maps (Tsao, Galea 
et al. 2008, Tsao, Danneels et al. 2011, Wand, Parkitny et al. 2011).  
I suggest that our clinical examination data, which shows evidence of 
alterations in two-point sensory discrimination thresholds and tactile 
threshold deficits, together with the GM alterations in motor and sensory 
representational areas we have demonstrated, provides evidence of 
changes in S1 and M1 body schema in CLBP. Furthermore, I suggest 
that our data are further evidence of shared neural mechanisms 
underlying CLBP and other conditions such as PLP and CRPS. Our data 
show the neural correlates of deficits in motor control, muscle activation 
and proprioception that have been reported by other LBP studies (Flor 
2003, Hodges and Moseley 2003, Wand and O'Connell 2008, Wand, Di 
Pietro et al. 2010, Luomajoki and Moseley 2011, Wand, Parkitny et al. 
2011). Such theories set the stage for future studies with convergent 
methodologies incorporating not only examination of brain structure, 
resting-state brain function and basic clinical and psychometric 
investigations, but hypothesis-driven investigation of body schemas, for 
example using BOLD fMRI and electrophysiological techniques such as 
EEG and MEG.   
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 Conclusions 4.7
 Brain Morphometry And NuLBP  4.7.1
To the best of my knowledge, this is the first study to directly investigate 
the structural correlates of neuropathic and non-neuropathic CLBP and to 
directly compare and contrast between neuropathic and non-neuropathic 
CLBP groups. We have been able to demonstrate GM reductions in the 
OFC, anterior insula, mid cingulate, DLPFC and cerebellum and GM 
increases in the precuneus in NuLBP patients compared to MLBP.  
Prior to this current study, no studies attempted to investigate whether it 
was possible to identify a discrete morphometric neural signature for 
neuropathic low back pain. This is therefore the first study to show clearly 
identifiable structural differences in clearly characterised neuropathic and 
non-neuropathic CLBP patient groups. Although there have been 
numerous studies investigating the structural components of CLBP 
(Apkarian, Sosa et al. 2004, Schmidt-Wilcke, Leinisch et al. 2006, 
Buckalew, Haut et al. 2008, Seminowicz, Wideman et al. 2011, Ivo, 
Nicklas et al. 2013, Kong, Spaeth et al. 2013, Wu, Inman et al. 2013), 
comparison of morphometry across CLBP studies is problematic due to 
the wide variations in patient selection criteria, methodologies and results 
(as discussed previously), which we have attempted to overcome by 
better phenotyping  methods. In particular, only two studies attempted to 
characterise patients groups into neuropathic and non-neuropathic sub-
groups (Apkarian, Sosa et al. 2004, Wu, Inman et al. 2013). Davis’ group 
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had some similar areas of GM volume reductions (primary 
somatosensory cortex, insula, anterior mid-cingulate cortex and anterior 
cingulate cortex) and increases (putamen and thalamus) to our study 
(Wu, Inman et al. 2013). Unfortunately, further comparisons are 
problematic as they chose a CLBP group with a specific pathology 
Ankylosing Spondilitis (AS) and used cortical thickness analysis to 
measure volume, rather than VBM. Apkarian’s study showed decreased 
GM density in the DLPFC and thalamus. Reductions in density in the 
DLPFC but not in the thalamus were greater in the neuropathic cohort 
compared to the non-neuropathic subjects. (Apkarian, Sosa et al. 2004). 
However, neither study compared and contrasted neuropathic and non-
neuropathic patient groups which is central to this thesis.  
 Future Directions 4.7.2
Different neuropathic clinical conditions and different neuropathic pain 
symptoms appear to involve different neural mechanisms (Ducreux, Attal 
et al. 2006, Youssef, Gustin et al. 2014). Structural neuroimaging studies 
show GM alterations specific to each individual clinical condition (May 
2011, Smallwood, Laird et al. 2013). Further studies need to be 
undertaken to identify the neural correlates of differing neuropathic 
clinical presentations either by clinical diagnosis (i.e. neuralgia compared 
to neuropathy) or by symptoms (i.e. conditions characterised 
predominantly by spontaneous pain compared to conditions 
characterised by mechanically evoked pain). For instance, another study 
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could examine different neural correlates of NuLBP with clinical 
identifiable neuropathy compared to NuLBP with neuralgia alone. 
 Final Conclusion  4.8
Reviews of chronic pain neuroimaging (Tracey and Bushnell 2009, Henry, 
Chiodo et al. 2011, Lee and Tracey 2013) have described a distinct 
neural signature associated with chronic pain, which does not primarily 
engage brain areas involved with sensory discrimination but rather areas 
associated with affective and cognitive processing – the so-called 
“emotional brain” (Baliki, Chialvo et al. 2006). 
This study has demonstrated significant GM volume alterations in 
patients with CLBP compared to controls. CLBP patients show changes 
in areas associated in particular with cognitive-evaluative and affective-
motivational processing related to pain modulation and behavioural 
decision-making. I also suggest that taken as a whole, these areas 
represent a neural correlate for feelings of loss of body identity and 
awareness. I have also shown significant GM volume alterations in 
patients with CLBP that differ due to underlying clinical phenotypes; 
NuLBP subjects show distinct GM volume reductions in areas associated 
with interoception, evaluation of environment and stimulus saliency and 
neuroeconomic processing of behavioural choices, reflecting the 
increasing cognitive–evaluative and affective-motivational burden of 
NuLBP. 
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Chapter 5 INVESTIGATION OF ONGOING 
PAIN IN CLBP USING ARTERIAL SPIN 
LABELLING 
 Introduction 5.1
In the previous chapter I described the morphological changes that were 
seen in CLBP and CLBP subgroups. In this chapter I will investigate the 
potential supraspinal functional neuroplastic changes that are associated 
with the ongoing experience of CLBP by observing regional cerebral 
blood flow (rCBF) as a correlate of neural activity.  
This study has two main hypotheses:  
1. There are differences in rCBF between CLBP and controls.  
2. There are differences in rCBF between NuLBP and MLBP 
subgroups. 
In this section I will discuss the challenges of measuring brain activity in 
CLBP. I will begin with a discussion of evoked experimental pain studies, 
then illustrate the limited amount of neuroimaging work that has 
attempted to describe the clinical experience of CLBP. 
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 Evoked Pain Studies 5.1.1
There are substantial methodological difficulties in the analysis and 
measurement of brain activity associated with ongoing pain states, 
including LBP. Therefore, the majority of pain studies have measured 
brain activity using experimental evoked pain stimuli. Responses to acute 
pain stimuli given to healthy volunteers show a relatively consistent range 
of brain activation patterns (Tracey 2008), often referred to as the pain 
neuromatrix. Recently there has been a critical reappraisal of this concept 
questioning the significance of many acute pain studies and the 
consistency of their findings (Mouraux, Diukova et al. 2011). In contrast to 
acute pain, chronic pain studies show a wide variety of responses to 
experimental stimuli (Tracey 2008, Apkarian, Baliki et al. 2009, Davis and 
Moayedi 2013). Studies of clinical pain states including CLBP, show 
conflicting data – some show lower pain thresholds and increased neural 
activity to both local and distal stimulation; others show lower pain 
thresholds and increased neural activity to stimulation of the lower back 
only. 
An MEG study of 10 low back pain patients with symptoms averaging 12 
years in duration (no detail was given about the patients’ symptoms other 
than none had neurological involvement), demonstrated lower pain 
thresholds to noxious electrical stimulation of the lumbar spine and 
increased power of the evoked field in low back pain patients compared 
to controls, relative to the chronicity of the subjects’ symptoms (Flor, 
Braun et al. 1997). A more recent functional magnetic resonance imaging 
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(fMRI) study of mechanical pressure stimulation of the back in 6 subjects 
and 8 controls also showed lower pain thresholds with ratings of greater 
pain ‘unpleasantness’ in the CLBP group. Activation of an expansive 
network of pain-related brain regions, particularly in areas associated with 
the affective processing (prefrontal, insula, cingulate) and motor 
preparation (supplementary and premotor) was observed in both groups 
but at lower ratings of pain intensity in the CLBP group. At higher pain 
intensity, CLBP patients alone showed activation in the right thalamus 
(Kobayashi, Kurata et al. 2009). In contrast, Baliki et al showed no 
differences between CLBP and controls in pain thresholds to a noxious 
thermal stimulus to the back (Baliki, Geha et al. 2010). 
Available studies also show conflicting data regarding decreased pain 
thresholds at sites away from the lower back. Flor et al. showed no 
differences in thresholds or MEG brain activity to stimulation of the index 
finger in CLBP patients compared to controls (Flor, Braun et al. 1997). 
Consistent with this, a group of 16 CLBP patients showed little difference 
in pain ratings and fMRI brain activity from control subjects to thermal 
stimuli to the back of the hand (Derbyshire, Jones et al. 2002). In 
contrast, both CLBP patients and fibromyalgia syndrome (FMS) patients 
showed decreased pressure pain thresholds at the thumbnail compared 
to controls (Giesecke, Gracely et al. 2004) although the somewhat more 
crude form of pain stimulus applied might explain this difference. All 
subjects, including controls, showed activation in similar areas to a painful 
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stimulus (contralateral primary and secondary [S2] somatosensory 
cortices, inferior parietal lobule, cerebellum, and ipsilateral S2). 
The data above show conflicting evidence regarding distal pain 
thresholds and also conflicting evidence as to whether differences in pain 
processing and brain activity exist between CLBP subjects and controls. 
Data from previous sections of this thesis show that CLBP patients 
demonstrate increased tactile and 2PD thresholds, which have been 
associated with hypersensitivity to noxious stimuli in other studies, 
suggestive of altered central processing. Further work is needed to 
examine whether clinical, rather than experimentally evoked pain, shows 
differences in rCBF in CLBP patients compared to controls. 
 Clinical Pain Studies: BOLD fMRI 5.1.2
Clinical pain is fundamentally different, however, to stimulus-dependent 
experimental pain (Melzack and Wall 1996, Kupers and Kehlet 2006, 
Tracey and Mantyh 2007). Clinical pain is frequently tonic and ongoing. It 
may be spontaneously generated and have an unclear relationship with 
triggering factors. Pain perception may appear out of proportion to 
aggravating activities and may have uncertain spatial or temporal 
characteristics. Clinical pain may also demonstrate strong relationships 
with environmental, cognitive and affective components. Therefore, 
separate investigation of the neural characteristics of clinical pain is 
necessary. Blood oxygen level dependent (BOLD) functional magnetic 
resonance imaging (fMRI) is a suitable method to measure evoked, 
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stimulus-dependent experimental pain. However, BOLD presents with 
substantial methodological difficulties in the acquisition and analysis of 
the neural correlates of clinical pain and is problematic for measuring 
ongoing tonic pain or long-term treatment effects (Aguirre, Detre et al. 
2002, Cahana, Carota et al. 2004). Its utility in chronic ongoing pain 
studies has therefore been questioned (Tracey and Johns 2010) (see 
section 5.1.4 for further discussion of this topic). 
Apkarian and colleagues devised a method using a manual logging 
device to allow BOLD to be used to measure non-evoked pain (Apkarian, 
Krauss et al. 2001, Baliki, Chialvo et al. 2006). The subject in the scanner 
records the intensity of perceived pain via a finger-spanning device 
attached to the thumb and index finger. Placing the thumb and finger 
together corresponds to ‘no pain’ and stretching thumb and finger 
maximally apart corresponds to ‘maximum pain’. Brain regions involved in 
the finger-spanning task are excluded from the analysis or finger 
movement is treated as a confounder in a regression analysis. Using the 
finger-spanning device, brain activity in CLBP patients with spontaneous, 
non-evoked pain was measured while lying in the MRI scanner (Baliki, 
Chialvo et al. 2006). Although psychometric data were included in the 
supplementary material to the paper, there was no record of patients’ 
clinical diagnosis or mechanical or neuropathic presentation (However, 
when referring to the study in a later paper on spontaneous pain in (PHN) 
(Geha, Baliki et al. 2007) the authors state that the LBP patients were 
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considered neuropathic as they all had some degree of radiculopathy in 
their history). 
The authors reported two essential phases of the spontaneous pain 
experience; a) when spontaneous pain was rapidly increasing and b) 
when spontaneous pain was at a sustained high level. During periods of 
increasing pain, activity was found in brain areas comparable to acute 
pain from noxious thermal stimulation to the finger, such as the insula, 
anterior cingulate cortex (ACC), multiple cortical parietal regions and the 
cerebellum. When the pain level was high and constant, however, a 
different pattern of activity was described; the medial prefrontal cortex 
(MPFC) was most active, with lesser activity seen in the amygdala and 
the ventral striatum. It was suggested ongoing pain was sustained by 
neural activity in the MPFC, in contrast to the multi-region activity 
associated with processing nociceptive information related to the initial 
pain experience. MPFC activity was strongly correlated with pain intensity 
and negatively correlated with DLPFC activity. The authors reflected this 
suggests a “tight interplay between brain activity, neuronal death, and 
cognitive abnormalities in chronic back pain” and that spontaneous CBP 
switches on the MPFC, the "emotional-mentalising region of the brain into 
a state of continued negative emotions (suffering) regarding the self, 
punctuated by occasional nociceptive inputs that perpetuate the state.”   
I suggest that there may be problems with this interpretation. Firstly it 
suggests that there is a nociceptive basis for CLBP, in that the ongoing 
activity in the MPFC needs to be maintained by a nociceptive driver. 
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However, there is no real evidence of a relationship between CLBP and 
damage or pathology to the lumbar spine. Secondly, this interpretation 
seems to suggest a central brain locus for chronic pain in the MPFC (and 
in the relationship of the MPFC with the DLPFC), as if the experience of 
chronic pain can be concentrated in  “a chronic pain centre”. I would 
suggest that chronic pain is instead a multi-dimensional experience 
involving cognition, emotions and sensory dimensions, whose neural 
correlates involve multiple areas involved in processing these 
dimensions, rather than one sole centre. This is the central tenet of the 
work presented throughout this thesis and supported by the data from 
previous chapters. 
Furthermore, I suggest that there are methodological problems with the 
use of the finger-spanning device in this study. Although, this study is 
predicated on demonstrating the neural correlates of spontaneous pain, 
the task demands inherent in the subject’s use of the device means that 
brain activity is not related to a ‘naturalistic’ record of spontaneous pain 
alone. Although Baliki and colleagues state that activity relating to use of 
the device is excluded from the analysis or is treated as a confounder in a 
regression analysis, the use of subtraction designs has been criticised 
(Friston, Price et al. 1996). Brain activity involved in monitoring of sensory 
input and motor planning and execution is complex and involves the use 
of multiple systems and networks, which are not easily removed from the 
analysis. Most importantly, attentional or distractional and motor 
processes are known to modulate the experience of pain (Tracey, 
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Ploghaus et al. 2002, Valet, Sprenger et al. 2004). By using the device, 
attention is given to the pain, which may in itself be an important 
mechanism in the amplification of pain perception (Bantick, Wise et al. 
2002); alternately, the device could in fact distract from the pain 
experience. In either case, I propose that Baliki and colleagues’ study is 
therefore not a true record of pain in a resting state. In light of these 
criticisms I decided to explore alternatives to the use of BOLD fMRI to 
record non-evoked brain activity associated with chronic pain utilising 
Arterial Spin Labelling (ASL). An extensive critique of the limitations of 
BOLD together with a justification for the use of ASL (and potential 
alternative methodologies) are detailed in the following sections. 
 Methods For Neuroimaging Of Chronic Pain  5.1.3
 Positron Emission Tomography (PET) 5.1.3.1
Positron Emission Tomography (PET) was used extensively in the 1990s 
before BOLD fMRI became the preferred medium for experimental pain 
studies. Several historical PET studies reported rCBF (regional cerebral 
blood flow) differences in the thalamus in cancer pain (Di Piero, Jones et 
al. 1991), neuropathic pain (Hsieh, Belfrage et al. 1995) and central pain 
(Peyron, Garcia-Larrea et al. 1995, Garcia-Larrea, Peyron et al. 1999) 
although one study showed thalamic hyperactivity in post-stroke pain 
(Cesaro, Mann et al. 1991). However, all of these studies used extremely 
small patient groups of between two and five subjects. Furthermore, 
these studies all used methods to reduce pain in their subjects, in order to 
compare the painful state with a pain-free state, rather than comparing 
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patients in pain with healthy controls. Evidence from structural and 
functional neuroimaging studies carried out since this early work and 
detailed throughout this thesis, shows that fundamental neuroplastic 
changes occur in patients with chronic pain, making them unsuitable for 
use as control subjects, even in the pain free state. In light of these 
limitations, care must be exercised in interpreting these studies. However, 
although PET is better suited than fMRI to examine brain blood flow and 
metabolic responses in ongoing pain, its use is limited, as it is invasive 
and expensive, requiring a radioactive tracer as a contrast agent to 
record a signal as it passes through tissue. It also demonstrates 
comparatively poor temporal and spatial resolution (Kupers and Kehlet 
2006, Tracey and Mantyh 2007); inconsistencies in PET chronic pain 
data have been attributed to these technical limitations (Youssef, Gustin 
et al. 2014).  
The last 15 years have seen BOLD fMRI become the dominant medium 
for imaging pain. Unfortunately, BOLD fMRI is not ideally suited to study 
clinical tonic pain states. These limitations of its usefulness in studying 
chronic pain are discussed below. 
  266 
 BOLD Presents With Methodological Difficulties In 5.1.4
The Acquisition And Measurement Of The Neural 
Correlates Of Clinical Pain. 
 BOLD Is Not An Effective Technique For Recording Ongoing 5.1.4.1
Neuronal Activity. 
Although BOLD is a suitable method for recording phasic experimental 
pain stimuli, it is not ideally suited to record changes in neural activity 
over long periods of time (i.e. greater than 1 minute). This is due to 
susceptibility to noise contamination caused by low frequency drift in the 
scanner and physiological noise, which renders the use of BOLD 
problematic in inverse proportion to task frequency (Aguirre, Detre et al. 
2002, Wang, Aguirre et al. 2003). BOLD, therefore, is not an effective 
technique for recording the ongoing neuronal activity at rest associated 
with tonic pain (Gusnard, Raichle et al. 2001, Owen, Clarke et al. 2010, 
Segerdahl, Xie et al. 2012).  
 BOLD Is Not Able To Record Absolute Baseline 5.1.4.2
Measurements.  
BOLD relies on a relative measure of contrast such as a before and after 
event-related task or experimental stimulus (Wang, Aguirre et al. 2003). 
Although BOLD is dependent on CBF (cerebral blood flow), BOLD signal 
changes cannot be expressed in quantifiable physiologic units but only as 
a percentage signal change or statistical significance level based on a 
statistical model. Measurements obtained are therefore relative, not 
quantitative.  BOLD is not able to record absolute baseline 
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measurements, which limits the remit of conventional ‘evoked-response’ 
fMRI to assessing changes between states only. While BOLD imaging 
methodologies can be used to assess inter-relationships between brain 
regions (so-called ‘resting-state’ fMRI), this methodology is not included 
within the scope of this thesis. 
 Arterial Spin Labelling (ASL) 5.1.5
Recent advances in the use of arterial spin labelling (ASL) have enabled 
researchers to measure spontaneous pain in patients at rest over long 
periods, free from the signal to noise constraints inherent in BOLD fMRI 
technique (Howard, Krause et al. 2011). ASL relies on labelling the water 
content of inflowing arterial blood using radiofrequency pulses (Petersen, 
Zimine et al. 2006, Dai, Garcia et al. 2008). Unlike PET imaging, no 
radioactive tracers are required. 
 ASL Is Able To Monitor Tonic Activity   5.1.5.1
ASL is able to measure resting state basal activity as low frequency drifts 
are eliminated due to pairwise subtraction of tagged and control labeled 
images. It therefore offers improved sensitivity over BOLD in measuring 
neural activity for task frequencies of less than 0.006 Hz (ie periods of 
greater than 1-2 minutes) and therefore is ideal for measuring tonic pain 
states, characteristic of clinical pain (Aguirre, Detre et al. 2002).  
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 ASL Provides A Quantifiable Measurement Of rCBF   5.1.5.2
ASL uses a quantifiable perfusion contrast rather than relative blood 
oxygenation contrast to measure functional brain activation (Wong 2014). 
The technique provides a non-invasive, in vivo quantitative measurement 
of blood flow, measured as the volume of blood that travels through 
tissue over time (ml/100g/min). Quantifiable units offer the desirable 
benefit of being able to compare directly differences across studies. 
 ASL May Be A Better Marker Of Neuronal Activity Than 5.1.5.3
BOLD 
It has also been suggested that ASL perfusion may be a better marker of 
neuronal activity as ASL measures just one physiological parameter 
(perfusion), whereas the BOLD signal is dependent on several 
physiological parameters including cerebral blood flow, cerebral blood 
volume and cerebral metabolic rate of oxygen uptake (CMRO2) (Menon 
2001, Aguirre, Detre et al. 2002).  
 ASL Demonstrates Superior Spatial Localisation Than BOLD  5.1.5.4
In addition, ASL provides superior spatial localisation in areas of relevant 
neural activity, primarily recording signals from capillary beds.  BOLD 
signal responses are more pronounced in venous draining networks in 
the region of activation, due to the low deoxhaemoyglobin level, resulting 
in a less uniform and more diffuse activation picture, compared to ASL 
(Aguirre, Detre et al. 2002, Duong, Yacoub et al. 2002, Wang, Aguirre et 
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al. 2003, Kim, Whyte et al. 2006, Petersen, Zimine et al. 2006, Huettel 
2008, Liu, Hao et al. 2013).  
In summary, ASL provides a quantifiable measurement of blood flow in 
the brain that allows for monitoring of low frequency activity (Petersen, 
Zimine et al. 2006). ASL has been shown to be effective in measuring 
experimental pain (Owen, Bureau et al. 2008, Owen, Clarke et al. 2010) 
Most importantly, the ability of ASL to study brain activity with prolonged 
stimuli and in particular, ongoing pain, makes it an ideal tool for 
measuring pain in chronic, clinical scenarios (Tracey and Johns 2010). 
ASL is increasingly being used to study diverse clinical conditions such 
as 3rd molar tooth extraction (Howard, Krause et al. 2011), migraine 
(Kato, Araki et al. 2010), osteoarthritis (Howard, Fotopoulou et al. 2012), 
low back pain (Wasan, Loggia et al. 2011) and neuropathic pain 
(Segerdahl, Xie et al. 2012, Liu, Hao et al. 2013, Youssef, Gustin et al. 
2014). 
 ASL In Studies Of CLBP  5.1.5.5
Wasan and colleagues used ASL to examine the neural correlates of 16 
patients with CLBP (Wasan, Loggia et al. 2011). The patients were a mix 
of those with predominantly axial pain and those whose main complaint 
was leg pain. The authors chose to study pain exacerbations provoked by 
clinical manoeuvres. In the axial group, pelvic tilting was chosen as the 
aggravating technique and in the patients considered to have radicular 
symptoms, a bilateral straight leg raising technique was employed. Each 
clinical manoeuvre was repeated 12 times and held for 10 seconds. 
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Patients were excluded from the study if their pain failed to return to 
baseline levels within 30 seconds after each stimulation. The authors 
stated that this allowed them to “distinguish between and assess pain 
exacerbations and ongoing chronic pain”. They found significant activity 
in areas frequently associated with sensory-discriminative processing of 
experimental pain, such as S1, S2. They also found that medial prefrontal 
cortex and insula activity was associated with higher ratings of evoked 
pain. 
Furthermore, Wasan and colleagues suggested that the use of clinical 
manoeuvres produced an experience analogous to chronic clinical pain 
rather than an experimentally induced pain experience. However, by 
choosing to examine neural activity associated with pain exacerbations, I 
would suggest that they, in fact, designed a study that investigates the 
neural correlates not of chronic pain but rather, of acute pain; arguably a 
phenomenon which has been previously studied using BOLD fMRI, albeit 
not directly using clinical manoeuvres. To choose to study manoeuvre-
dependent acute pain rather than ongoing pain appears to be a missed 
opportunity to utilise the full ability of ASL to examine persistent 
spontaneous pain and to compare and contrast ASL data with the only 
previous study to attempt to study ongoing CLBP using BOLD (Baliki, 
Chialvo et al. 2006)(see section 5.1.2.2). 
It should be noted that increased regional cerebral blood flow (rCBF) was 
only observed when pain levels had increased by greater than 30% in the 
CLBP group (it was not seen in thermal pain applied to the leg, which 
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caused a pain increase of approximately 19% in CLBP and only a 
transient pain increase in healthy controls). Therefore differences were 
only seen within CLBP subjects and between CLBP and controls at >30% 
pain increase. No differences were reported between CLBP subjects and 
controls at rest (although this is not explicitly stated within the article). 
One is therefore tempted to speculate that an exacerbation manoeuvre 
was consequently chosen in order to identify differences between groups.  
The reasons why differences were not identified between CLBP and 
controls were not discussed by Wasan et al and remain unclear. 
Extensive developmental work from several members of our group has 
demonstrated clear differences between patients and healthy controls at 
rest, without additional stimuli, in 3rd molar tooth extraction (Howard, 
Krause et al. 2011) and osteoarthritis (Howard, Fotopoulou et al. 2012), 
employing a pseudo-continuous arterial spin labelling technique (pCASL). 
pCASL displays a superior signal to noise ratio of around 30% over 
pulsed arterial spin labelling (pASL),  employed by Wasan et al.(Wong, 
Buxton et al. 1998, Luh, Wong et al. 1999, Dai, Garcia et al. 2008, Owen, 
Bureau et al. 2008). Furthermore, the specific pCASL implementation 
employed here utilises a fast spin echo (FSE) readout that does not suffer 
from susceptibility artifacts inherent in echo planar imaging (EPI) readout 
methodologies most commonly employed with pASL. By contrast FSE is 
much slower to collect a single volume, requiring approximately six 
minutes taken to collect a single volume for each pCASL sequence as 
compared to several seconds as may be expected using EPI.   
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I have therefore chosen this technique to examine not only differences in 
functional plasticity between controls and CLBP patients but also to 
explore differences between NuLBP and MLBP groups. This study is the 
first to my knowledge to use ASL to examine brain activity in 
spontaneous, non-stimulus dependent CLBP. 
 Materials and Methods 5.2
 Image Acquisition And Pre-Processing 5.2.1
All ASL images were acquired during the same session as the structural 
scans taken for our VBM study, employing the same scanner and head 
coil. rCBF measurements were made using a pseudo-continuous arterial 
spin labelling technique (pCASL) (Dai, Garcia et al. 2008). We used 
exactly the same pCASL imaging sequence as used in recent studies in 
the same scanner (Hodkinson, Krause et al. 2013). Detail regarding this 
sequence is provided in the Appendix: 2. This sequence has been proven 
to be both reliable (Hodkinson, Krause et al. 2013) and sensitive to detect 
changes in regional cerebral blood flow that represent ongoing clinical 
pain in a resting state (Howard, Krause et al. 2011, Howard, Sanders et 
al. 2012).  
 ASL Preprocessing 5.2.2
Image pre-processing and analysis were carried out using Statistical 
Parametric Mapping software 8 (SPM 8) (Wellcome Department of 
Cognitive Neurology, London, UK, 2008; www.fil.ion.ucl.ac.uk/spm), 
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running under Matlab 7.12 (MathWorks, Natick, MA, USA). For each 
subject, the high-resolution T1-weighted structural images were used to 
align the data to MNI152 standard space (a T1-weighted brain image 
constructed from the average of 152 healthy individuals, collected at the 
Montreal Neurological Institute (MNI), Montreal, QC, Canada). Spatial 
normalisation was performed by co-registering each pCASL image to the 
segmented grey-matter (GM) image. Linear registration only was 
employed as the GM and pCASL images were from the same individual. 
The spatial normalization parameters required to warp the T1 image to 
MNI space were estimated (via SPM unified segmentation) and these 
parameters were applied to all the pCASL images. This strategy was 
adopted to reduce the likelihood of misregistration of the pCASL images. 
Finally, the images were spatially smoothed using a 10mm (full-width at 
half maximum) isotropic gaussian kernel to accommodate for gyral 
variability across subjects. 
 Statistical Analysis Of ASL Data 5.2.3
A voxelwise general linear model was used to identify differences 
between all three groups (controls, MLBP, and NuLBP) using one-way 
analysis of variance (ANOVA). For each subject, a simple average of the 
four rCBF maps was computed, which was used for groupwise analysis. 
Contrasts were specified comparing CBF values between MLBP, NuLBP 
and control groups. Global CBF values, in addition to age and gender, 
were included in the model as nuisance covariates. 
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Results were height thresholded at p<0.01, corrected for voxelwise 
multiple comparisons using non-stationary cluster extent correction at 
threshold of p<0.05 using the VBM8 toolbox in SPM8 developed by 
Christian Glaser http://dbm.neuro.uni-jena.de/vbm/non-stationary-cluster-extent-
correction/). Non-stationary cluster extent correction corrects for 
heterogeneity in the smoothness of the height thresholded corrected t-
statistic and allows for valid cluster-level inference (Hayasaka and 
Nichols 2004). Use of non-stationary cluster extent correction has already 
been discussed in the MRI Statistical Analysis section of Chapter 2 (see 
2.3.5.4).   
For significant clusters, the mean rCBF values (in ml/100g/min) across all 
voxels within the cluster were extracted for each group individually and 
plotted as simple bar plots. Further statistical analysis of group 
differences on the extracted data was not employed in order to avoid the 
pitfall of circular analysis – so called “double dipping” (Kriegeskorte, 
Simmons et al. 2009). It is important to recognize that bar charts and 
tables are only representative, as they are raw summary estimates 
(means) of significant voxels identified in the mass univariate GLM 
analysis. Two important differences should be highlighted; (i) the mass 
univariate analysis identifies differences between groups having 
accounted for relationships between rCBF, global CBF, age and gender; 
(ii) significant clusters identified in the mass univariate analysis are 
inferred having accounted for non-stationarity across the image volume. 
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I also chose to explore the relationship of our between group data with 
psychological variables. I therefore chose to use the same approach that 
was taken with the VBM data of comparing the results of individual group 
regression analysis of the CES-D and STAI scores and rCBF and the 
ANCOVA group rCBF differences. Please see section 4.4 for a full 
account of the methods used. 
 
 Results 5.3
 CLBP Patients Demonstrate Reduced rCBF 5.3.1
Compared To Controls. 
CLBP subjects demonstrated reduced rCBF compared to controls in a 
cluster extending posteriorly from the left lateral inferior division of the 
occipital cortex (visual cortex, V4, 5) extending anteriorly in to the middle 
temporal gyrus (temporo-occipital part) (see Table 57, Figure 52). Mean 
rCBF values are shown in Figure 53 and Table 58. 
Table 57: Reduced rCBF in CLBP compared to controls 
 
* rCBF = regional cerebral blood flow; Region = brain region; Cluster size = number of voxels in 
the cluster; Left = left hemisphere, Right = right hemisphere; T-Stat local maxima = T value of 
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Figure 52: Reduced rCBF in CLBP compared to controls. 
A cluster with reduced rCBF is seen in the lateral occipital cortex extending in to the left temporal 
gyrus. 
* Results are height thresholded at p<0.01 (t=2.39), corrected for voxelwise multiple comparisons 
using non-stationary cluster extent correction at threshold of p<0.05.  Values of the t-statistic are 
colour coded, range is 2.39-3.03; Image is seen in neurological convention. 
 
 
Figure 53: Mean rCBF values across groups (ml/100g/min). 
Reduced rCBF in MLBP and NuLBP groups compared to controls is seen in the lateral occipital 
cortex 
t 2.39 3.03 
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Table 58: Mean rCBF group values (ml/100g/min) for significant clusters. 
SD = standard deviation, DLPFC = dorsolateral prefrontal cortex, OFC = orbitofrontal cortex, SCC 
= subcallosal cortex 
 
 
Control 20 67.40 15.14 44.79 9.83 46.28 13.72 57.87 12.91 52.72 12.22 50.54 16.20
MLBP 24 59.79 11.57 44.28 9.10 45.28 12.28 56.16 12.26 49.64 10.35 46.10 9.82
NuLBP 22 59.66 11.48 43.99 7.55 40.28 8.43 52.39 8.89 45.21 8.71 49.40 10.25
Mean S.D Mean S.D
Group Lateral>Occipital>cortexN Insula DLPFC OFC SCC Superior>parietal>cortex
Mean S.D Mean S.D Mean S.D Mean S.D
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 CLBP Patients Demonstrate Increased rCBF Compared 5.3.2
To Controls. 
CLBP subjects showed increased rCBF compared to controls in a cluster 
extending anteriorly and superiorly in the right temporal pole into the anterior 
insula cortex, (see Table 59, Figure 54). 
Table 59: Increased rCBF in CLBP compared to Controls. 
 
* rCBF = regional cerebral blood flow; Region = brain region; Cluster size = number of voxels in the cluster; Left = 
left hemisphere, Right = right hemisphere; T-Stat local maxima = T value of peak activation voxels in the cluster; x, 
y, z  = orientations in MNI space. 
 
 
Figure 54: Increased rCBF in CLBP compared to Controls. 
Increased rCBF is seen in a cluster in the right temporal pole and anterior insula.  
* Results are height thresholded at p<0.01 (t=2.39), corrected for voxelwise multiple comparisons 
using non-stationary cluster extent correction at threshold of p<0.05.  Values of the t-statistic are colour 
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 NuLBP Patients Demonstrate Reduced rCBF Compared 5.3.3
To MLBP. 
NuLBP subjects had reduced rCBF compared to MLBP subjects in a large 
cluster extending posteriorly from the left medial prefrontal cortex bilaterally 
into the subcallosal cortex and extending superiorly into the lower margins of 
the rostral anterior cingulate cortex. The left and right lateral borders of the 
cluster extended into the orbito-frontal cortex on either side. A further cluster 
was observed on the right in the frontal pole, anterior to the OFC (see Table 
60,  
Figure 55,  
Figure 56). 
Another large cluster was identified in the right orbitofrontal cortex (26, 24, -
8), extending laterally and posteriorly and superiorly into the right anterior 
insula cortex (see Table 60,  
Figure 55,  
Figure 56). 
One more cluster was seen in the dorsolateral prefrontal cortex extending 
anteriorly into the right superior frontal gyrus (see Table 59, Table 60,  
Figure 55,  
Figure 56).  





Table 60: Reduced rCBF in NuLBP compared to MLBP patients. 
 
* rCBF = regional cerebral blood flow; Region = brain region; Cluster size = number of voxels in the cluster; Left = 
left hemisphere, Right = right hemisphere; T-Stat local maxima = T value of peak activation voxels in the cluster; x, 




Figure 55: Reduced rCBF in NuLBP compared to MLBP patients. 
Clusters were seen centrally encompassing the left medial prefrontal cortex, subcallosal cortex and 
lower margins of the rostral anterior cingulate cortex. Another cluster was seen in the right in the 
orbitofrontal cortex. 
* Results are height thresholded at p<0.01 (t=2.39), corrected for voxelwise multiple comparisons 
using non-stationary cluster extent correction at threshold of p<0.05.  Values of the t-statistic are colour 
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Figure 56: Reduced rCBF in NuLBP compared to MLBP patients. 
Clusters were seen in the subcallosal cortex, superiorly in dorsolateral prefrontal cortex and in the right 
superior frontal gyrus. 
* Results are height thresholded at p<0.01 (t=2.39), corrected for voxelwise multiple comparisons 
using non-stationary cluster extent correction at threshold of p<0.05.  Values of the t-statistic are colour 
coded, range is 2.39-3.03; Image is seen in neurological convention. 
 
 
Figure 57: Mean rCBF values across groups (ml/100g/min)  
Reduced rCBF in NuLBP patients compared to MLBP is seen in the DLPFC (Dorsolateral prefrontal 
cortex). 
t 2.39 3.59 
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Figure 58: Mean rCBF values across groups (ml/100g/min) 
 Reduced rCBF in NuLBP patients compared to MLBP is seen in the OFC (orbitofrontal cortex). 
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Figure 59: Mean rCBF values across groups (ml/100g/min). 
Reduced rCBF in NuLBP patients compared to MLBP was seen in the SSC (subcallosal cortex). 
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 NuLBP Patients Demonstrate Increased rCBF 5.3.4
Compared To MLBP. 
NuLBP subjects had increased rCBF compared to MLBP subjects in a 
cluster situated in the right posterior superior parietal lobule which extended 
immediately inferior and posterior into the superior division of the lateral 
occipital cortex (see Table 61, Figure 60). 
Mean rCBF values are shown in Table 58 and Figure 61. 
Table 61: Increased rCBF in NuLBP compared to MLBP. 
 
* rCBF = regional cerebral blood flow; Region = brain region; Cluster size = number of voxels in the 
cluster; Left = left hemisphere, Right = right hemisphere; T-Stat local maxima = T value of peak 
activation voxels in the cluster; x, y, z  = orientations in MNI space. 
 
 
Figure 60: Increased rCBF in NuLBP compared to MLBP. 
Clusters are seen in the right posterior superior parietal lobule and superior division of the lateral 
occipital cortex. 
* Results are height thresholded at p<0.01 (t=2.39), corrected for voxelwise multiple comparisons 
using non-stationary cluster extent correction at threshold of p<0.05.  Values of the t-statistic are colour 
coded, range is 2.39-3.59; Image is seen in neurological convention. 
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Figure 61: Mean rCBF values across groups (ml/100g/min). 
Increased rCBF in NuLBP patients compared to MLBP was seen in the superior parietal cortex. 
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 Regression analysis 5.3.5
 CES-D 5.3.5.1
Comparison of regression analysis using CES-D with analysis of group 
differences (ANOVA) showed negligible overlap in areas in which rCBF 
alterations were observed.  
 
Figure 62:	  Composite image showing results of a) analysis of group differences (ANOVA) and b) CES-
D regression analysis. 
Areas in green show all significant alterations in rCBF (increases or decreases) between groups 
(ANOVA: CLBP & controls, MLBP & NuLBP). Areas in red show significant relationships between 
alterations in rCBF (increases or decreases) and CES-D scores (Regression analysis). Areas in yellow 





Comparison of regression analysis using STAI-state with analysis of group 
differences (ANOVA) showed negligible overlap in areas in which rCBF 
alterations were observed.  
 
Figure 63:	   Composite image showing results of a) analysis of group differences (ANOVA) and b) 
STAI-state regression analysis. 
Areas in green show all significant alterations in rCBF (increases or decreases) between groups 
(ANOVA: CLBP & controls, MLBP & NuLBP). Areas in red show significant relationships between 
alterations in rCBF (increases or decreases) and STAI-state scores (Regression analysis). Areas in 





 Summary Of Results 5.4.1
We have demonstrated significant differences in rCBF not only between 
patients with CLBP and controls but also between MLBP and NuLBP 
patients. 
Patients with CLBP showed reduced rCBF in the middle temporal gyrus and 
increased rCBF in the right anterior insula cortex compared to controls. 
NuLBP subjects demonstrated reduced rCBF compared to MLBP subjects in 
the medial prefrontal cortex, subcallosal cortex, anterior cingulate cortex, 
orbito-frontal and insula cortex and dorsolateral prefrontal cortex. 
In the following sections I will describe rCBF increases and decreases 
initially in comparison of CLBP with controls, followed by alterations in rCBF 
in NuLBP compared to MLBP sub-groups.  
 Patients With CLBP Show Reduced rCBF In The Middle 5.4.2
Temporal Gyrus Compared To Controls. 
Patients with CLBP showed reduced rCBF compared to controls in a cluster 
extending posteriorly from the left lateral inferior division of the occipital 
cortex (visual cortex, V4, 5), extending anteriorly in to the middle temporal 
gyrus (temporo-occipital part). This area has been described as the 
extrastriatal body area (EBA) and proposed as a key area involved in 
processing the visual appearance of the body, as opposed to facial 
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recognition (Downing, Jiang et al. 2001). It may be involved in appreciation of 
the configuration of movement and action (Downing, Jiang et al. 2001). 
Importantly, it may be involved in regulation of the body schema (the sense 
of the body, its position, posture and appearance in space) via proprioceptive 
input and/or communication via motor networks (even in the absence of 
visual feedback) (Astafiev, Stanley et al. 2004), thereby dynamically updating 
bodily representation via sensory and proprioceptive feedback during 
movement. Activation of the EBA has also been implicated during 
observation of ‘emotional’ body postures (Peelen, Atkinson et al. 2007). 
Although it is assumed that altered posture, movement patterns, and motor 
function seen in CLBP are a consequence of local pathology (Jull and 
Richardson 2000), I suggest they may also have a relationship with the 
affective component of CLBP as seen in this study’s behavioural and VBM 
data. For instance, fear of movement is associated with muscle guarding and 
‘bracing’. The maintenance of aberrant movement patterns, often associated 
with muscle ‘dysfunction’ by physiotherapists, may also be linked to an 
emotional reaction to back pain (Hodges and Moseley 2003). The 
behavioural and VBM data from this study has shown that there is a large 
affective component to the experience of CLBP, which may be linked to 
these ‘emotional’ body postures. Although the EBA is a visual processing 
area, the involvement of the EBA in monitoring bodily movement does not 
necessarily depend on visual feedback (Astafiev, Stanley et al. 2004). The 
EBA may have an important role in monitoring movement in an environment 
or context specific manner, where movement and task completion has 
changed from being effortless and thoughtless, in a healthy individual, to 
 291 
uncertain and challenging, consistent with reports from patients with CLBP 
(Lethem, Slade et al. 1983, Linton 2000, Vlaeyen and Linton 2000, Leeuw, 
Goossens et al. 2007).  
I suggest that reduced perfusion in the EBA may represent the demands of 
monitoring posture, movement and maintaining a coherent body schema in 
response to profound changes in motor function, proprioceptive input and 
aberrant afferent input. This is consistent with the notion of embodiment and 
enmeshment (Osborn and Smith 2006) discussed previously and suggest 
that together these data add further evidence to the proposal that alterations 
in body schema and sense of self-identity are present in CLBP due to 
alterations in motor, and representational networks. 
Future work is necessary to explore the directional relationships between 
alterations in posture and movement patterns (negative ‘emotional ‘postures) 
and negative emotional states and cognitive impairment. Damasio’s somatic 
marker hypothesis (Damasio, Grabowski et al. 2000, Damasio 2005), states 
that bodily signals (i.e. initial pain and spasm as a consequence of local 
pathology) give rise to emotional states that influence decision-making (i.e. 
‘gut feelings’). These data also need to be examined in relation to existing 
evidence of the cognitive impairment seen in patients with CLBP. Impaired 
neuropsychological performance (NP) has been demonstrated previously in 
patients with osteoarthritic CLBP compared with pain-free subjects. In 
particular, CLBP patients were found to have deficits in attention, visual-
spatial awareness, mental flexibility and mental dexterity. Pain severity was 
inversely correlated with NP performance (Weiner, Sakamoto et al. 2006). 
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Specifically, CLBP patients were impaired on the IOWA gambling task, a 
task designed to assess ‘real-life’ decision-making. Task performance was 
negatively related to pain intensity at the time of the task. The deficits in 
emotional decision-making did not occur in healthy patients subject to an 
acute pain stimulus. The authors suggested that chronic pain engages areas 
of the brain involved in emotional cognitive processing which may not be 
activated in acute pain conditions. Engagement of these emotional 
processing areas may have clinical correlations in the levels of distress that 
chronic pain patients feel and performance in emotional decision-making 
(Apkarian, Sosa et al. 2004). In particular, the frontal regions in which we 
observed reductions in rCBF in in NuLBP patients (DLPFC and orbito-frontal 
cortex) have been associated with reduced levels of N-acetyl aspartate 
(NAA) shown in magnetic resonance spectroscopy (MRS) studies of CLBP 
(Grachev, Fredrickson et al. 2002, Grachev, Ramachandran et al. 2003) 
Reductions in NAA levels are typically a sign of neuronal loss or damage in 
pathologic conditions involving neurons such as multiple sclerosis, 
Alzheimer’s disease and stroke (Befroy and Shulman 2011). Other pain 
studies using MRS have also shown reductions in NAA and other 
metabolites and neurotransmitters such as glutamate and glutamine in 
migraine (Prescot, Becerra et al. 2009), neuropathic pain (Fukui, Matsuno et 
al. 2006) and spinal cord injury (SCI) (Pattany, Yezierski et al. 2002). Siddall 
and colleagues have stated that MR spectroscopy data in conjunction with a 
pattern recognition method (Statistical Classification Strategy) can 
differentiate between subjects with CLBP and healthy controls with a 
reported accuracy of between 97-100% (Siddall, Stanwell et al. 2006). This 
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data relates directly to the potential for chemical neuroplasticity in CLBP. 
Given the multi-system changes observed in persistent pain demonstrated 
by the convergent behavioural, functional and structural neuroplastic 
changes observed in this thesis, chemical neuroplastic sequelae are 
inevitable.  
The relationship between cognition, emotional distress and, in particular, 
underlying neuropathic or mechanical pain mechanisms needs further 
investigation. In addition to cognitive dysfunction, changes in 
neurotransmitter and metabolite concentration in frontal brain areas and 
elsewhere have led to the suggestion that neuro-degenerative processes 
should also be considered as an additional contributor to the psychological 
and behavioral maladaptive coping strategies that CLBP patients 
demonstrate. As neuropathic pain patients are reported to complain both of 
greater physical and psychological distress (Dworkin 2002) these findings 
may reflect a common neurobiological substrate for psychological co-
morbidities and chronic neuropathic pain. Furthermore, the same changes in 
cognitive function may contribute to the refractory nature of CLBP and 
reduce the likelihood of successful intervention.  Whether the processes 
underlying intractable clinical pain are neurodegenerative, i.e. truly 
irreversible, remains a contentious topic; it is undoubtedly complex and may 
well be underpinned by multiple processes, for example, specificity of 
initiating underlying disease state, psychometric profile, pain intensity and 
chronicity of symptoms (Pleger, Dinse et al. 2001, Pleger, Tegenthoff et al. 
2005, Pleger, Ragert et al. 2006, May 2008, Gwilym, Filippini et al. 2010).  
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 Patients With CLBP Show Increased rCBF In The 5.4.3
Anterior Insula. 
In addition, we observed increased rCBF in the anterior insula in CLBP 
patients, compared to individuals in the control group. The anterior insula is a 
key area involved in monitoring information about the condition and location 
of the body, stimulus saliency (including pain) and the internal and external 
environment. This region has been discussed at some length in the previous 
chapter. It is suggested that the insula is a hub that monitors the external and 
internal world in order to produce overall awareness of the present moment, 
described by Craig as a “global emotional moment” (Craig 2009). I propose 
that involvement of this region is further evidence of the negative impact of 
CLBP not just on a sensory level but on a profound level that affects the well-
being of the sufferer in all respects. 
To summarise, the two areas we have identified as showing significant 
alterations in rCBF in CLBP patients compared to controls are both involved 
in monitoring and regulating the internal and external environment and are 
crucially involved in monitoring motor performance. I also suggest that they 
may have an important role to play in the maintenance and regulation of 
body schema and are adversely affected in CLBP.  
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 Comparison Of NuLBP With MLBP Patients Shows 5.4.4
rCBF Reductions In The Subcallosal Cortex.  
NuLBP subjects had reduced rCBF compared to MLBP subjects in a large 
cluster that included the left medial prefrontal cortex, bilateral subcallosal 
cortex (SCC) and the rostral anterior cingulate cortex. Additionally reductions 
were seen in a cluster in the right OFC and anterior insula and in the right 
DLPFC and SFG. Increases were seen in a cluster in the superior parietal 
and lateral occipital cortex. 
I suggest that the reductions in rCBF observed in the SCC, OFC, DLPFC 
reflect alterations in networks involved in multiple functions concerned with 
evaluation and maintenance of homeostasis. Alterations in grey matter 
volume and rCBF reported in the SCC, subgenual ACC (sACC), DLPFC and 
orbitofrontal cortex and are associated with various mood disorders (Sheline 
2003, Drevets, Price et al. 2008), particularly depression (Mayberg, Lozano 
et al. 2005, Hajek, Kozeny et al. 2008). Failure of homeostatic self–regulation 
in these brain areas under conditions of “cognitive, emotional, or somatic 
stress” has been suggested as a mechanism underpinning long term 
depression (Mayberg 2009). The behavioural data of this cohort was 
reported in chapter 2. The psychometric correlates of cognitive, emotional, or 
somatic stress in CLBP patients (compared to controls) and, in particular, 
NuLBP patients (compared to MLBP) were discussed. These findings are 
consistent with studies that report significantly lower quality of life scores 
across a number of domains in individuals with neuropathic pain (Dworkin 
2002, Jensen, Chodroff et al. 2007). Furthermore, there is increasing 
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evidence that neuroimmune mechanisms may underlie depression and pain 
comorbidity (Walker, Kavelaars et al. 2014). In fact, Mayberg’s theory of 
dysregulation of prefrontal and cortico-limbic homeostatic mechanisms in 
depression may also apply to the unhappy triad of neuropathic symptoms, 
pain intensity and low mood. 
I suggest that the data from this study provide evidence in support of a 
theory that the SCC mediates the behavioural experience of both high pain 
intensity and low mood associated with NuLBP. Preclinical anatomical 
studies show SCC projections to and from multiple areas that may support a 
dual mechanisms theory of pain and depression. These areas include the 
periaqueductal grey matter, nucleus accumbens, brainstem, insula, 
hypothalamus and hippocampus (For a review of SCC connections see 
(Mayberg 2009) and (Hamani, Mayberg et al. 2011)). However, although 
form and function may be linked, they are not the same. The additional use 
of other modalities is necessary in order to explore the relationships between 
brain regions and the multi-dimensional experience of pain. Increasingly, 
fMRI has been used to examine functional connectivity between brain 
regions in so-called resting state networks (RSN) (Biswal, Yetkin et al. 1995, 
Xiong, Parsons et al. 1999, Hampson, Peterson et al. 2002). Several studies 
have explored connectivity in specific networks associated with evoked 
experimental pain, mostly using healthy volunteers (Davis and Moayedi 
2013). Recently a study explored sustained evoked pain using a pressure 
cuff, arguing that its longer duration had a greater relevance to clinical pain 
and found that the somatotopic representation of the stimulated leg in the 
 297 
somatosensory cortex became less connected to the sensorimotor RSN and 
more to regions associated with the salience RSN (Kim, Loggia et al. 2013).  
Functional connectivity has been reported in spontaneous, non-evoked 
clinical pain between the DMN and the insula cortex in fibromyalgia 
syndrome (Napadow, LaCount et al. 2010, Napadow, Kim et al. 2012). 
Loggia and colleagues (Loggia, Kim et al. 2013), using the same CLBP 
patient group and pain exacerbation protocol as in a previous study (Wasan, 
Loggia et al. 2011) examined functional connectivity in the default mode 
network (DMN), a network of regions that are active when the brain is not 
involved in a specific task, i.e. at rest (Raichle, MacLeod et al. 2001). Loggia 
et al were able to observe differences between patients and controls at 
baseline using functional connectivity (patients showed stronger DMN 
connectivity with the pregenual anterior cingulate cortex (pACC), insula and 
inferior parietal lobule. After pain exacerbation, greater pain was associated 
with reduced connectivity between the DMN and the pregenual anterior 
cingulate cortex and greater connectivity between the DMN and insula. While 
the mechanisms underpinning the correlations between brain regions, as 
revealed by resting-state fMRI, remain poorly understood (Castellanos, Di 
Martino et al. 2013), the technique offers promise in the understanding of 
clinical ongoing pain. I hope to explore the potential relationships between 
brain activity as seen in this study and functional connectivity across brain 
networks in future work.  
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 Patients With NuLBP Show Reduced rCBF In The 5.4.5
Anterior Insula. 
Interestingly, reductions were seen in the anterior insula, in contrast to the 
increases in a more inferiorly situated cluster, seen in CLBP compared to 
controls. Activation in the anterior insula has been observed in response to 
brush-evoked mechanical allodynia in neuropathic pain patients 
(Schweinhardt, Glynn et al. 2006). The anterior insula is involved in 
monitoring internal and external environments in order to arrive at an 
evaluation of the present moment (see 5.4.3). I suggest that increases in 
anterior insula rCBF in CLBP patients reflect a system actively working (or 
possibly overworking) to monitor and evaluate the internal and external 
perturbations of CLBP across a broad range of domains. However, I suggest 
that rCBF reductions in the anterior insula in NuLBP patients reflect 
evaluative and mentoring processes that are struggling to cope or possibly 
shutting down, in response a clinical picture of chronic NuLBP that is 
increasingly demanding and possibly overwhelming. Further work is needed 
to examine the relationship between brain activity and the ability to cope with 
ongoing pain and distress (using measurements such as the Chronic Pain 
Coping Inventory (Jensen, Turner et al. 1995) or the Coping Strategies 
Questionnaire (Rosenstiel and Keefe 1983) in neuropathic and non-
neuropathic LBP patients. 
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 NuLBP Patients Show rCBF Increases In The Right 5.4.6
Posterior Superior Parietal Cortex  
rCBF increases were also observed in the right posterior superior parietal 
cortex. Posterior areas of the parietal cortex have been described as 
‘integrative’ or ‘associative’ areas involved in multisensory integration of 
information relating to the representation of the state of one’s own body 
(Wolpert, Goodbody et al. 1998, Azanon and Haggard 2009, Longo, Azanon 
et al. 2010). Lesions to this area are associated with disruption to this 
internal representation (Daprati, Sirigu et al. 2010). Interestingly, it appears 
to share similar functions with the EBA, namely regulation of the body 
schema via integration of sensory and motor information (Azanon and 
Haggard 2009). Whereas the somatosensory cortex, located in the anterior 
aspect of the parietal lobe is associated with primary somatosensory 
functions of localisation and discrimination of sensory input, the posterior 
parietal regions are associated with so-called ‘higher’ somatosensory 
functions of multisensory integration of sensory information, representation of 
the body schema (Tsakiris, Costantini et al. 2008) and dynamic 
representation of the body moving through space (Bolognini and Maravita 
2007). I suggest that increases in rCBF in this area together with the rCBF 
changes seen in the EBA, demonstrate the involvement of networks 
dedicated to the maintenance and regulation of the state of the body under 
threat from an increasing sensory, cognitive and affective load. Further work 
is required to explore relationships between areas involved in representation 
of the body schema and body image (De Preester 2005), examination data 
(proprioception, sensory discrimination) and qualitative analysis of sense of 
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ownership of the body and self-identity (De Preester 2005, Osborn and Smith 
2006). 
 Conclusion 5.5
The aims of this chapter were to investigate two main hypotheses:  
1. There are differences in regional cerebral blood flow (rCBF) between 
CLBP and controls.  
2. There are differences in regional cerebral blood flow (rCBF) between 
NuLBP and MLBP subgroups. 
These results show significant differences in rCBF between CLBP and 
controls and between NuLBP and MLBP subgroups. Most importantly, we 
have been able to identify alterations in brain activity that clearly distinguish 
CLBP phenotypes. I have argued that the changes in rCBF in NuLBP 
patients, in particular, reflect a maladaptive functional plasticity as a result of 
the increasing sensory, cognitive and affective burden of NuLBP, further 
supported by the behavioural, examination and structural data already 
reported in this thesis. 
In comparison to the widespread alterations in GM seen in the VBM data, 
there are relatively fewer areas of rCBF alterations identified in the ASL data. 
As the two methodologies are entirely different there is no reason that the 
results should be equivalent. As detailed in section 5.1.5.5, methodical 
aspects of ASL data acquisition (in particular, the relatively poor signal to 
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noise ration of ASL) make collection of the ASL signal challenging. However, 
in contrast to a previous CLBP study using ASL, this study is the first to 
identify differences in rCBF in back pain patients at rest.  
In addition, as detailed in sections 5.1.5 & 5.1.5.4, ASL provides superior 
spatial localisation compared with BOLD in areas of relevant neural activity, 
with less contamination of signal from venous draining networks. This results 
in a more localized and less diffuse activation picture, compared to BOLD. 
It is difficult to compare the results of this ASL study with other studies due to 
the use of different methodologies (PET, BOLD fMRI), different paradigms 
(evoked and non-evoked pain) and a wide variation in study sizes. However, 
the only other CLBP study to examine non-evoked pain in the scanner also 
demonstrated a discrete activation pattern in contrast to the widespread 
patterns seen in evoked pain studies (Baliki, Chialvo et al. 2006). Further 
studies are required to examine clinical rCBF profiles of different clinical 
conditions using this methodology. Only very recently have studies by Liu et 
al (Post-Herpetic Neuralgia -PHN) (Liu, Hao et al. 2013) and Youseff et al 
(Trigeminal Neuropathy - PTN, Temperomandibular Disorder- TMD) 
(Youssef, Gustin et al. 2014) related to ongoing clinical conditions rather than 
pain evoked by tissue damage or mechanical pressure (OA, tonic muscular 
pain). Together this latter study and the results presented here provide 
evidence to suggest that different clinical conditions are likely to demonstrate 
different functional profiles, just as have been shown in morphometric 
structural MRI studies (Tracey and Bushnell 2009, Lee and Tracey 2010, 
Apkarian, Hashmi et al. 2011, Lee and Tracey 2013).  
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In particular, more studies need to be undertaken to compare and contrast 
neuropathic and non-neuropathic clinical phenotypes using this 
methodology. The rCBF profiles of neuropathic and mechanical CLBP 
subgroups demonstrated by this study are markedly different from the 
profiles of PTN and TMD groups shown in the recent study by Youssef et al 
(Youssef, Gustin et al. 2014). Evidence suggests that different functional 
imaging profiles may exist within neuropathic pain itself, relating to different 
mechanisms underlying the different clinical presentations of neuropathic 
pain. For instance, fMRI studies of allodynia show no unique allodynic 
cortical signature or network - mechanical and cold allodynia show 
differences in brain activation patterns, with cold allodynia showing similar 
cortical activation patterns to normal cold pain in patients with syringomyelia 
(Ducreux, Attal et al. 2006). I suggest that neuropathic pain is not an 
homogenous ‘all-or-nothing’ state but rather an heterogeneous condition 
whose multiple clinical profiles reflect a wide variation in underlying 
neuropathic pain mechanisms. Vital further work needs to be undertaken to 
match clinical symptom clusters and sensory testing profiles of neuropathic 
pain patients with functional and structural imaging data to better understand 
similarities and differences in neuropathic pain in CLBP and beyond. 
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Chapter 6 GENERAL DISCUSSION  
 
 Overview 6.1
The aim of this study was to demonstrate differences in behavioural, 
examination and functional and structural neuroimaging data between CLBP 
patients and controls and, in particular, between NuLBP and MLBP patients.  
In chapter 3, significant differences were identified between CLBP patients 
and controls and between NuLBP and MLBP patients in multiple behavioural 
domains measuring sensory discriminative dimensions of pain, function and 
psychological well-being and distress. Significant differences were also 
identified between CLBP patients and controls and between NuLBP and 
MLBP in tactile threshold discrimination and between CLBP patients and 
controls in two-point discrimination. In chapters 4 & 5, using functional and 
structural neuroimaging, we identified significant differences in CLBP 
patients and controls and between NuLBP and MLBP patients in widespread 
regions to do with evaluation and assessment, decision-making and 
planning, mood and emotion, modulation of pain and representation of the 
body schema. 
The following discussion highlights the main themes and issues that have 
been identified in this thesis. Future directions for further research are also 
suggested.  
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 Brain resources are devoted to the evaluation of 6.2
threat and stimulus saliency. 
The data from this study show the impact of CLBP on the individual, in terms 
of physical and psychological suffering, particularly in the CLBP patients that 
were identified by painDETECT as having a significant neuropathic 
component. Chronic pain is a stressor, as it is a threat to well-being and 
homeostatic balance (Sapolsky 2004). The behavioural data show not only 
evidence of increased levels of pain, functional disability and physical health 
problems but also greater levels of anxiety, depression and general mental 
health problems in CLBP patients and, in particular, NuLBP patients. The 
observed association of on-going pain intensity with reduced psychological 
well being may overwhelm the ability of the individual to maintain normal 
physiological functioning (allostasis) and lead to allostatic systems becoming 
dysregulated. Changes to physiological maintenance systems, including 
neuroimmune functioning, may lead to an amplification and prolongation of 
the pain state by mechanisms that include changes to brain structure and 
function (Borsook, Maleki et al. 2012, Vachon-Presseau, Roy et al. 2013). 
The imaging data reported here revealed several regions that may be 
involved in mediating and regulating mood and affective components of the 
pain experience. A novel finding was reduced rCBF in the SCC in NuLBP 
patients, an area that has been associated with long-term depression. We 
also observed GM alterations in the DLPFC, orbitofrontal cortex, 
hippocampus, basal ganglia and ACC. These areas have well established 
roles in the processing of the affective components of the pain experience 
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and are also implicated in low mood and depression. We also observed GM 
reductions in the hippocampus in NuLBP patients compared to controls. 
Reduced hippocampal volume is also associated with major depression 
(Lee, Reif et al. 2013) and has been observed in patients with CLBP,  in 
conjunction with increased levels of cortisol and activation in the anterior 
parahippocampal gyrus, suggestive of a sustained stress response (Vachon-
Presseau, Roy et al. 2013). I propose that together, the changes within the 
hippocampus, SCC, DLPFC, orbitofrontal cortex, basal ganglia and ACC are 
likely to be associated with mediating the stress and low mood that patients 
with CLBP demonstrate in our behavioural data, and to a significantly greater 
extent, in the NuLBP population.  
A key finding of the neuroimaging chapters of this study is the amount GM 
alterations in brain regions devoted to evaluation and assessment of stimulus 
saliency such as the cingulate cortex and anterior insula. Our data show that 
patients with CLBP are involved in an on-going assessment of internal and 
external stimuli, in order to evaluate potential threats and rewards based on 
the saliency of competing stimuli in areas such as the OFC, anterior insula, 
basal ganglia and DLPFC. I suggest that as pain increases, it becomes 
increasingly more threatening to the sufferer and therefore increasingly 
salient, resulting in higher states of alertness and responsiveness to both 
painful and non-painful stimuli seen in patients with CLBP. I suggest that GM 
alterations observed in the salience network and planning and evaluative 
regions reflect the hypervigilance shown by patients as internal and external 
inputs become increasing more of a threat (Asmundson and 
 306 
Hadjistavropoulos 2007). GM loss and alterations blood flow in the imaging 
data suggest that patients with CLBP devote increasing resources to 
planning, evaluation and decision making. It is unclear whether these 
alterations are adaptive and reflect a system coping with increased demand 
or maladaptive, reflecting evaluative and decision-making networks that are 
no longer able to cope.  
As pain increases, decision-making becomes increasing problematic as the 
rewards and punishments (increased pain or pain relief) become greater. 
Deficits in ‘neuroeconomic’ decision-making that occur in association with the 
observed rCBF and GM alterations in key areas such as the DLPFC may 
reflect the less than optimal strategies employed by CLBP patients. GM 
increases in the basal ganglia reflect the demands of integrating and 
modulating sensory, cognitive and affective elements of the pain experience 
in order to plan and execute motor strategies. Deficits in motor strategies 
seen by clinicians managing low back pain have usually been attributed to 
local tissue pathology and spawned a specialist industry using elaborate 
muscle training regimes (“core stability”) with little evidence of efficacy 
(Lederman 2010). One may speculate that rather than local pathology, local 
muscle dysfunction and problems in recruitment and coordination of muscle 
groups may stem instead from higher order processes. In addition, the fact 
that GM alterations in the basal ganglia and motor cortex were seen in MLBP 
(and not NuLBP) subjects compared to controls possibly suggests that 
increases are an adaptive response in MLBP patients who are actively 
involved in integration of sensory and motor stimuli to coordinate motor 
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activity. However, dysregulation in pain modulatory systems such as the 
OFC and DLPFC and cingulate in the NuLBP population might make an 
appropriate motor response too challenging. The NuLBP population instead 
may direct resources towards vigilance and prevention of pain by reducing 
activity and less towards planning motor strategies as the behavioural data 
demonstrates. Therefore, the type of neuroplastic change revealed in the 
basal ganglia and motor cortex in my work may be a key indicator (in some 
patients) of the transition from mechanical to neuropathic back pain.  
Furthermore, we witnessed GM and rCBF alterations in the anterior insula, 
which according to Domasio’s somatic marker hypothesis is involved in 
emotional responses based on underlying physiological markers that 
influence decision-making. Dysregulation in the anterior insula may predicate 
the CLBP patient to a heightened emotional response (i.e fear/anxiety) in 
response to alterations in muscle tone/guarding. In turn a heightened 
emotional response may result in altered muscle response. Over time, the 
resultant muscle and emotional responses may become conditioned and 
account for the difficulty faced by physiotherapists in rehabilitating patients 
with aberrant movement patterns and sub-optimal muscle function.  
In addition to the challenges and uncertainties of moving the physical body, 
the imaging data suggests that alterations in perfusion in the EBA and 
increased GM in the somatosensory and motor cortex may reflect the 
demands of maintaining a coherent body schema when the back no longer 
moves as it once did. Alterations in body schema and sense of self-identity 
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are present in CLBP and may reflect neuroplasticity in motor, and 
representational networks. 
 CLBP patients show evidence of alterations to 6.3
body schema.   
In addition to the challenges and uncertainties of moving the physical body 
detailed above, our imaging data suggest that increased GM in the 
somatosensory and motor cortex may also reflect the demands of 
maintaining a coherent body schema in the face of alterations to movement 
patterns, activity, muscle function and proprioception that have all been 
associated with CLBP and discussed in this thesis. Neuroplasticity in motor 
and representational networks relating to the virtual representation of the 
body and body schema have been described in CLBP and discussed 
extensively in this thesis. The imaging data show alterations in rCBF in 
‘higher’ association areas (the extrastriatal body area (EBA) and posterior 
superior parietal cortex) involved in processing and integrating multisensory 
information concerned with representation of the state of one’s own body. 
The behavioural data show an increasing sensory, cognitive and affective 
load that increases in line with an increasing neuropathic component as 
measured by painDETECT. Additionally, the examination data show that 
patients with CLBP have poorer sensory discrimination in both two point 
discrimination and tactile thresholds and that NuLBP patients have poorer 
tactile threshold discrimination than MLBP patients. I suggest that together 
these alterations in sensory discrimination are associated with changes 
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observed in areas that represent body schema such as the extrastriatal body 
area, posterior parietal and somatosensory cortex. I speculate that the loss 
of discrimination may reflect a deeper loss of a sense of embodiment and 
connection to the physical being, the sense of being secure and stable in a 
physical identity that has been discussed in relation to the phenomenon of 
neglect experienced by patients with chronic pain and CLBP. I suggest that 
the neuroimaging data and subtle changes in discrimination thresholds relate 
to a diminution of the sense of ownership of the body and ultimately, self-
identity. Our behavioural data demonstrate the profound impact of CLBP not 
only on physical but also mental health across a number of physical, 
emotional and psychological domains that suggest the struggle of the CLBP 
sufferer to maintain a representation of an established self-identity 
associated with a role in family, social and work settings. The multi-
dimensional impact of CLBP undermines the old familiar self-identity and 
body schema that is associated with normal pain-free activity and function. In 
addition, I suggest that body image is linked not only to the physical 
dimensions of the experience of LBP but the poorer mental health scores 
that reflect an existential anxiety, loss of agency and uncertainty about the 
sufferer’s place in a world that is limited by low back pain. Indeed, at some 
level, reductions in tactile sensitivity may represent an adaptive response by 
the sufferer to free themselves from the “enmeshment” postulated by Pincus 
and Morley (Pincus and Morley 2001) in which pain in the body becomes 
entangled with a rejected and negative view of the self, forming an 
“enmeshment” from which the patient cannot escape. This is likely to occur 
at the supraspinal level and may correlate to the structural and functional 
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plasticity observed in my study. These representational changes may be an 
adaptive strategy that the nervous employs to free the person from this 
enmeshment by reducing attentional resources. 
I suggest therefore that this study’s examination, imaging and behavioural 
data represent a loss of psychological and physical well-being in CLBP may 
even extend to the sense of self-identity and self-worth and ownership of 
agency. Although these ideas are speculative, it would be interesting to 
explore further the relationships between body schema, body image, 
examination data (proprioception, sensory discrimination) and qualitative 
analysis employing a combined cognitive psychology and neuroimaging 
approach. 
 Grey Matter and rCBF Group Differences (as 6.4
identified by PainDETECT) Do Not Relate To 
Differences in Psychological Variables scores. 
Our results showed that there was negligible overlap between areas in which 
regression analysis showed a significant relationship between GM and rCBF 
alterations and psychological variables (CES-D and STAI state) and ANOVA 
group comparison areas in which GM and rCBF differences were seen. 
These results strongly indicate that that GM and rCBF differences that were 
identified in the CLBP, MLBP and NuLBP groups were not related to these 
psychological variables. 
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 Neuroplasticity and neuropathic pain. 6.5
CLBP patients in this study demonstrate a continuum of painDETECT scores 
that show a clinical spectrum from definitely non-neuropathic (i.e. 
mechanical), through ‘unclear’, to definitely having a significant neuropathic 
component. Whilst an explanation based on peripheral nervous system 
mechanisms may account for the location of the patient on the continuum, I 
suggest an alternative, that spinal and supraspinal mechanisms, especially in 
the absence of any lesion or disease mechanism, may also account for a 
neuropathic presentation. The neuroimaging data from this study shows 
clear signs of structural and functional neuroplasticity in patients with CLBP 
compared to controls and, of particular relevance to this discussion, NuLBP 
patients compared to MLBP. Unfortunately, functional and structural MRI are 
not sensitive enough media to demonstrate the exact underlying 
mechanisms at play. However, throughout this thesis I have presented 
evidence from studies of CLBP and other pain conditions that show that 
structural, functional and chemical neuroplasticity is associated with chronic 
pain. Animal models demonstrate evidence of sensitised neurones not only 
in the in the dorsal horn (Woolf and Salter 2000, Woolf 2011) but also in the 
brain (Guilbaud, Benoist et al. 1992, Paulson, Casey et al. 2002). 
Neuropathic pain profiles, outside classic textbook descriptions may occur 
due to spinal and supraspinal mechanisms, despite no obvious lesion state 
(Wall 1991).  
I suggest that this calls in to question the validity of the IASP redefinition of 
neuropathic pain requiring a lesion or disease and rather suggests that the 
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pain experience, in itself, may lead to supraspinal neuroplastic changes as 
demonstrated by my data and a large body of literature. These neuroplastic 
changes may then constitute an ‘injury’ to the nervous system i.e. the pain 
experience itself ‘pathologises’, leading to the constellation of signs and 
symptoms that fulfil the diagnostic criteria of neuropathic pain.  
I suggest that the painDETECT score continuum reflects an increasingly 
‘pathologised’ nervous system resulting in an increasing predominance of 
neuropathic mechanisms. Patients at the lowest ‘mechanical’ end of the 
scale are thought to have symptoms that are mediated primarily by 
nociceptive input from tissue-based pathology - these are patients who 
should respond to tissue-based treatments, whether pharamacological or 
physically based. The behavioural data from this study supports the clinical 
observation that they are generally less in need of psychological support. 
Further along the continuum, increasing signs and symptoms across a broad 
range of domains, not just pain intensity, show a clinical picture that may be 
mediated by an increasingly dysfunctional or maladaptive CNS. The 
behavioural manifestations of increasing dysregulation of the CNS are shown 
in our behavioural data and in the wide range of clinical presentations across 
a broad range of domains reflecting the multi-dimensional nature of the 
chronic neuropathic pain experience.  
The data from this study show that CLBP is not simply a sensory-
discriminatory disorder but is associated with increasing psychological 
comorbidity and pain severity as the neuropathic component increases. This 
is consistent with studies showing the burden of neuropathic pain on quality 
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of life across a number of domains (Dworkin 2002, Jensen, Chodroff et al. 
2007). This study’s neuroimaging data have shown volumetric and rCBF 
changes in multiple regions implicated in both pain and mood that may 
account for the impact of CLBP and NuLBP across both sensory and 
psychological dimensions.  
Mayberg has described chronic depression as a failure of homeostatic self-
regulation in the face of overwhelming stressors (Mayberg 2009). 
Behavioural data from this study show that CLBP and in particular NuLBP 
patients have to deal with considerable pain and psychological stressors. I 
therefore suggest that the linear relationship between pain and psychological 
comorbidities demonstrated along the neuropathic continuum in our data 
reflect the failure of self-regulation across a number of domains associated 
with increasing neuropathic mechanisms. Neuroimmune interactions may 
underlie psychological and pain comorbidities (Walker, Kavelaars et al. 2014) 
which, in turn, may cause changes to brain structure and function (Borsook, 
Maleki et al. 2012, Vachon-Presseau, Roy et al. 2013). Investigation of this 
hypothesis would involve a new study paradigm in itself, which could provide 
a useful avenue for future work. 
I suggest, therefore, that, it is time to abandon a dualistic approach to pain 
and pain comorbidities, and to stop treating them clinically and conceptually 
as separate entities. Rather, chronic pain needs to be reconsidered as a 
multidimensional experience, involving sensory-discriminative, affective-
motivational and cognitive-evaluative components. Treatment that focuses 
on tissue-based mechanisms distracts from an understanding of pain along 
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the neuropathic continuum as a product of maladaptive neuropathic CNS 
mechanisms. I suggest that the grey matter and rCBF alterations in the 
neuroimaging data, the altered sensory profiles in the examination data and 
the behavioural data demonstrate the impact of chronic pain and are 
correlates of neuropathic mechanisms. Novel treatments need to be 
developed to target not only sensory and psychological components of 
chronic back pain but also to address the dysfunctional maladaptive 
supraspinal plasticity that this thesis has identified.  
Initial efforts to develop therapies targeting supraspinal neuroplastic changes 
have begun and have their origin in the management of CRPS and phantom 
limb pain. In common with back pain and my data, these painful conditions 
are characterised by a profile of behavioural, sensory-motor and neuroplastic 
alterations.  
The methods employed to manage these conditions have included both 
motor re-education and sensory discrimination re-education strategies (see 
(Moseley and Flor 2012) for an extensive review of the literature). At present 
there is a paucity of data available on their use in CLBP. It is likely that one 
future direction will be an attempt to directly alter brain activation by brain 
stimulation or neurofeedback either in isolation or as adjuncts to behavioural 
treatments. In addition, visualisation or virtual reality technologies might be 
used to re-establish cortical mapping and body schema. Another possible 
strategy may involve extinction training, either in isolation or combined with 
pharmacological interventions that directly modulate plasticity and enhance 
extinction of specific symptoms and/or behaviours.  
 315 
 
 Do the neuroimaging results show a neuropathic 6.6
pain signature? 
A key aim of this thesis was to establish if there is a cortical signature for 
CLBP and, in particular, neuropathic low back pain, in order to develop 
potential clinical biomarkers for CLBP. These biomarkers could be used to 
identify underlying mechanisms and differentiate mechanistic processes in 
CLBP. A recent study (Gustin, Peck et al. 2011) has attempted to similarly 
compare and contrast morphometric profiles of trigeminal neuropathic pain 
patients compared to tempromandibular (TMD) patients using VBM. Using 
their own data and findings of others, the authors asserted that neuropathic 
pain is strongly associated with thalamic atrophy (Gustin, Peck et al. 2011).   
In contrast, my data has shown evidence of increased GM volume in the 
margin of the right thalamus in CLBP patients. Other VBM CLBP studies 
show similarly conflicting data; reductions (Apkarian, Sosa et al. 2004, Ivo, 
Nicklas et al. 2013), increases (Schmidt-Wilcke, Leinisch et al. 2006, Wu, 
Inman et al. 2013), and no significant alterations (Buckalew, Haut et al. 2008, 
Seminowicz, Wideman et al. 2011, Kong, Spaeth et al. 2013). It is difficult to 
therefore to draw any firm conclusions from these studies. Variation in results 
may be due to differences in patient selection criteria and methodologies 
employed. Together with my data this body of work challenges the legitimacy 
of the proposal by Gustin et al that thalamic atrophy is a reliable biomarker of 
neuropathic pain.  
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Functional alterations have also been reported, for example a reduction in 
thalamic blood flow has also been suggested as a biomarker for 
spontaneous neuropathic pain (Haanpaa, Attal et al. 2011 ). Historical PET 
studies of either neuropathic pain or pain suggestive of a significant 
neuropathic component, have mainly reported reductions in rCBF (Di Piero, 
Jones et al. 1991, Hsieh, Belfrage et al. 1995, Peyron, Garcia-Larrea et al. 
1995, Garcia-Larrea, Peyron et al. 1999) although one study has showed 
thalamic hyperactivity (Cesaro, Mann et al. 1991). However, all of these 
studies used extremely small patient groups of between two and five 
subjects and all used methods to reduce pain in their subjects, in order to 
compare the painful state with a pain-free state, rather than comparing 
patients in pain with healthy controls. Evidence from structural and functional 
neuroimaging studies carried out since this early work and detailed 
throughout this thesis, shows that fundamental neuroplastic changes occur in 
patients with chronic pain, making them unsuitable for use as control 
subjects, even in the pain free state. Clearly, in light of these limitations, care 
must be exercised in interpreting these studies. A recent study, found 
thalamic and brainstem rCBF decreases in neuropathic PTN subjects (but 
not non-neuropathic TMD disorder subjects, using ASL (Youssef, Gustin et 
al. 2014). However, we did not demonstrate any alterations in thalamic rCBF 
in CLBP overall (in line with another recent ASL CLBP study (Wasan, Loggia 
et al. 2011) and furthermore, I found no alterations in the individual analysis 
of mechanical or neuropathic subgroups.  
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I suggest that data is lacking at present to support the idea of specific 
structural or functional regional neuroimaging ‘signatures’ associated with 
neuropathic pain, nor is there evidence for a specific cortical signature for 
neuropathic pain.  
My data show that CLBP patients overall, and MLBP and NuLBP subgroups, 
show distinct differences in structural and functional neuroimaging, clinical 
examination and behavioural profiles compared to healthy controls. I suggest 
that my behavioural and examination data are associated with the 
neuroplastic changes seen in the functional and structural imaging chapters.  
However, I believe that we are not yet able to say that we have discovered 
‘biomarkers’ of mechanical and neuropathic low back pain. I think the search 
for a mechanical or neuropathic low back pain neuroimaging profile is 
conceptually problematic. The idea of a specific pain imaging neuromatrix 
has often been discussed in imaging literature (Tracey and Mantyh 2007) as 
if it were possible to identify an anatomically distinct pattern to identify the 
experience of pain. However, recent work has called this notion into 
question, suggesting that the communality of results in acute pain 
neuroimaging is rather more to do with stimulus saliency than with the 
experience of pain (Iannetti and Mouraux 2010). In this thesis, I have also 
demonstrated alterations within the saliency network, which adds support to 
this idea.  
I would suggest, therefore, that the neuroimaging results seen in this study 
reflect the individual experience of CLBP patients across the sensory-
discriminative, affective-motivational and cognitive-evaluative dimensions of 
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pain that I have discussed throughout this thesis. Each individual has a 
unique experience of pain. Across the groups however, all the data in this 
study clearly reflect the differences in pain intensity, affect and cognitive 
burden seen in chronic low back pain patients compared to healthy controls 
and in particular of NuLBP compared to MLBP patients. 
Chapter 7 CONCLUSION 
This body of work has demonstrated the ability to characterise CLBP using a 
battery of behavioural, examination and functional and structural 
neuroimaging methodologies. I have established that these modalities have 
the ability to differentiate between CLBP patients and controls and 
importantly, between NuLBP and MLBP patients. This work demonstrates 
the impact of CLBP across sensory-discriminative, affective-motivational and 
cognitive-evaluative dimensions of the pain experience and shows the 
increased impact and burden on those who suffer with neuropathic 
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IASP definition of neuropathic pain 
Note: Neuropathic pain is a clinical description (and not a diagnosis) which 
requires a demonstrable lesion or a disease that satisfies established 
neurological diagnostic criteria. The term lesion is commonly used when 
diagnostic investigations (e.g. imaging, neurophysiology, biopsies, lab tests) 
reveal an abnormality or when there was obvious trauma. The term disease 
is commonly used when the underlying cause of the lesion is known (e.g. 
stroke, vasculitis, diabetes mellitus, genetic abnormality). Somatosensory 
refers to information about the body per se including visceral organs, rather 
than information about the external world (e.g., vision, hearing, or olfaction). 
The presence of symptoms or signs (e.g., touch-evoked pain) alone does not 
justify the use of the term neuropathic. Some disease entities, such as 
trigeminal neuralgia, are currently defined by their clinical presentation rather 
than by objective diagnostic testing. Other diagnoses such as postherpetic 
neuralgia are normally based upon the history. It is common when 
investigating neuropathic pain that diagnostic testing may yield inconclusive 
or even inconsistent data. In such instances, clinical judgment is required to 
reduce the totality of findings in a patient into one putative diagnosis or 
concise group of diagnoses. 
Central neuropathic pain:  Pain caused by a lesion or disease of the central 
somatosensory nervous system. See neuropathic pain note. 
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Peripheral neuropathic pain: Pain caused by a lesion or disease of the 





Arterial blood was labelled using a 1.5s train of Hanning radio frequency (RF) 
pulse of 500µs duration, with an inter-pulse period (τ) of 1500µs. The 
amplitude of each Hanning RF pulse was 8.4µT, (effective flip angle of 32.3 
degrees). Gradient pulses of the same duration and repetition rate (each 
followed by a refocusing lobe) accompanied the RF train to achieve flow-
driven adiabatic inversion.   
We employed a post-labeling delay of 1.5 seconds. This delay has been 
found to be appropriate to minimize vascular artefacts (Alsop and Detre 
1996, Dai, Garcia et al. 2008) and has been employed successfully in 
several studies that utilized a single TI ASL method in healthy volunteers 
(Howard, Krause et al. 2011, Howard, Sanders et al. 2012, Marquand, 
O'Daly et al. 2012, Towgood, Pitkanen et al. 2012, El-Hage, Zelaya et al. 
2013, Handley, Zelaya et al. 2013). The image was acquired with a 3D Fast 
Spin Echo (FSE) spiral multi-slice readout.  To minimize blurring, the spiral 
acquisition was very short (4ms), and the required resolution was achieved 
with 8 spiral interleaves (effective TE 32ms/TR = 5500ms; Echo Train Length 
(ETL) = 64).  Images were acquired at a 48 x 64 x 60 matrix on a 18 x 24 x 
18cm field of view and reconstructed to a 2562 in plane matrix, resulting in a 
nominal spatial resolution of 1x1 x 3mm. For signal averaging purposes, 
three pairs of tagged-untagged images were collected in succession.  
Selective saturation of the image slab was applied at 4.3s before acquisition, 
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selective inversion was applied 3s before acquisition with further non-
selective inversions at 1.5s, 764ms, 334ms and 84ms before imaging.  This 
repeated inversion achieved successful suppression of the background static 
tissue signal, thus maximizing the sensitivity to blood perfusion (Maleki, Dai 
et al. 2012). 
Following the three arterial spin labeling (ASL) control-label pair averages, 
reference images were acquired with the same imaging sequence but with 
inversion recovery preparation, instead of ASL. One sequence with 
saturation of 4.3s and then an inversion at 1650ms before imaging was used 
to create a fluid suppressed image. A second sequence with saturation at 
4.3s and then inversion at both 2408ms and 511ms was also acquired to 
create a fluid and white matter suppressed image.  For both these 
sequences, the receiver gain was automatically lowered by 21 dB relative to 
the ASL sequence to avoid receiver saturation. These images were used to 
quantify blood flow from the mean perfusion weighted difference image 
computed from the three tagged-untagged pairs, as described below. The 
sensitivity of the image was also calibrated to water at each voxel in order to 
account for the relative sensitivity of the coil elements (Williams, Detre et al. 
1992, Alsop and Detre 1996, Buxton, Frank et al. 1998).  By means of a 
neighborhood maximum algorithm to avoid regions with partial volume of 
suppressed fluid, a low-resolution sensitivity map was created. This map was 
calibrated for water sensitivity by assuming the tissue was predominantly 
white matter with a water concentration of 0.735 gm/ml (Herscovitch and 
Raichle 1985) and a T1 of 900ms, and using the equations for inversion 
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recovery signal attenuation.  This calibration produced a sensitivity map, C, 
equal to the fully relaxed MRI signal intensity produced by one gm of water 
per ml of brain.   It is worth noting that assuming pure grey matter produces 
only a 5% calibration difference. With this co-registered sensitivity map C, 




where ρb is 1.05g/ml (the density of brain tissue; (Herscovitch and Raichle 
1985)), α is the labeling efficiency (assumed to be 95% for labeling times 
75% for background suppression; (Garcia, Duhamel et al. 2005), w is 1.5s 
(the post-labeling delay; (Alsop and Detre 1996)), tl is 500ms (the labeling 
duration), T1a is  1.4 ms (the T1 of arterial blood which was slightly lower 
than the value of  (Lu, Clingman et al. 2004)), ωa 0.85 g/ml (the density of 
water in blood(Herscovitch and Raichle 1985)), Sl and Sc are the signal 
intensities in the labeled and control images, respectively.  
The whole ASL pulse sequence, including the acquisition of calibration 
images, was performed in 6:08min and repeated 4 times in succession 
during the scan. T1 and T2 weighted FSE images were acquired for co-








































recovery (FLAIR FSE) scan was made in order to allow radiological 





List of Medications and Previous Non-Conservative 
Treatment for CLBP subjects.  
 
 
MLBP MLBP% F 46 Paracetamol,%co2codamol
MLBP MLBP F 28 nil Epidural,%Facet%Joint%Injections
MLBP MLBP M 32 nil
MLBP MLBP F 43 Ibuprofen
MLBP (L)%S1%NR F 21 Amitriptyline%and%paracetamol
MLBP Neurogenic%claudication M 41 nil
MLBP MLBP M 48 nil
MLBP MLBP M 26 nil
MLBP LBP F 37 Co2codamol
MLBP MLBP F 26 nil
MLBP LBP F 34 nil
MLBP LBP F 49 Paracetamol,%naproxen
MLBP MLBP F 33 nil
MLBP CLBP F 46 Ibuprofen
MLBP MLBP F 28 nil
MLBP MLBP F 30 nil
MLBP Discogenic%low%back%pain%with%lateral%stenosis%L4/5 M 50 Ibuprofen
MLBP MLBP F 45 Co2codamol,%paracetamol
MLBP MLBP M 37 Co2dydramol
MLBP MLBP F 54 nil
MLBP LBP F 42 Pregablin,%duloxetine
MLBP MLBP%with%L%L5/S1%Sensory%Radiculopathy F 47 Co2codamol
MLBP NO%INFO M 50 Paracetamol,%amitriptyline Discectomy
MLBP MLBP F 28 Paracetamol,%ibuprofen
MLBP MLBP M 39 nil
MLBP MLBP F 32 Paracetamol
NuLBP L4/L5%stenosis%leading%to%L4/5%sciatica M 31 Paracetamol
NuLBP NO%INFO M 50 Ibuprofen
NuLBP MLBP M 35 Naproxen,%Paracetamol,
NuLBP MLBP M 25 nil Nerve%root%injection
NuLBP MLBP F 40 Tramadol,%cellebrex,%imigram
NuLBP LBP M 49 Amitriptyline
NuLBP MLBP F 43 Dihydrocoedine,%paracetamol
NuLBP MLBP%&%%distribution%leg%pain F 53 Tramadol
NuLBP MLBP F 38 nil
NuLBP Lumbar%canal%STENOSIS F 54 Paracetamol,%Gabapentin
NuLBP MLBP%+STENOSIS M 47 Co2codamol,%voltarol Discectomy
NuLBP Spinal%canal%stenosis%L4/L5%with%left%L5%radiculopathy F 51 Diclofenac,%ibuprofen
NuLBP Spinal%pain F 46 Paracetamol,%duloxatine,%amitriptyline%and%pregabalin
NuLBP MLBP F 31 nil
NuLBP MLBP F 53 Co2dydramol,paracetamol
NuLBP Radicular%pain%L5%right%leg F 57 Clonazepam,%co2codamol,%diclofenac, Nerve%root,%facet%joint%injections,%radio%frequency%denervation
NuLBP MLBP F 52 Co2codamol,%diclofenac
NuLBP L5%Nerve%root%pain F 26 Coedine,%diclofenac,%diazepam
NuLBP LBP%2%left%leg%pain F 49 Etoricoxib
NuLBP Left%S1%nerve%root M 44 Ibuprofen
NuLBP LBP F 26 Paracetamol,%co2codamol,%ibuprofen
NuLBP right%L5%nerve%root%pain M 48 Co2codamol,%amitriptyline
NuLBP Mechanical%LBP F 29 Amitriptyline%(long2term,%finished%2%weeks%previous%to%scan)
NuLBP L5%sens%radiculopathy M 48 Co2codamol,%ibuprofen epidural%injections%x%2
%painDETECT%Diagnostic%Category Diagnosis%by%treating%Clinician Gender Age Medication Previous%Non2Conservative%Intervention
